DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Hapvida Participações e Investimentos S.A.

Parent company and consolidated interim statements for the six-month period ended June 30, 2024

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Contents

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

2Q24
Earnings Release

hapvida NotreDame Intermédica

Earnings Call Presentation

August 9th, 2024 (Friday)

Portuguese (with simultaneous translation to English)

10am (EDT – NY) | 11am (BRT)

ri.hapvida.com.br/en

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Summary

The company has remained disciplined and focused on its strategy of gradually recovering margins to healthy levels, with efforts dedicated to building an increasingly sustainable portfolio, responsible underwriting and cost management, always striving for a high quality and welcoming service. This strategy has allowed the Company's Cash Loss Ratio to show a significant reduction of 3.9 p.p. compared to 1H23, expanding the Adjusted EBITDA margin significantly, from 9.1% to 13.9% in the first half of 2024.

Throughout the quarter, the company remained delivering healthy cash flow levels, allowing it to continue the gradual deleveraging process and increasing its investments in the qualification and expansion of its own network.

Net Revenue (R$MM)



Cash MLR (R$MM; %NOR)



Beneficiaries (thousand)



Cash G&A (R$MM; %NOR)



Average Ticket (R$/month)



Sales Expenses (R$MM; %NOR)



Net Debt[1] (R$MM; ND/EBITDA LTM)



Adjusted EBITDA (R$MM; %NOR)



(1) Contractual covenant

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Operational Highlights

OWN NETWORK

At the end of the quarter, we had 85 hospitals, 77 emergency units, 347 clinics and 294 diagnostic imaging and laboratory collection units, making a total of 803 own service points, accessible to our beneficiaries throughout Brazil.





QUALITY OF CARE & CARE FOR PEOPLE

Quality of Care and Care for People of our more than 15 million beneficiaries has been an increasingly important topic for the Company's management. Since 2023, significant efforts have been made to ensure continuous improvements in the operation, which is still in the integration phase. As part of this process, the units in the South and Southeast regions of Brazil, including São Paulo, have started incorporating the indicators below after systems migration and protocol standardization.

SMR - Standardized Mortality Rate in ICU

The standardized mortality ratio is the ratio between deaths observed in the study group and deaths expected in the general population. The lower the rate, the better.



Waiting times in Emergencies

Percentage of services rendered within 15 minutes in emergencies. The higher, the better. 2Q24 was affected by the typical period of viral infections, as well as one of the biggest dengue epidemics in recent years.



Natural Births

Rate of natural birth deliveries per total number of deliveries. The higher, the better.



(1) AMIB - Brazilian Intensive Care Medicine Association (2) ANAHP - National Association of Private Hospitals

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Financial Results

NET REVENUE

In 2Q24, Net Revenue totaled R$7,150.4 million, an increase of 4.5% when compared to the previous quarter, benefiting mainly from the growth of the Health and Dental Plans business lines, as a result of price readjustments necessary for the financial balance of the contracts and the recomposition of the average ticket. This strategy more than offset a slight drop in the number of beneficiaries, the reduction in Medical and Hospital Services Revenue and the discontinuation of other lines of business in Other Activities.

(R$ million)	2Q24	1Q24	Var. % 2Q24/1Q24	2Q23	Var. % 2Q24/2Q23	1H24	1H23	Var. % 1H24/1H23
Health Plans	6,983.3	6,863.5	1.7%	6,645.5	5.1%	13,846.8	13,137.3	5.4%
Dental Plans	215.0	214.7	0.2%	206.0	4.4%	429.7	412.4	4.2%
Hospital Services	246.8	218.5	13.0%	294.3	-16.1%	465.3	585.2	-20.5%
Other Activities	-	-	n/a	45.0	-100.0%	-	115.3	-100.0%
Gross Revenue	**7,445.1**	**7,296.7**	**2.0%**	**7,190.9**	**3.5%**	**14,741.7**	**14,250.2**	**3.4%**
Deductions	(294.7)	(305.2)	-3.4%	(351.0)	-16.1%	(599.9)	(684.2)	-12.3%
Net Revenue	**7,150.4**	**6,991.4**	**2.3%**	**6,839.8**	**4.5%**	**14,141.8**	**13,566.0**	**4.2%**

HEALTH PLANS

Net revenue from Health Plans totaled R$6,983.3 million in 2Q24, growth of 5.1% compared to 2Q23 as a result of an increase in the average monthly ticket that went from R$245.0 in 2Q23 to R$267.4 in 2Q24.

Beneficiaries





In 2Q24, we had a net reduction of 12.8 thousand beneficiaries in health plans compared to 1Q24. The main impacts for the quarter are:

- Addition of 492.6 thousand beneficiaries, as a result of robust gross sales (261.1k Corporate, 109.0k SME and 122.5k Individual);
- Drop of 460.4 thousand beneficiaries, reflecting the reduction of loss-making contracts, as well as the processes of optimization, verticalization, and regulation of the accredited network of providers (228.3k Corporate, 118.4k SME and 113.6k Individual/Affinity); and
- Net loss of 45.0 thousand lives due to negative turnover (net dismissals and admissions within existing corporate contracts).

At the end of 2Q24, the company had 401.1 thousand beneficiaries in preferred provider organization plans (PPO), a net reduction of 17.8k thousand compared to 1Q24, due to our strategy to rationalize this portfolio.

HEALTH PLANS

Average Ticket

In 2Q24, the consolidated average health ticket increased by 9.1% between 2Q23 and 2Q24, reflecting the strategy of repricing and reviewing the client portfolio. The main impacts on the average ticket over the quarters are:

- +9.6% of Net Price, represented by the necessary adjustments to existing contracts, already net of the effects of product changes with increased vertical integration and co-participation; and
- -0.5% net negative impact of the mix of sales and cancellations, due to the loss of customers with higher average ticket but higher MLR, being replaced by new customers with a lower average ticket but expected lower MLR.

Average Ticket Breakdown
(R$/month)



Average Ticket Evolution
(R$/month)



DENTAL PLANS

In 2Q24, revenue from Dental Plans reached R$215.0 million, an increase of 4.4% compared to 2Q23, driven by an increase in the average monthly ticket (from R$9.8 in 2Q23 to R$10.3 in 2Q24), more than offsetting the reduction of 207.3 thousand lives in the period. The Cash Dental Loss Ratio (DLR) remains under control year after year, allowing for lower price adjustments.

Dental Beneficiaries Evolution
(thousand; EoP)



Average Ticket Evolution
(R$/month)



Hospital Services & Other Activities

In 2Q24, revenue from Hospital Services and Other Activities reached R$246.8 million, a reduction of 27.3% compared to 2Q23, mainly due to:

- Decrease of **R$47.5 million** in Hospital Services, reflecting the lower demand in the quarter, as well as our more selective approach in offering services to third parties, reducing our exposure to credit risk; and
- A reduction of **R$45.0 million** in Other Activities due to the divestments of São Francisco Resgate, Maida Health and ou occupational health business.



MEDICAL COSTS AND CASH MLR

Total cost of services comprises Cash Medical Losses, Depreciation and Amortization (D&A), Incurred But Not Reported (IBNR) provisions and SUS Reimbursement provisions, as detailed below:

(R$ million)	2Q24	1Q24	Var. % 2Q24/1Q24	2Q23	Var. % 2Q24/2Q23	1H24	1H23	Var. % 1H24/1H23
IBNR	(37.7)	1.0	*n/a*	28.8	*n/a*	(36.7)	27.0	*n/a*
SUS Reimbursement	58.1	52.3	*11.0%*	42.8	*35.8%*	110.5	120.7	*-8.5%*
Depreciation and Amortization	103.8	112.3	*-7.5%*	102.5	*1.3%*	216.1	213.0	*1.4%*
Cash Medical Losses	5,037.7	4,751.4	*6.0%*	5,055.2	*-0.3%*	9,789.1	9,915.2	*-1.3%*
Cash MLR	*70.5%*	*68.0%*	*2.5pp*	*73.9%*	*-3.4pp*	*69.2%*	*73.1%*	*-3.9pp*
Total Medical Costs	**5,162.7**	**4,917.6**	***5.0%***	**5,230.0**	***-1.3%***	**10,079.7**	**10,276.7**	***-1.9%***

Highlights for 2Q24 are:

- **R$37.7 million** of IBNR reversal, reflecting the continuity of strategies to increase verticalization, especially in the South and Southeast regions, a better mix of new sales concentrated in more vertical products, as well as the improvement in the profile of the cost of care in the accredited network; and
- **R$58.1 million** of SUS provision, an increase of R$15.3 million vs. 2Q23, according to the receipt of charges and invoices presented by the Brazilian regulatory agency ANS.

Cash MLR

Cash Medical Losses is the most important item in the cost of services provided and reflect the actual cost of care. Cash Medical Loss Ratio (Cash MLR) is the total Cash Medical Losses divided by Revenues. As such, Cash MLR is affected by cost control initiatives, increases or decreases in the level of utilization, verticalization and seasonality of the business.



In 2Q24, Cash MLR was 70.5%, a significant improvement of 3.4 p.p. compared to 2Q23, and an increase of 2.5 p.p. compared to 1Q24. The increase compared to 1Q24 reflects the seasonal increase in the segment's usage, including emergency consultations, exams and hospitals admissions related to the viruses typical of this period, as well as fewer holidays. Exceptionally this year, there was a significant increase in dengue fever in some regions.

Cash MLR went from 73.1% in 1H23 to 69.2% in 1H24, a reduction of 3.9 p.p., positively overcoming the seasonality implicit for these periods and reflecting the various successful margin recovery strategies developed since the beginning of 2023. In addition to initiatives to review prices and increase the sale of more verticalized products, the company has been working intensely on increasing verticalization, standardizing protocols, optimizing the network of providers and on cost control and management measures.

In 2Q24, HMO plans (HMO) reached levels of verticalization (carried out within our Own Network) of 81.8% for consultations and 78.7% for daily admissions. This increase translates into fairer prices and less exposure to the accredited network of providers.



ADMINISTRATIVE & SALES EXPENSES

Sales, General & Administrative Cash Expenses – Cash SG&A for 2Q24 amounted to R$1,134.3 million or 15.9% NOR, a reduction of 0.3p.p. and 0.9p.p. compared to 2Q23 and 1Q24, respectively.

Administrative & Sales Expenses
(R$ million; % NOR)



Administrative Cash Expenses

(R$ million)	2Q23	3Q23	4Q23	1Q24	2Q24	Var. R$ 2Q24/1Q24
Personnel	283.2	287.8	237.8	257.9	273.9	*16.0*
Third Party Services	171.5	190.3	165.3	194.0	161.1	*(33.0)*
Occupation and Utilities	72.7	72.6	93.9	68.3	77.1	*8.7*
Contingencies & Taxes	118.9	96.6	122.1	117.7	154.8	*37.1*
Other (revenue)/expenses	(21.4)	(32.4)	(12.9)	(14.0)	(28.5)	*(14.5)*
Cash G&A	**624.8**	**614.9**	**606.3**	**624.0**	**638.3**	**14.3**
%NOR	*9.1%*	*8.9%*	*8.7%*	*8.9%*	*8.9%*	*0.0%*

In 2Q24, Administrative Cash Expenses totaled R$638.3 million, an increase of R$14.3 million compared to 1Q24. The main favorable impacts were:

- **R$33.0 million** from Third Party Services, of which: (i) R$8.9 million from capitalization of investments in technology and (ii) R$6.5 million from reclassification of expenses to cost in line with accounting practices, both referring to previous periods. Additionally, in 1Q24 the item was negatively impacted by R$14.2 million in IT expenses related to the implementation and system integration process, affecting comparability; and
- **R$14.5 million** in Other (income)/expenses, where the company was able to renegotiate and settle in advance the installments withheld (escrow) from the acquisitions of Medical and Hospital do Coração de Camboriú, generating gains of R$7.5 million and R$3.6 million, respectively.

The main unfavorable impacts were:

- **R$37.1 million** in Contingencies and Taxes due to: (i) R$12.9 million in contingencies from acquired companies and (ii) an incremental R$8.6 million from unfavorable outcomes for the company. Additionally, in 1Q24 the item was positively impacted by R$4.5 million in judicial deposits, which were reversed in 2Q24, affecting comparability by R$9.0 million;
- **R$8.7 million** from Location and Operation, due to an increase in expenses with utilities, travel and accommodation expenses and IT infrastructure expenses to accommodate new systems; and
- **R$16.0 million** net in Personnel, impacted mainly by the receipt of R$8.1 million in accumulated rebates from benefit plans in previous periods.

Personnel Expenses Evolution(1)
(R$ million)



(1) For comparative purposes, 1Q24 benefited from the additional reversal of the 2023 bonus and the reclassification of the 2023 bonus to cost and expenses.

ADMINISTRATIVE & SALES EXPENSES

Sales Expenses

(R$ million)	2Q23	3Q23	4Q23	1Q24	2Q24	Var. R$ 2Q24/1Q24
Commission	306.0	334.9	332.1	315.8	314.3	*(1.5)*
Provision for credit losses	126.0	131.2	138.9	170.7	104.5	*(66.1)*
Marketing & Advertise	11.3	20.0	25.1	12.5	23.9	*11.4*
Personnel	34.3	33.4	43.1	43.6	42.1	*(1.5)*
Other expenses	4.4	11.7	10.9	8.7	11.1	*2.5*
Sales Expenses	**482.0**	**531.2**	**550.0**	**551.2**	**496.0**	**(55.2)**
%NOR	*7.0%*	*7.7%*	*7.9%*	*7.9%*	*6.9%*	*-0.9%*

In 2Q24, Sales Expenses totaled R$496.0 million, R$55.2 million lower than 1Q24, mainly due to the favorable impact of:

- **R$66.1 million** in Provision for Credit Losses (PDD), of which (i) R$15.0 million was from extraordinary collections resulting from a major campaign focused especially on SME and Individual clients, which resulted in a reduction in delinquency levels and, consequently, lower provisions in the quarter; and (ii) R$20.0 million related to reconciliation and bank reconciliation of receipts made in previous years. Additionally, in 1Q24, R$32.2 million was provisioned on a one-off basis due to the adoption of additional parameters relating to IFRS 9, an amount that was not repeated in 2Q24, affecting comparability.

And it was partially offset by:

- **R$11.4 million** increase in Marketing & Advertisement expenses, reflecting the national and regional institutional campaigns carried out between March and May in the markets that are the focus of customer growth and retention.

The Sales Expenses ratio (as a percentage of Net Revenues) remained practically stable when compared to 2Q23.

ADJUSTED EBITDA

Adjusted EBITDA[1] was R$957.9 million in 2Q24 (13.4% NOR) and R$1,969.5 million (13.9% NOR) in 1H24, an increase of 58.0% and 58.7% compared to 2Q23 and 1H23, respectively.

Adjusted EBITDA
(R$ million; %NOR)



Adjusted EBITDA performance and margin expansion in 2Q24 were mainly due to:

- An increase in net revenue, reflecting effective contract price adjustments, necessary for the financial rebalancing of the portfolio, more than offsetting the slight reduction in the beneficiary base and the discontinuation of non-core activities; and
- Reduction in Cash MLR, due to intense efforts to increase verticalization and control costs.

ADJUSTED NET INCOME

Adjusted Net Income[2] totaled R$490.2 million in 2Q24, an increase of R$268.6 million compared to 2Q23 and a reduction of R$16.6 million compared to 1Q24.

Adjusted Net Income
(R$ million; %NOR)



(R$ million)	2Q24	1Q24	Var. % 2Q24/1Q24	2Q23	Var. % 2Q24/2Q23	1H24	1H23	Var. % 1H24/1H23
Net Income (Losses)	**90.5**	**83.3**	*8.6%*	**(161.1)**	*n/a*	**173.8**	**(502.7)**	*n/a*
(+) Long term Incentive Plan (LTIP) and SOP	30.5	41.9	*-27.2%*	8.6	*253.7%*	72.3	46.8	*54.4%*
(+) Intangible Amortization	369.3	369.4	*0.0%*	374.1	*-1.3%*	738.7	710.5	*4.0%*
(+) Non-recurring expenses	-	12.3	*-100.0%*	-	*n/a*	12.3	-	*n/a*
Adjusted Net Income	**490.3**	**506.8**	***-3.3%***	**221.6**	***121.2%***	**997.1**	**254.7**	***291.6%***
(+) Income tax and social contribution	58.9	74.0	*-20.4%*	(21.0)	*n/a*	133.0	(16.2)	*n/a*
(+) Financial result	231.4	256.2	*-9.7%*	246.9	*-6.3%*	487.6	677.0	*-28.0%*
(+) Depreciation and Amortization	177.3	174.5	*1.6%*	158.7	*11.8%*	351.8	325.3	*8.2%*
Adjusted EBITDA	**957.9**	**1,011.6**	***-5.3%***	**606.2**	***58.0%***	**1,969.5**	**1,240.7**	***58.7%***
%NOR	*13.4%*	*14.5%*	*-1.1pp*	*8.9%*	*4.5pp*	*13.9%*	*9.1%*	*4.8pp*

(1) Adjusted EBITDA for Long-Term Incentive Plan (LTIP) expenses, Stock Option Plan (SOP), and non-recurring expenses
(2) Adjusted Net Income for Long-Term Incentive Plan (LTIP) expenses, Stock Option Plan (SOP), non-recurring expenses, and amortization of goodwill

FINANCIAL RESULT

Net Financial Result was an expense of R$231.4 million in 2Q24 and R$487.6 million in 1H24, a significant improvement of R$189.3 million compared to 1H23, reflecting the effects of robust cash generation, efficient and rational allocation, as well as the ongoing process of reducing our weighted cost of debt.

(R$ million)	2Q24	1Q24	Var. % 2Q24/1Q24	2Q23	Var. % 2Q24/2Q23	1H24	1H23	Var. % 1H24/1H23
Income from investments	200.2	186.3	*7.5%*	204.0	*-1.9%*	386.5	315.5	*22.5%*
Late payments penalties	28.9	29.2	*-0.9%*	28.7	*0.8%*	58.1	57.1	*1.7%*
Indexation credits - SUS	16.0	16.3	*-1.8%*	18.6	*-13.8%*	32.3	40.2	*-19.6%*
Indexation credits - Other	18.7	18.2	*3.0%*	27.6	*-32.2%*	36.9	46.8	*-21.0%*
Derivative instruments	23.8	19.0	*25.5%*	61.3	*-61.1%*	42.8	61.7	*-30.5%*
Exchange Revenue	-	-	*n/a*	13.4	*-100.0%*	-	17.1	*-100.0%*
Other financial revenues	3.5	6.6	*-47.2%*	0.8	*338.0%*	10.1	9.7	*4.4%*
Financial Revenues	**291.2**	**275.6**	***5.7%***	**354.4**	***-17.8%***	**566.8**	**548.0**	***3.4%***
Interest on debentures and loans	(351.7)	(344.6)	*2.1%*	(413.5)	*-14.9%*	(696.3)	(815.8)	*-14.7%*
Interest on leases	(79.5)	(80.5)	*-1.3%*	(68.8)	*15.5%*	(160.0)	(120.3)	*33.0%*
Indexation charges - Other	(75.0)	(85.5)	*-12.2%*	(100.7)	*-25.5%*	(160.5)	(208.7)	*-23.1%*
Derivative instruments - Equity	-	-	*n/a*	(0.3)	*-100.0%*	-	(19.8)	*-100.0%*
Bank expenses	(8.1)	(8.4)	*-3.4%*	(11.0)	*-26.1%*	(16.5)	(22.2)	*-25.5%*
Charges on Interest on Equity Received	-	-	*n/a*	-	*n/a*	-	-	*n/a*
Other finance expenses	(8.3)	(12.9)	*-35.6%*	(7.1)	*17.5%*	(21.2)	(38.2)	*-44.6%*
Financial Expenses	**(522.6)**	**(531.8)**	***-1.7%***	**(601.4)**	***-13.1%***	**(1,054.4)**	**(1,225.0)**	***-13.9%***
Net Financial Result	**(231.4)**	**(256.2)**	***-9.7%***	**(246.9)**	***-6.3%***	**(487.6)**	**(677.0)**	***-28.0%***

Financial Revenue in 2Q24 increased by R$15.6 million compared to 1Q24, from R$275.6 million to R$291.2 million. This growth is mainly due to the increase in the company's average cash position.

Financial Expenses went from R$531.8 million in 1Q24 to R$522.6 million in 2Q24, a reduction of R$9.2 million explained by:

- **R$10.4 million** in monetary restatements, of which (i) R$7.0 million in SUS charges, in line with data received from ANS; and (ii) R$3.4 million on the escrow accounts of acquired companies.

And partially offset by a R$7.1 million charge due to the increase in the Company's gross debt.

INCOME TAXES



The consolidated Income Taxes line is the result of the individual assessment of the companies controlled by the Company, including the holding company, which may show a profit or loss in certain periods, as well as the effects of eliminations and consolidations. This means that there may be a negative tax rate on a consolidated basis, but positive current income tax rates when looked at the subsidiaries individually, for example.

(R$ million)	Operational	Controlling	Consolidated
Current	(193.5)	-	(193.5)
Deferred	(274.9)	335.5	60.6

Current Tax - Operating



In 1H24, the Operating entities had Current Tax of R$193.5 million, of which R$147.7 million from the NDI vertical and R$45.8 million from the Hapvida vertical, mainly because of better operating performance.

The main current tax reducers in the period were the tax amortization of goodwill and capital gains from merged acquisitions (R$302.3 million) and the tax loss consumption (R$46.4 million).

Deferred Tax - Operating

In 1H24, Hapvida Participações e Investimentos S.A. (parent holding company) generated R$335.5 million in deferred tax assets, of which R$221.2 million in deferred tax on tax losses and R$131.7 million on value-added from the business combination with NotreDame Intermédica, which will be used after the incorporation of the operating entities.

CASH FLOW

Net cash went from R$7,757.5 million in March'24 to R$8,345.0 million in June'24, an increase of R$587.4 million mainly due to: (i) R$307.4 million from Free Cash Flow generation, (ii) R$1.0 billion raised (7th issue of debentures) and (iii) R$200.2 million from income on financial investments, partially offset by the payments of (iv) R$396.5 million in retained M&A installments and (v) R$517.8 million in interest.

Free Cash Flow



Free Cash Flow was positive at R$307.4 million and Cash Generation was R$539.2 million, representing 56.3% of 2Q24 Adjusted EBITDA. The main uses of cash include:

- **R$195.1 million** in deposits and judicial blockages, which mainly arise from: (i) cases related to SUS reimbursement, whose deposits are necessary for the Company to carry out its judicial defense without incurring late payment fines and charges, and (ii) civil cases, whose deposits and blockages are procedural reflections of the growing judicialization in the sector;
- **R$53.8 million** increase in receivables from medical and hospital services' clients;
- **R$50.0 million** in IRPF and INSS disbursements related to the payment of the 2023 variable compensation in 1Q24;
- **R$46.7 million** in tax credits, although the Current Tax was R$84.5 million, there is a displacement between calculation and actual disbursement; and
- **R$185.1 million** in CapEx, showing a gradual return to historical levels of investment, mainly in IT.

M&A Activities



M&A activities consumed R$396.5 million, mainly explained by the disbursements of:

- **R$269.1 million** from the release of the retained portion of the acquisition of Grupo São Francisco;
- **R$90.0 million** corresponding to the initial installment of the agreement with the seller of NotreDame Intermédica (a transaction that took place in 2014). The agreement also provides for monthly installments of R$15 million until Nov'25 and a final installment of R$11 million in Dec'25, totaling R$356 million; and
- **R$37.4 million** in payments of installments withheld from acquisitions made by the Company:
  - R$19.3 million, from Medical; R$14.2 million, from H. do Coração de Camboriú; R$3.1 million, from BeloDente; and R$0.8 million, from Ecoimagem.

Financing Activities



Financial Activities in 2Q24 generated R$676.5 million, mainly explained by:

- **R$994.1 million** raised from the 7th issue of debentures in May'24; and
- **R$200.2 million** in Financial Revenue, a return of 2.6% on the company's average cash, above the CDI rate for the period.

And partially offset by:

- **R$517.8 million** in interest payments.

NET DEBT

Net Debt was R$4,348.4 million at quarter end (equivalent to 1.03x EBITDA - contractual covenant), a reduction from R$4,392.3 million (equivalent to 1.13x EBITDA - contractual covenant) in 1Q24, mainly as a result of cash generation and an increase in LTM EBITDA from R$3,876.2 million in 1Q24 to R$4,206.4 million in 2Q24.



Net Debt/EBITDA LTM calculation according to contractual covenants:

(R$ million)	2Q24	1Q24	Var. R$	Var. %
Loans, financing and debentures	11,761.3	10,933.9	*827.5*	*7.6%*
Installments retained from acquired companies	829.2	1,143.7	*(314.5)*	*-27.5%*
Derivative financial instruments	102.7	72.2	*30.6*	*42.3%*
Gross Debt	**12,693.3**	**12,149.8**	***543.5***	***4.5%***
(-) Cash and cash equivalents and Investments	(8,345.0)	(7,757.5)	*(587.4)*	*7.6%*
Net Debt	**4,348.4**	**4,392.3**	***(43.9)***	***-1.0%***
EBITDA LTM[1]	4,206.5	3,876.2	*330.3*	*8.5%*
Net Debt/ EBITDA LTM	**1.03x**	**1.13x**	***-0.10x***	***-8.8%***

DEBT

At quarter end compared to 1Q24, debt duration increased from 3.2 years to 3.3 years (due to newly issued debt) and the average cost of debt fell from CDI+1.41% p.a. to CDI+1.32% p.a. (due to changes in the long-term yield curve).

In May'24, the 7th issue of debentures was concluded in the amount of R$1.0 billion, at a cost of CDI+1.60% per year and maturing in 2031 (amortizations in 2029/30/31).

Below is the current debt amortization schedule (Loans, Financing and Debentures)





(1) LTM EBITDA comprises Adjusted EBITDA without the effect of provisions for impairment of accounts receivable

REGULATORY REQUIREMENTS

Technical Provisions

Free cash went from R$4,819.3 million in 1Q24 to R$5,479.7 million at quarter end, an increase of R$660.4 million.

(R$ million)	2Q24	1Q24	Var. R$ 2Q24/1Q24	2Q23	Var. R$ 2Q24/2Q23
Required Technical Provisions	**(3,131.4)**	**(3,056.4)**	***(75.0)***	**(3,157.4)**	***26.0***
(-) SUS Provisions (net of judicial deposits)	(1,130.8)	(1,042.4)	*(88.4)*	(1,395.2)	*264.4*
(-) IBNR Provision	(953.6)	(991.2)	*37.7*	(1,039.3)	*85.8*
(-) Outstanding claims reserve	(1,044.0)	(1,019.5)	*(24.5)*	(718.9)	*(325.1)*
(-) Reserve for benefit granted	(3.0)	(3.2)	*0.2*	(4.0)	*1.0*
Assets	**8,611.1**	**7,875.7**	***735.4***	**7,538.3**	***1,072.9***
(+) Cash and financial investments	8,345.0	7,757.5	*587.4*	7,417.8	*927.2*
(+) Real estate pledged	266.2	118.2	*148.0*	120.5	*145.7*
Free Cash	**5,479.7**	**4,819.3**	***660.4***	**4,380.9**	***1,098.8***

Required Technical Provisions went from R$3,056.4 million in 1Q24 to R$3,131.4 million in 2Q24, an increase of R$75.0 million due mainly to (i) a reduction in the adjustments to the SUS reimbursement provisions in accordance with ANS rules and (ii) an increase in medical costs received at the end of the quarter (claims payable provision).

Assets increased by R$735.4 million, of which (i) R$587.4 million was due to the net increase in cash and financial investments and (ii) R$148.0 million was due to the inclusion of additional hospitals' real estate pledged.

Regulatory Capital

At quarter end, all the group's healthcare operators had a Regulatory Capital (RC) requirement surplus, totaling R$3,136.9 million (simple sum of the operators), an increase of R$1,213.7 million compared to 1Q24.



Risk-based Capital increased by R$228.5 million, from R$4,105.2 million in 1Q24 to R$4,333.6 million in 2Q24, of which (i) R$135.6 million came from the incorporation of BCBF Participações by the operator NDI Saúde and (ii) R$92.9 million was due to the nominal increases in Revenue and MLR from the operators' recurring activities.

Adjusted Shareholders' Equity went from R$6,028.3 million in 1Q24 to R$7,470.5 million in 2Q24, an increase of R$1,442.1 million, mainly due to the favorable effects of

- **R$1,060.6 million** capital increase, net of HAM's hedge accounting (R$51.4 million); and
- **R$675.5 million** in net income for operators.

Partially offset by:

- **R$138.7 million** in Intangible Assets, mainly due to investments in technology; and
- **R$142.4 million** from the net effects of the incorporation of BCBF by NDI Saúde, which had a negative impact on R$3,317.1 million by increasing the stakes in operators and Intangible Assets, partially offset by the increase of R$3,174.7 million in the Operator's Shareholders' Equity (NDI Saúde).

(1) Represents the sum of the individual operators' Outstanding claims reserve before consolidations and eliminations

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

DISCLAIMER

Hapvida Participações e Investimentos S.A. informs its shareholders and the market in general that the financial information contained in this document derives from the audited financial statements, relating to six months period ended on June, 2024, prepared in accordance with IFRS 4 – Contracts of Insurance, internalized in Brazil by CPC 11, which were disclosed, on an extraordinary basis, for the purposes of monitoring business performance and comparability between periods. Therefore, this financial information does not consider the accounting standard currently in force, IFRS 17 – Insurance Contracts, internalized in Brazil by CPC 50, which must be considered for all purposes of applicable legislation and regulations, and which will result in financial information different from that presented in this material.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Audit Committee's Opinion on the parent company and consolidated interim statements for the period ended June 30, 2024

The Audit Committee of Hapvida Participações e Investimentos S.A., in compliance with legal and statutory provisions, reviewed the parent company and consolidated interim statements for the period ended June 30, 2024, accompanied by the Independent Auditor's Quarterly Information Review Report of PricewaterhouseCoopers Auditores Independentes Ltda., and based on the activities, information and clarifications received during the period, unanimously issued its opinion that the aforementioned documents fairly reflect, in their material aspects, the financial situation of the Company and its subsidiaries as of June 30, 2024 and are in a position to be submitted for consideration by the Board of Directors.

Fortaleza, August 8, 2024.

Audit Committee	
Coordinator	José Luis Camargo Junior
Member	Luiz Pereira Gomes Júnior
Member	Maria Paula Soares Aranha
Member	Wagner Aparecido Mardegan
Member	Wanderbilt Cavalcante Maia

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Supervisory Board's Opinion on the parent company and consolidated interim financial statements

The Supervisory Board of Hapvida Participações e Investimentos S.A., in compliance with legal and statutory provisions, reviewed the parent company and consolidated interim financial statements for the period ended June 30, 2024, accompanied by the Independent Auditor's Quarterly Information Review Report of PricewaterhouseCoopers Auditores Independentes Ltda., and based on the activities, information and clarifications received during the period, unanimously did not oppose the disclosure of the respective individual and consolidated interim financial statements of the Company and its subsidiaries as of June 30, 2024.

Fortaleza, August 8, 2024.

Supervisory Board	
Member	Ademir José Scarpin
Member	Heloisa Helena Silva de Oliveira
Member	Armando Lima Caminha Filho
Alternate Board Member	Rosangela Costa Suffert
Alternate Board Member	Adelino Dias Pinho

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Statement of the Executive Officers on the parent company and consolidated interim statements for the period ended June 30, 2024

Pursuant to Article 27, Paragraph One, item VI of CVM Resolution 80/22, the officers responsible for preparing the respective parent company and consolidated interim statements of the Company and its subsidiaries hereby declare that they have reviewed, discussed and agreed with the parent company and consolidated interim statements for the period ended June 30, 2024.

Fortaleza, August 8, 2024.

Jorge Fontoura Pinheiro Koren de Lima
President

Luccas Augusto Adib
Vice-President and Chief Finance and Investor Relations Officer

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Statement of the Executive Officers Report on the review of quarterly information

Pursuant to Article 27, Paragraph One, item V of CVM Resolution 80/22, the officers responsible for preparing the respective parent company and consolidated interim statements of the Company and its subsidiaries hereby declare that they have reviewed, discussed and agreed with the opinions expressed in Review Report of the Independent Auditors' quarterly information of the Company and its subsidiaries, issued by PricewaterhouseCoopers Auditores Independentes Ltda., regarding the parent company and consolidated interim financial statements for period ended June 30, 2024.

Fortaleza, August 8, 2024.

Jorge Fontoura Pinheiro Koren de Lima
President

Luccas Augusto Adib
Vice-President and Chief Finance and Investor Relations Officer

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

(A free translation of the original in Portuguese)

Report on review of parent company and consolidated interim financial statements

To the Board of Directors and Stockholders
Hapvida Participações e Investimentos S.A.

Introduction

We have reviewed the accompanying interim statement of financial position of Hapvida Participações e Investimentos S.A. ("Company") as at June 30, 2024 and the related statements of profit or loss and comprehensive income for the quarter and six-month period then ended, and the statements of changes in equity and cash flows for the six-month period then ended, as well as the accompanying consolidated statement of financial position of Hapvida Participações e Investimentos S.A. and its subsidiaries ("Consolidated") as at June 30, 2024 and the related consolidated statements of profit or loss and comprehensive income for the quarter and six-month period then ended, and the consolidated statements of changes in equity and cash flows for the six-month period then ended, and notes, comprising material accounting policies and other explanatory information.

Management is responsible for the preparation and fair presentation of these parent company and consolidated interim financial statements in accordance with the accounting standard CPC 21 - "Interim Financial Reporting", of the Brazilian Accounting Pronouncements Committee (CPC), and International Accounting Standard (IAS) 34 - "Interim Financial Reporting", issued by the International Accounting Standards Board (IASB). Our responsibility is to express a conclusion on these interim financial statements based on our review.

Scope of review

We conducted our review in accordance with Brazilian and International Standards on Reviews of Interim Financial Information (NBC TR 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", and ISRE 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", respectively). A review of interim information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Brazilian and International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

PricewaterhouseCoopers Auditores Independentes Ltda., Av. Desembargador Moreira, 1300, Sala 1513,
Torre Norte, BS Design Corporate Towers, Fortaleza, CE, Brasil, 60170-002
T: 4004-8000, www.pwc.com.br

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Hapvida Participações e Investimentos S.A.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying parent company and consolidated interim financial statements referred to above do not present fairly, in all material respects, the financial position of Hapvida Participações e Investimentos S.A. and of Hapvida Participações e Investimentos S.A. and its subsidiaries as at June 30, 2024, the financial performance for the quarter and six-month period then ended and the cash flows for the six-month period then ended, and the consolidated financial performance for the quarter and six-month period then ended and the consolidated cash flows for the six-month period then ended, in accordance with the accounting standard CPC 21 - "Interim Financial Reporting", and with the International Accounting Standard (IAS) 34 - "Interim Financial Reporting" issued by the International Accounting Standards Board (IASB).

Emphasis of matter

Corresponding figures for comparison purposes

We draw attention to Note 2.3 to the parent company and consolidated interim financial statements which, due to the adoption of Technical Pronouncement CPC 50 - "Insurance Contracts", presents the corresponding parent company and consolidated amounts for the period ended June 30, 2023 for comparison purposes. These amounts were adjusted and are being restated as provided for in Technical Pronouncement CPC 23 - "Accounting Policies, Changes in Accounting Estimates and Errors". Our conclusion is not modified in respect of this matter.

Other matters

Statements of value added

The interim financial statements referred to above include the parent company and consolidated statements of value added for the six-month period ended June 30, 2024. These statements are the responsibility of the Company's management and are presented as supplementary information under IAS 34. These statements have been subjected to review procedures performed together with the review of the interim financial statements for the purpose of concluding whether they are reconciled with the interim financial statements and accounting records, as applicable, and if their form and content are in accordance with the criteria defined in the accounting standard CPC 09 - "Statement of Value Added". Based on our review, nothing has come to our attention that causes us to believe that these statements of value added have not been properly prepared, in all material respects, in accordance with the criteria defined in this accounting standard and consistently with the parent company and consolidated interim financial statements taken as a whole.

Fortaleza, August 8, 2024

PricewaterhouseCoopers
Auditores Independentes Ltda.
CRC 2CE003292/F-9

DocuSigned by
Signed By: VINICIUS FERREIRA BRITTO REGO:92933610515
CPF: 92933610515
Signing Time: 14 de agosto de 2024 | 18:57 BRT
O: ICP-Brasil, OU: Secretaria da Receita Federal do Brasil - RFB
C: BR
Issuer: AC SERASA RFB v5
5DBCCF00B7834A4...

Vinicius Ferreira Britto Rego
Contador CRC 1BA024501/O-9

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Hapvida Participações e Investimentos S.A.

Statements of Financial Position at June 30, 2024 and December 31, 2023

(Amounts expressed in thousands of reais)

		Parent Company		Consolidated	
Current assets	**Notes**	**06/30/2024**	**12/31/2023**	**06/30/2024**	**12/31/2023**
Cash and cash equivalents	34.(iii).d	6,663	857,991	419,682	1,430,144
Short and long term investments	10	9,105	226,979	7,371,940	5,573,479
Trade accounts receivable	11	-	-	536,592	475,733
Insurance contract assets	18	-	-	115,805	153,693
Inventories		-	-	403,939	318,605
Recoverable taxes	12	172,651	203,423	814,025	835,057
Other assets	14	13,192	13,114	437,295	379,989
		201,611	**1,301,507**	**10,099,278**	**9,166,700**
Net assets of subsidiaries intended for sale		-	-	-	14,880
Total current assets		**201,611**	**1,301,507**	**10,099,278**	**9,181,580**
Short and long term investments	10	141	133	553,331	886,276
Deferred tax assets	33.b	1,416,984	1,167,069	4,133,328	3,590,915
Judicial deposits	23	10,978	10,689	2,575,578	2,226,206
Derivative financial instruments	34	-	-	12,154	772
Other credits with related parties	13	940	1,688	3,289	5,219
Other assets	14	6,185	8,585	125,880	121,774
Total long-term assets		**1,435,228**	**1,188,164**	**7,403,560**	**6,831,162**
Investments	15	57,432,048	56,467,389	4,728	5,518
Property, plant and equipment	16	4,073	4,363	6,756,877	6,882,558
Intangible assets	17	1	2	49,931,242	50,285,327
Total non-current assets		**58,871,350**	**57,659,918**	**64,096,407**	**64,004,565**
Total assets		**59,072,961**	**58,961,425**	**74,195,685**	**73,186,145**

		Parent Company		Consolidated	
Liabilities and equity	**Notes**	**06/30/2024**	**12/31/2023**	**06/30/2024**	**12/31/2023**
Loans, financing and debentures	19	955,070	1,800,299	1,274,341	2,109,941
Suppliers		2,841	2,241	350,644	317,861
Insurance contract liabilities	18	-	-	3,134,110	2,165,974
Debits from health care operations		-	-	54,926	-
Social security charges	21	37,329	1,545	909,289	657,640
Taxes and contributions payable	22	16,757	20,145	430,213	467,460
Income tax and social contribution	33.a	-	-	60,569	28,261
Dividends and interest on shareholders' equity payable	13 e 25.c	2,552	2,552	12,629	12,629
Leases payable	20	15	1	480,616	475,179
Derivative financial instruments	34	-	-	114,898	25,088
Other debits with related parties	13	242,720	224,261	4,018	5,737
Other accounts payable	24	100,228	22,251	444,105	406,911
Total current liabilities		**1,357,512**	**2,073,295**	**7,270,358**	**6,672,681**
Loans, financing and debentures	19	8,939,866	7,610,115	10,486,984	9,416,473
Suppliers		-	-	3,261	-
Taxes and contributions payable	22	-	-	141,911	161,394
Leases payable	20	153	167	2,842,607	2,862,830
Deferred tax liabilities	33.b	-	-	2,071,260	1,841,538
Provision for tax, civil and labor risks	23	2,170	2,074	1,314,933	1,267,316
Derivative financial instruments	34	-	-	-	24,100
Other accounts payable	24	18,700	22,000	1,307,008	1,684,670
Total non-current liabilities		**8,960,889**	**7,634,356**	**18,167,964**	**17,258,321**
Equity	**25**				
Share capital		38,866,199	38,866,199	38,866,199	38,866,199
Treasury shares		(423,099)	(451,967)	(423,099)	(451,967)
Capital reserve		9,771,190	9,892,386	9,771,190	9,892,386
Legal reserve		201,486	201,486	201,486	201,486
Profit reserves		761,472	761,472	761,472	761,472
Other comprehensive income		(106,613)	(15,802)	(106,613)	(15,802)
Retained earnings/(losses) in the period		(316,075)	-	(316,075)	-
Equity attributable to controlling shareholders		**48,754,560**	**49,253,774**	**48,754,560**	**49,253,774**
Non-controlling interest		-	-	2,803	1,369
Total equity		**48,754,560**	**49,253,774**	**48,757,363**	**49,255,143**
Total liabilities and equity		**59,072,961**	**58,961,425**	**74,195,685**	**73,186,145**

See the accompanying notes to the parent company and consolidated interim statements.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Hapvida Participações e Investimentos S.A.

Statements of profit or loss

Periods ended June 30, 2024 and June 30, 2023

(Amounts expressed in thousands of reais)

		Parent Company				Consolidated			
		Accumulated	Quarter	Accumulated	Quarter	Accumulated	Quarter	Accumulated	Quarter
	Notes	06/30/2024	06/30/2024	06/30/2023 (Restated)	06/30/2023 (Restated)	06/30/2024	06/30/2024	06/30/2023 (Restated)	06/30/2023 (Restated)
Insurance revenue	27	-	-	-	-	13,385,339	6,405,434	13,045,176	6,549,578
Insurance expense	27	-	-	-	-	(12,011,436)	(6,176,796)	(11,342,423)	(5,722,389)
Net operating revenue	28	-	-	-	-	384,641	208,460	490,678	251,077
Costs of services rendered	29	-	-	-	-	(614,945)	(287,198)	(1,117,210)	(544,184)
Gross income		**-**	**-**	**-**	**-**	**1,143,599**	**149,900**	**1,076,221**	**534,082**
Sales expenses	30	(247)	(247)	(626)	(27)	(151,014)	(82,310)	(117,171)	(60,136)
Administrative expenses	31	(261,688)	(110,865)	(189,343)	(101,438)	(839,505)	(407,213)	(828,143)	(430,902)
Equity in net income of subsidiaries	15	190,655	(141,447)	3,910	4,537	-	-	-	-
Other operating (expenses) revenues, net		2,632	1,576	(59,498)	(59,532)	32,486	26,217	51,351	39,197
Subtotal		**(68,648)**	**(250,983)**	**(245,557)**	**(156,460)**	**(958,033)**	**(463,306)**	**(893,963)**	**(451,841)**
Income/(loss) before financial income (loss) and taxes		**(68,648)**	**(250,983)**	**(245,557)**	**(156,460)**	**185,566**	**(313,406)**	**182,258**	**82,241**
Financial revenues	32	7,276	1,207	30,013	29,519	566,769	307,474	548,028	376,035
Financial expenses	32	(504,618)	(255,087)	(535,574)	(288,232)	(1,193,010)	(558,565)	(1,282,865)	(831,797)
Net financial revenues (expenses)		**(497,342)**	**(253,880)**	**(505,561)**	**(258,713)**	**(626,241)**	**(251,091)**	**(734,837)**	**(455,762)**
Income (loss) before income tax and social contribution		**(565,990)**	**(504,863)**	**(751,118)**	**(415,173)**	**(440,675)**	**(564,497)**	**(552,579)**	**(373,521)**
Current income tax and social contribution	33.a	-	-	-	-	(193,545)	(84,528)	(214,021)	(147,856)
Deferred income tax and social contribution	33	249,915	123,511	225,935	128,531	312,691	268,302	241,372	233,666
Net income/(loss) from continued operations for the period		**(316,075)**	**(381,352)**	**(525,183)**	**(286,642)**	**(321,529)**	**(380,723)**	**(525,228)**	**(287,711)**
Net income/(loss) from discontinued operations for the period	**38**	**-**	**-**	**-**	**-**	**5,965**	**-**	**803**	**803**
Net income/(loss) for the period		**(316,075)**	**(381,352)**	**(525,183)**	**(286,642)**	**(315,564)**	**(380,723)**	**(524,425)**	**(286,908)**
Attributable to:									
Non-controlling shareholders		-	-	-	-	511	629	758	(266)
Controlling shareholders		(316,075)	(381,352)	(525,183)	(286,642)	(316,075)	(381,352)	(525,183)	(286,642)
Basic and diluted earnings/(losses) per share	25.e	(0.04)	(0.05)	(0.07)	(0.04)	(0.04)	(0.05)	(0.07)	(0.04)

See the accompanying notes to the parent company and consolidated interim statements.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Hapvida Participações e Investimentos S.A.

Statements of comprehensive income

Periods ended June 30, 2024 and June 30, 2023

(Amounts expressed in thousands of reais)

		Parent Company				Consolidated			
		Accumulated	Quarter	Accumulated	Quarter	Accumulated	Quarter	Accumulated	Quarter
	Notes	06/30/2024	06/30/2024	06/30/2023 (Restated)	06/30/2023 (Restated)	06/30/2024	06/30/2024	06/30/2023 (Restated)	06/30/2023 (Restated)
Loss for the period		**(316,075)**	**(381,352)**	**(525,183)**	**(286,642)**	**(315,564)**	**(380,723)**	**(524,425)**	**(286,908)**
Other comprehensive income to be reclassified to income for the period in subsequent period									
Net gain/(loss) on cash flow hedge	34.(iii).f	(90,811)	(51,420)	16,115	7,027	(90,811)	(51,420)	16,115	7,027
Total comprehensive income		**(406,886)**	**(432,772)**	**(509,068)**	**(279,615)**	**(406,375)**	**(432,143)**	**(508,310)**	**(279,881)**
Attributable to non-controlling shareholders		-	-	-	-	511	629	758	(266)
Controlling shareholders		(406,886)	(432,772)	(509,068)	(279,615)	(406,886)	(432,772)	(509,068)	(279,615)

See the accompanying notes to the parent company and consolidated interim statements.

Hapvida Participações e Investimentos S.A.

Statements of changes in equity

Periods ended June 30, 2024 and June 30, 2023

(Amounts expressed in thousands of reais)

		Attributable to controlling shareholders									
					Profit reserves						
	Notes	Capital	Treasury shares	Capital reserves	Legal reserve	Profit reserve	Other comprehensive income	(Losses)/ Retained earnings	Total	Non-controlling interest	Total equity
Balances at 01/01/2023		**37,833,969**	**(427,776)**	**9,844,362**	**201,486**	**1,519,327**	**(42,184)**	**-**	**48,929,184**	**7,274**	**48,936,458**
Income (loss) for the period		-	-		-	-	-	(525,183)	(525,183)	758	(524,425)
Capital increase		1,059,155	-		-	-	-	-	1,059,155	(315)	1,058,840
Share issuance costs		(24,744)	-	-	-	-	-	-	(24,744)	-	(24,744)
Repurchase of shares		-	2,209		-	-	-	-	2,209	-	2,209
Transactions with share-based payments		-	-	46,842	-	-	-	-	46,842	-	46,842
Net gain/(loss) on cash flow hedge		-	-		-	-	16,115	-	16,115	-	16,115
Equity valuation adjustments		-	-	(12,636)		75	-	-	(12,561)	-	(12,561)
Balances at 06/30/2023 (Restated)		**38,868,380**	**(425,567)**	**9,878,568**	**201,486**	**1,519,402**	**(26,069)**	**(525,183)**	**49,491,017**	**7,717**	**49,498,734**
Balances at 12/31/2023		**38,866,199**	**(451,967)**	**9,892,386**	**201,486**	**761,472**	**(15,802)**	**-**	**49,253,774**	**1,369**	**49,255,143**
Income (loss) for the year		-	-	-	-	-	-	(316,075)	(316,075)	511	(315,564)
Capital increase (decrease)		-	-	-	-	-	-	-	-	923	923
Repurchase of shares	25.d)	-	(19,387)	-	-	-	-	-	(19,387)	-	(19,387)
Transactions with share-based payments		-	48,255	(121,378)	-	-	-	-	(73,123)	-	(73,123)
Net gain (loss) on cash flow hedge	34.(iii).f	-	-	-	-	-	(90,811)	-	(90,811)	-	(90,811)
Equity valuation adjustments		-	-	182	-	-	-	-	182	-	182
Balances at 06/30/2024		**38,866,199**	**(423,099)**	**9,771,190**	**201,486**	**761,472**	**(106,613)**	**(316,075)**	**48,754,560**	**2,803**	**48,757,363**

See the accompanying notes to the parent company and consolidated interim statements.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Hapvida Participações e Investimentos S.A.

Statements of cash flows - Indirect method

Periods ended June 30, 2024 and June 30, 2023

(Amounts expressed in thousands of reais)

	Parent Company		Consolidated	
	06/30/2024	06/30/2023 (Restated)	06/30/2024	06/30/2023 (Restated)
Cash flows from operating activities				
(Loss) net income for the period	**(316,075)**	**(525,183)**	**(315,564)**	**(524,425)**
Adjustments to reconcile net income (loss) for the period with cash generated by operating activities:				
Depreciation and amortization	135,854	94,857	723,174	681,684
Amortization of right-of-use	3	2	115,616	102,371
Write-off of fair value surplus of PP&E	-	60,467	-	93,560
Sale & leaseback	-	-	-	(112,540)
Equity in net income of subsidiaries	(190,655)	(3,910)	-	-
Provision for losses and effective credit losses	-	-	9,126	18,916
Write-off of property, plant and equipment	-	-	7,867	1,508
Write-off of intangible assets	-	-	4,342	32,326
Provision for tax, civil and labor risks	473	696	201,104	216,290
Mark-to-market of short and long term investments	-	-	197	611
Yield from short and long term investments	(5,849)	(18,457)	(386,501)	(310,775)
Loss (gain) with derivative financial instruments	-	8,289	(27,411)	(11,763)
Interest and inflation adjustment of lease	8	7	159,960	120,307
Interest and financial charges from loans, financing and debentures	501,472	507,171	662,554	799,437
Exchange-rate change	27	-	34,099	(16,991)
Share-based payment transactions	72,340	46,842	72,340	46,842
Income tax and social contribution	-	-	193,545	214,021
Deferred taxes	(249,915)	(225,935)	(312,691)	(241,372)
Other	-	-	-	(7,072)
	(52,317)	**(55,154)**	**1,141,757**	**1,102,935**
(Increase) decrease in asset accounts:				
Trade accounts receivable	-	-	(69,985)	(23,583)
Inventories	-	-	(85,334)	(685)
Recoverable taxes	30,772	(6,008)	(27,901)	(68,512)
Judicial deposits	(289)	(2,390)	(353,990)	(193,228)
Insurance contract assets	-	-	37,888	578,275
Other assets	2,322	9,294	(14,877)	11,727
Increase (decrease) in liability accounts:				
Debits from health care operations	-	-	54,925	-
Social security charges	(125)	49	215,740	79,617
Suppliers	573	(226)	27,474	44,339
Taxes and contributions payable	(3,388)	(4,047)	(49,717)	(46,460)
Provision for tax, civil and labor risks	(377)	(179)	(123,843)	(100,799)
Insurance contract liabilities	-	-	968,136	60,627
Other accounts payable	(7,103)	30,500	(144,801)	(274,848)
Cash generated by (used in) operating activities	**(29,932)**	**(28,161)**	**1,575,472**	**1,169,405**
Income tax and social contribution paid	-	-	(140,595)	(137,374)
Net cash flow from (used in) continued operating activities	**(29,932)**	**(28,161)**	**1,434,877**	**1,032,031**
Net cash flow from (used in) discontinued operating activities	-	-	5,621	(10,074)
Net cash flow from (used in) operating activities	**(29,932)**	**(28,161)**	**1,440,498**	**1,021,957**
Cash flows from investing activities				
(Payments) Receipts from related parties	19,207	12,381	211	(3,830)
Acquisition of property, plant and equipment	-	(229)	(87,445)	(146,007)
Acquisition of intangible assets	-	-	(202,455)	(92,451)
Acquisition of investments	-	-	-	(630,641)
Paid-up capital in investees	-	(740,005)	-	-
Balances attributed to the acquisition of investees	-	-	-	3,194
Advance for future capital increase	(1,000,100)	(376,777)	-	-
Dividends received	-	116,475	-	-
Proceeds from sale & leaseback operations	-	-	-	1,250,000
Short and long term investments	(31,440)	(849,900)	(9,762,642)	(12,205,721)
Redemptions of short and long term investments	255,155	580,952	8,704,708	10,325,000
Cash flow used in continued investment activities	**(757,178)**	**(1,257,103)**	**(1,347,623)**	**(1,500,456)**
Cash flow used in discontinued investment activities	-	-	(29,167)	(32,385)
Cash flow used in investment activities	**(757,178)**	**(1,257,103)**	**(1,376,790)**	**(1,532,841)**
Cash flows from financing activities				
Issue of debentures	1,000,000	750,000	1,000,000	750,000
Funding of loans and financing	330,000	-	-	260,000
Proceeds from issuance of shares	-	1,059,155	-	1,059,155
Share issuance costs	-	(24,744)	-	(24,744)
Repurchase of own shares	(20,724)	2,209	(20,724)	2,209
Payment of loan principal, financing and debentures	(750,000)	(34,373)	(750,000)	(1,276,492)
Payment of interest from loans, financing and debentures	(591,043)	(430,663)	(697,265)	(660,479)
Transaction costs related to funding	(5,907)	-	(5,907)	(2,655)
Acquisition of subsidiaries - Payments	-	-	(308,194)	(7,942)
Payment of lease	(8)	(8)	(242,248)	(211,689)
Payment of Stock grant plan	(26,536)	-	(26,536)	-
(Payment)/Receipt of derivative financial instruments	-	(29,228)	(17,082)	(78,272)
Net cash from (used in) continued financing activities	**(64,218)**	**1,292,348**	**(1,067,956)**	**(190,909)**
Net cash from discontinued financing activities	-	-	8,666	112
Net cash from (used in) financing activities	**(64,218)**	**1,292,348**	**(1,059,290)**	**(190,797)**
Increase (decrease) in cash and cash equivalents from continued operations	**(851,328)**	**7,084**	**(980,702)**	**(659,334)**
Decrease in cash and cash equivalents from discontinued operations	-	-	(14,880)	(42,347)
Increase (Decrease) in cash and cash equivalents	**(851,328)**	**7,084**	**(995,582)**	**(701,681)**
Cash and cash equivalents at the beginning of the period	857,991	3,242	1,430,144	1,267,915
Cash and cash equivalents at the end of the period	6,663	10,326	419,682	547,962
Changes in cash and cash equivalents from discontinued operations	-	-	(14,880)	(18,272)
Increase (Decrease) in cash and cash equivalents	**(851,328)**	**7,084**	**(995,582)**	**(701,681)**

See the accompanying notes to the parent company and consolidated interim statements.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Hapvida Participações e Investimentos S.A.

Statements of added value

Periods ended June 30, 2024 and June 30, 2023

(Amounts expressed in thousands of reais)

	Parent Company		Consolidated	
	06/30/2024	06/30/2023 (Restated)	06/30/2024	06/30/2023 (Restated)
Revenues (1)	**3,300**	**1,134**	**14,230,924**	**14,211,987**
Revenues from issued insurance operations	-	-	13,385,339	13,045,176
Other revenues	3,300	1,134	854,711	1,185,727
Estimated losses on doubtful accounts - Reversal / (Formation)	-	-	(9,126)	(18,916)
Expenses (2)	**-**	**-**	**(12,011,436)**	**(11,342,423)**
Expenses with issued insurance operations	-	-	(12,011,436)	(11,342,423)
Inputs purchased from third parties (3)	**(13,907)**	**(7,901)**	**(814,962)**	**(1,231,375)**
Materials, energy and others	(1,871)	(1,483)	(624,229)	(754,897)
Outsourced services, net commissions	(12,036)	(6,418)	(190,733)	(476,478)
Gross added value (1)-(2)-(3) = (4)	**(10,607)**	**(6,767)**	**1,404,526**	**1,638,189**
Depreciation and amortization (5)	(135,857)	(94,859)	(218,586)	(228,033)
Net value added produced by the Company (4) - (5) = (6)	**(146,464)**	**(101,626)**	**1,185,940**	**1,410,156**
Added value received as transfer (7)	**197,224**	**33,923**	**1,655,738**	**1,810,937**
Equity in results of subsidiaries	190,655	3,910	-	-
Financial revenues	7,276	30,013	566,769	548,028
Other	(707)	-	1,088,969	1,262,909
Undistributed value added from continued operations (6)+(7)=(8)	**50,760**	**(67,703)**	**2,841,678**	**3,221,093**
Undistributed value added from discontinued operations (9)	**-**	**-**	**5,965**	**803**
Total added value payable (8) + (9)	**50,760**	**(67,703)**	**2,847,643**	**3,221,896**
Distribution of added value				
Personnel	**(109,176)**	**(83,916)**	**(1,558,510)**	**(1,478,883)**
Direct remuneration	(108,988)	(83,855)	(1,293,313)	(1,156,013)
Benefits	(196)	(18)	(188,582)	(186,010)
Severance Pay Fund (FGTS)	8	(43)	(76,615)	(136,860)
Taxes, rates and contributions	**246,807**	**222,544**	**(822,349)**	**(972,363)**
Federal	246,847	222,594	(758,545)	(718,652)
State	(40)	-	(1,779)	(633)
Municipal	-	(50)	(62,025)	(253,078)
Third-party capital remuneration	**(504,466)**	**(596,108)**	**(782,348)**	**(1,295,075)**
Interest	(503,690)	(535,493)	(635,212)	(921,887)
Rents	(102)	-	(14,154)	(24,938)
Other	(674)	(60,615)	(132,982)	(348,250)
Remuneration of own capital	**316,075**	**525,183**	**315,564**	**524,425**
Retained earnings/(losses)	316,075	525,183	316,075	525,183
Non-controlling interest in retained losses/(earnings)	-	-	(511)	(758)
Distributed added value	**(50,760)**	**67,703**	**(2,847,643)**	**(3,221,896)**

See the accompanying notes to the parent company and consolidated interim statements.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Notes to the parent company and consolidated statements

(Amounts expressed in thousands of reais)

1 Operations

Hapvida Participações e Investimentos S.A. (the "Company") is a holding company organized as a corporation with registered offices at Av. Heráclito Graça, 406 in the city of Fortaleza/CE. The parent company and consolidated interim statements include the Company and its subsidiaries ("Company and its subsidiaries") or ("Group"). The Company and its subsidiaries are mainly engaged in: (i) sale of health insurance plans being also responsible for the majority of health care at its own network (hospitals, clinics, imaging diagnostics and laboratories); and (ii) the sale of dental insurance plans with the services provided by accredited network.

Hapvida Participações e Investimentos S.A. obtained the registration as a publicly-held company on April 20, 2018 and started trading its shares in the Novo Mercado (New Market) special segment at [B]3 – Brasil Bolsa Balcão, on April 25, 2018, under ticker HAPV3.

The Company's shareholding structure is presented as follows:

Partner	Number of shares	(%) Interest
PPAR Pinheiro Participações S.A.	2,713,267,990	36.20%
Outstanding shares	4,781,122,060	63.80%
(-) Treasury shares	45,073,213	-
Total	**7,539,463,263**	**100.00%**

As of June 30, 2024, the Company and its subsidiaries recorded, at a consolidated level, positive Net Working Capital of R$ 2,828,920 (positive Net Working Capital of R$ 2,508,899 as of December 31, 2023).

The Company (parent company) presented negative Net Working Capital of R$ 1,155,901 (negative by 771,788 on December 31, 2023), mainly due to its obligations arising from debentures in the short term. The Group has centralized cash management mechanisms so that, if there is a need for cash in a specific company within the Group, the entities will reallocate cash. In the case of the Company, its subsidiaries (mainly operators) proceed to distribute profits.

Management assessed the ability of the Company and its subsidiaries to continue as a going concern in the next twelve months and, based on its analysis, believes it has the required resources to allow the going concern of its business for the future. Additionally, Management is not aware of any material uncertainty that may generate significant doubts about its ability to continue operating. Thus, these parent company and consolidated interim statements were prepared based on the going concern assumption.

The disclosure of the parent company and consolidated interim statements was authorized by the Board of Directors on August 8, 2024**.**

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

2 Other matters

2.1 Climate change-related risk

Floods in the State of Rio Grande do Sul

The Company and its subsidiaries have monitored the impacts of the floods that occurred in the state of Rio Grande do Sul. The Company's management evaluated the direct and indirect exposures and the main impacts are highlighted below. The Group has 1 hospital, 1 emergency room, 9 clinics and 13 imaging diagnostic and laboratory collection units in the state of Rio Grande do Sul with a portfolio of approximately 188 thousand beneficiaries (approximately 1% of the total) in the period ended June 30, 2024. Some units were affected by the floods and had to temporarily close their operations, but currently all units are operating normally.

The Company's Management measured immaterial impacts on its business and its interim financial statements and its subsidiaries are not exposed to additional risks or direct or indirect effects other than those mentioned above.

Study of climate risks and opportunities

The Company and its subsidiaries carried out a study of climate risks and opportunities considering the time horizons of 2030 and 2050, assessing the main physical risks linked to global warming and the effects of climate change on the increase in demand for health services in the short, medium and long term, aiming to obtain a better understanding and technical information to assist decision-making in climate change adaptation plans.

Among the aspects identified in the study, it is worth highlighting the possible impacts of extreme weather events on the units and facilities, as well as the consequences of climate change on the health of populations and the search for medical care.

The Company and its subsidiaries work constantly to mitigate risks to the physical integrity of the units, considering the occurrence of storms, floods, cyclones and hail when planning works and renovations.

In certain cases, the possibility of changing the address of an asset based on the impossibility of adapting the infrastructure to provide service within the established safety and quality standards is also assessed. Moreover, the insurance policies of the Company and its subsidiaries include coverage for extreme events.

The increase in cases of respiratory diseases resulting from a drop in temperature or an increase in pollution, cardiovascular diseases caused by an increase in temperature and diseases limited to certain geographic areas (such as dengue, whose vector is related to the accumulation of water and may be impacted by the rainfall regime) are monitored by the Company and its subsidiaries on a recurring basis.

Finally, ongoing investments are made in the geographic diversification of care units, in preventive medicine programs and in educational and awareness-raising actions through communication channels.

Until June 30, 2024, no relevant impacts arising from climate change risks were identified by Management in the parent company and consolidated interim statements of the Company and its subsidiaries, regarding: i) impairment of non-financial assets; ii) financial instruments; iii) Contingent provisions and liabilities; iv) fair value measurements; v) deferred taxes; vi) material judgments and estimates; or any other impacts.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

2.2 Consumption tax reform

On December 20, 2023, Constitutional Amendment (“EC”) 132 was enacted, which establishes the Tax Reform (“Reform”) on consumption. Several topics, including the rates of new taxes, are still pending regulation by Complementary Laws (“LC”), which must be submitted for evaluation by Brazil’s National Congress within 180 days.

The Reform model is based on a VAT divided into two competences (“dual VAT”): one federal (Contribution on Goods and Services – “CBS”), with the transition set to be completed by 2027 and one sub-national (Tax on Goods and Services – “IBS”), which will replace the taxes currently known as PIS, COFINS, ICMS, and ISS.

A Selective Tax (“IS”) [a type of excise tax] was also created, under federal jurisdiction, which will apply to the production, extraction, trading or import of goods and services that are harmful to health and the environment, under the terms of a Complementary Law (“LC”).

There will be a transition period from 2024 to 2032, for the IBS, in which the two tax systems – old and new – will coexist. The impacts of the Reform on the calculation of the aforementioned taxes, from the beginning of the transition period, will only be fully known when the process of regulating pending issues through a Complementary Law is finalized.

As of June 30, 2024, there are already bills under consideration, including the approval of Bill (PL) 68/2024 by the House of Representatives, as well as the ongoing discussion of PL 108/24 (Establishment of the Management Committee for the Goods and Services Tax – CG-IBS). The initial estimated rate was set at 26.5% – (17.7% for IBS and 8.8% for CBS).

There was no effect of the Reform on the Company’s parent company and consolidated interim financial statements and its subsidiaries.

2.3 Restatement of interim statements – Comparative figures

The financial statements as of June 30, 2023, originally approved and issued on August 9, 2023, are being restated to include the impacts of IFRS 17 (CPC 50) – Insurance Contracts, replacing IFRS 4 (CPC 11) – Insurance Contracts. This restatement was carried out on a basis consistent with the restatement of the financial statements as of December 31, 2023, issued on May 13, 2024.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

a) Statement of Profit or Loss – Period ended June 30, 2023.

	Parent Company		
	June 30, 2023		
Statement of profit or loss	**Original**	**Adjustment (i)**	**Restated**
Sales expenses	(626)	-	(626)
Administrative expenses	(441,040)	251,697	(189,343)
Equity in net income of subsidiaries	191,764	(187,854)	3,910
Other operating (expenses) revenues, net	(59,498)	-	(59,498)
Subtotal	**(309,400)**	**63,843**	**(245,557)**
Income/(loss) before financial income (loss) and taxes	**(309,400)**	**63,843**	**(245,557)**
Net financial (expenses)	**(505,561)**	**-**	**(505,561)**
Income (loss) before income tax and social contribution	**(814,961)**	**63,843**	**(751,118)**
Income tax and social contribution	311,512	(85,577)	225,935
Income/(loss) for the period	**(503,449)**	**(21,734)**	**(525,183)**
Basic and diluted earnings/(losses) per share	(0.07)		(0.07)

(i) Adjustments from impacts on the results of subsidiaries, arising from the remeasurement of contracts according to IFRS 17 (CPC 50).

	Consolidated		
	June 30, 2023		
Statement of profit or loss	**Original**	**Adjustment**	**Restated**
Net revenue from services rendered	13,566,017	(13,075,339) (i)	490,678
Insurance revenue	-	13,045,176 (i)	13,045,176
Cost of services rendered	(10,275,981)	9,158,771 (ii)	(1,117,210)
Insurance expense	-	(11,342,423) (ii)	(11,342,423)
Gross income	**3,290,036**	**(2,213,815)**	**1,076,221**
Sales expenses	(1,001,995)	884,824 (ii)	(117,171)
Administrative expenses	(2,182,083)	1,353,940 (ii)	(828,143)
Other operating (expenses) revenues, net	51,351	-	51,351
Subtotal	**(3,132,727)**	**2,238,764**	**(893,963)**
Income/(loss) before financial income (loss) and taxes	**157,309**	**24,949**	**182,258**
Net financial (expenses)	**(676,958)**	**(57,879)**	**(734,837)**
Income (loss) before income tax and social contribution	**(519,649)**	**(32,930)**	**(552,579)**
Income tax and social contribution	16,154	11,197	27,351
Income/(loss) from continued operations for the period	**(503,495)**	**(21,733)**	**(525,228)**
Income from discontinued operations for the period	**803**	**-**	**803**
Income/(loss) for the period	**(502,692)**	**(21,733)**	**(524,425)**
Basic and diluted earnings/(losses) per share	(0.07)		(0.07)

(i) Under IFRS 4 (CPC 11), insurance revenues were presented under net service revenues, on the same item line as revenue from IFRS 15 (CPC 47). Since the adoption of IFRS 17 (CPC 50), revenues from insurance contracts have been presented under Insurance revenue.
(ii) Under IFRS 17 (CPC 50), expenses allocated to insurance contracts, such as administrative expenses, sales expenses, and claims expenses, are presented under Insurance expenses.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

b) Statement of cash flow – Periods ended June 30, 2023

	Parent Company		
	June 30, 2023		
Statement of cash flows	**Original**	**Adjustment (i)**	**Restated**
Income/(loss) for the period	**(503,449)**	**(21,734)**	**(525,183)**
Reconciliation adjustments to cash income/(loss)			
Depreciation and amortization	346,554	(251,697)	94,857
Equity in net income of subsidiaries	(191,764)	187,854	(3,910)
Deferred taxes	(311,512)	85,577	(225,935)
Other adjustments to (loss) changes	605,017	-	605,017
Subtotal	**(55,154)**	**-**	**(55,154)**
Changes in asset and liability accounts			
Other changes in operating activities	26,993	-	26,993
Net cash (used) generated in operating activities	**(28,161)**	**-**	**(28,161)**
Net cash (used in) generated in investing activities	**(1,257,103)**	**-**	**(1,257,103)**
Net cash (used) generated in financing activities	**1,292,348**	**-**	**1,292,348**
Increase (Decrease) in cash and cash equivalents	**7,084**	**-**	**7,084**

(i) Adjustments from impacts on the results of subsidiaries, resulting from the remeasurement of contracts according to IFRS 17 (CPC 50).

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

	Consolidated		
	June 30, 2023		
Statement of cash flows	**Original**	**Adjustment (i)**	**Restated**
(Loss) for the period	**(502,692)**	**(21,733)**	**(524,425)**
Reconciliation adjustments to cash income/(loss)			
Depreciation and amortization	933,381	(251,697)	681,684
Technical reserves for health care operations	26,848	(26,848)	-
Impairment loss on trade receivables	280,107	(261,191)	18,916
Amortization of deferred sales expenses	323,433	(323,433)	-
Deferred taxes	(230,175)	(11,197)	(241,372)
Other changes in adjustments to income/(loss)	1,168,132	-	1,168,132
Subtotal	**1,999,034**	**(896,099)**	**1,102,935**
Changes in asset and liability accounts			
Trade accounts receivable	(240,344)	216,761	(23,583)
Inventories	(685)	-	(685)
Recoverable taxes	(68,512)	-	(68,512)
Judicial deposits	(193,228)	-	(193,228)
Insurance contract assets	-	578,275	578,275
Other assets	40,201	(28,474)	11,727
Deferred sales expenses	(361,260)	361,260	-
Technical reserves for health care operations	181,127	(181,127)	-
Debits from health care operations	26,285	(26,285)	-
Social security charges	79,617	-	79,617
Suppliers	(76,213)	120,552	44,339
Taxes and contributions payable	(46,460)	-	(46,460)
Provision for tax, civil and labor risks	(100,799)	-	(100,799)
Insurance contract liabilities	-	60,627	60,627
Other accounts payable	(69,358)	(205,490)	(274,848)
Income tax and social contribution paid	(137,374)	-	(137,374)
Net cash (used) generated in continued operating activities	**1,032,031**	**-**	**1,032,031**
Net cash (used) generated in discontinued operating activities	(10,074)	-	(10,074)
Net cash (used) generated in operating activities	**1,021,957**	**-**	**1,021,957**
Net cash (used) generated in continued investment financing activities	**(1,500,456)**	**-**	**(1,500,456)**
Net cash (used) generated in discontinued investment financing activities	(32,385)	-	(32,385)
Net cash (used in) generated in investment activities	**(1,532,841)**	**-**	**(1,532,841)**
Net cash (used) generated in continued financing activities	**(190,909)**	**-**	**(190,909)**
Net cash (used) generated in discontinued financing activities	112	-	112
Net cash generated (used) in financing activities	**(190,797)**	**-**	**(190,797)**
Increase (Decrease) in cash and cash equivalents from continued operations	**(659,334)**	**-**	**(659,334)**
Increase (Decrease) in cash and cash equivalents from discontinued operations	(42,347)	-	(42,347)
Increase (Decrease) in cash and cash equivalents	**(701,681)**	**-**	**(701,681)**

(i) Adjustments from the impacts arising from the remeasurement of contracts of the Company's subsidiaries according to IFRS 17 (CPC 50) and the respective effects on their assets, liabilities and income (loss).

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

c) Statement of added value - Period ended June 30, 2023

	Parent Company			
	June 30, 2023			
	Original	Adjustment (i)		Restated
Revenues (1)	**1,134**	**-**		**1,134**
Other (expenses) revenues	1,134	(1,134)	(ii)	-
Other	-	1,134	**(ii)**	1,134
Inputs purchased from third parties (2)	**(7,901)**	**-**		**(7,901)**
Materials, energy and others	-	(1,483)(ii)		(1,483)
Third-party services, net commissions	-	(6,418)(ii)		(6,418)
Materials, energy, outsourced services and others	(7,901)	7,901(ii)		-
Gross added value (1) - (2) = (3)	**(6,767)**	**-**		**(6,767)**
Depreciation and amortization (4)	(346,556)	251,697(i)/(iii)		(94,859)
Net value added produced by the Company (5) - (6) = (7)	**(353,323)**	**251,697**		**(101,626)**
Added value received as transfer (8)	**221,153**	**(187,230)**		**33,923**
Equity in net income of subsidiaries	191,764	(187,854)(i)		3,910
Financial revenues	30,013	-		30,013
Other	(624)	624(i)		-
Undistributed value added from continued operations (7) + (8) = (9)	**(132,170)**	**64,467**		**(67,703)**
Distribution of added value				
Personnel	**(83,916)**	**-**		**(83,916)**
Direct remuneration	(83,955)	-		(83,955)
Benefits	(18)	-		(18)
Severance Pay Fund (FGTS)	(43)	-		(43)
Taxes, rates and contributions	**308,121**	**(85,577)**		**222,544**
Federal	308,171	(85,577)(i)		222,594
State	-	-		-
Municipal	(50)	-		(50)
Third-party capital remuneration	**(595,484)**	**(624)**		**(596,108)**
Interest	(534,869)	(624)(i)		(535,493)
Rents	-	-		-
Other	(60,615)	-		(60,615)
Remuneration of own capital	**503,449**	**21,734**		**525,183**
Retained earnings/(losses)	503,449	21,734(i)		525,183
Distributed added value	**132,170**	**(64,467)**		**67,703**

(i) Adjustments from the impacts arising from the remeasurement of contracts of the Company's subsidiaries according to IFRS 17 (CPC 50) and the respective effects on their income (loss).
(ii) The Company and its subsidiaries have early adopted CPC 09 (R1), as permitted by CVM Resolution No. 199, since they have contracts within the scope of IFRS 17 (CPC 50).
(iii) With the adoption of IFRS 17 (CPC 50), the Company remeasured the intangible assets identified in the business combination of Grupo NotreDame Intermédica (GNDI).

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

	Consolidated			
	June 30, 2023			
	Original	**Adjustment (i)**		**Restated**
Revenues (1)	**13,978,981**	**233,006**		**14,211,987**
Revenues from issued insurance operations	-	13,045,176	(i)	13,045,176
Operating revenue	14,123,918	(14,123,918)	(i)	-
Other (expenses) revenues	137,008	(137,008)	(i)/(ii)	-
Impairment loss on trade receivables	(281,945)	281,945	(i)/(ii)	-
Other	-	1,185,727	(i)/(ii)	1,185,727
Estimated losses on doubtful accounts - Reversal / (Formation)	-	(18,916)	(i)/(ii)	(18,916)
Expenses (2)	**-**	**(11,342,423)**		**(11,342,423)**
Expenses with issued insurance operations	-	(11,342,423)	(i)/(iii)	(11,342,423)
Inputs purchased from third parties (3)	**(9,802,709)**	**8,571,334**		**(1,231,375)**
Cost of services rendered	(6,745,226)	6,745,226	(i)/(ii)	-
Materials, energy, outsourced services and other	(3,057,483)	3,057,483	(i)/(ii)	-
Materials, energy and others	-	(754,897)	(i)/(ii)	(754,897)
Outsourced services, net commissions	-	(476,478)	(i)/(ii)	(476,478)
Gross added value (1)-(2)-(3) = (4)	**4,176,272**	**(2,538,083)**		**1,638,189**
Depreciation and amortization (5)	(1,035,752)	807,719	(i)/(iii)	(228,033)
Net added value produced by the Company (4) - (5) = (6)	**3,140,520**	**(1,730,364)**		**1,410,156**
Added value received as transfer (7)	**760,403**	**1,050,534**		**1,810,937**
Financial revenues	548,028	-		548,028
Other	212,375	1,050,534	(i)	1,262,909
Undistributed value added from continued operations (6) + (7) = (8)	**3,900,923**	**(679,830)**		**3,221,093**
Undistributed value added from discontinued operations (9)	803	**-**		**803**
Total added value payable (8) + (9)	**3,901,726**	**(679,830)**		**3,221,896**
Distribution of added value				
Personnel	**(1,986,209)**	**507,326**		**(1,478,883)**
Direct remuneration	(1,664,879)	508,866	(i)	(1,156,013)
Benefits	(184,470)	(1,540)	(i)	(186,010)
Severance Pay Fund (FGTS)	(136,860)	-		(136,860)
Taxes, rates and contributions	**(937,588)**	**(34,775)**		**(972,363)**
Federal	(683,877)	(34,775)	(i)	(718,652)
State	(633)	-		(633)
Municipal	(253,078)	-		(253,078)
Third-party capital remuneration	**(1,480,621)**	**185,546**		**(1,295,075)**
Interest	(1,104,129)	182,242	(i)	(921,887)
Rents	(4,850)	(20,088)	(i)	(24,938)
Other	(371,642)	23,392	(i)/(ii)	(348,250)
			(i)/(ii)	
Remuneration of own capital	**502,692**	**21,733**	(i)/(ii)	**524,425**
Retained (earnings)/losses	503,449	21,734	(i)/(ii)	525,183
Non-controlling interest in retained (earnings)/losses	(757)	(1)		(758)
Distributed added value	**(3,901,726)**	**679,830**	(i)/(iii)	**(3,221,896)**

(i) Adjustments from the impacts arising from the remeasurement of contracts of the Company's subsidiaries according to IFRS 17 (CPC 50) and the respective effects on their income (loss).
(ii) The Company and its subsidiaries have early adopted CPC 09 (R1), as permitted by CVM Resolution No. 199, since they have contracts within the scope of IFRS 17 (CPC 50).
(iii) With the adoption of IFRS 17 (CPC 50), the Company remeasured the intangible assets identified in the business combination of Grupo NotreDame Intermédica (GNDI).

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

2.4 Clarification on Official Letter 13/2024/CVM/SEP/GEA-2

As disclosed in the Material Fact dated January 19, 2024, the Company and its subsidiaries clarify that they received notification from the Public Ministry of the State of São Paulo regarding a civil proceeding that investigates issues related to assistance coverage and compliance with court decisions. The Company and its subsidiaries inform that they have presented the relevant clarifications and will monitor the progress of such proceeding.

3 Subsidiaries

The Parent Company and Consolidated interim statements include the following direct and indirect subsidiaries of Hapvida Participações e Investimentos S.A.:

				06/30/2024		12/31/2023	
Entity		**Acquisition date**	**Merger date**	**Direct**	**Indirect**	**Direct**	**Indirect**
Hapvida Assistência Médica S.A. (a)	Health care plan	-	-	100%	-	100%	-
Hapvida Call Center e Tecnologia Ltda.	Technology	-	-	-	100%	-	100%
Maida Health Participações Societárias S.A. *	Technology	09/01/2019	-	-	-	-	75.00%
Maida Haptech Soluções Inteligentes Ltda. *	Technology	-	-	-	-	-	74.99%
Maida Infoway Tecnologia e Gestão em Saúde Ltda. *	Technology	09/01/2019	-	-	-	-	74.99%
Tercepta Consultoria em Informática Ltda. *	Technology	09/01/2021	-	-	-	-	75.00%
Lifeplace Maida Ltda. *	Agency services	-	-	-	-	-	75.00%
Lifeplace Hapvida Ltda.	Agency services	-	-	100%	-	100%	-
HB Saúde Group (c)		**01/01/2023**					
H.B. Saúde S.A.	Health care plan		-	-	100%	-	100%
H.B. Saúde Prestação de Serviços Médicos Ltda.	Health		-	-	100%	-	100%
H.B. Saúde Centro de Diagnóstico Ltda.	Health		-	-	100%	-	100%
Centro Integrado de Atendimento Ltda.	Health		-	-	100%	-	100%
Grupo Notre Dame Intermédica – GNDI (b)		**02/01/2022**					
Notre Dame Intermédica Participações S.A.	Holding		-	100%	-	100%	-
BCBF Participações S.A.	Holding		03/28/2024	-	-	18.85%	81.15%
Notre Dame Intermédica Saúde S.A.	Health care plan		-	16.40%	83.60%	-	100%
São Lucas Saúde S.A.	Health care plan		-	-	100%	-	100%
São Lucas Serviços Médicos Ltda.	Health		-	-	100%	-	100%
Hospital São Lucas S.A.	Health		-	-	97.63%	-	87.75%
Clinipam – Clín. Médica Paranaense de Assistência Médica Ltda.	Health care plan		-	-	99.99%	-	100%
Hospital e Maternidade Santa Mônica S.A.	Health		-	-	100%	-	99.94%
INCORD – Inst. de Neurologia e de Coração de Divinópolis Ltda.	Laboratorial		-	-	100%	-	100%
Bioimagem Diag. por Imagem e Lab. de Análises Clín. Ltda.	Laboratorial		-	-	97.75%	-	96.33%
SMV Serviços Médicos Ltda.	Management		-	-	99.62%	-	99.30%
Lifecenter Sistema de Saúde S.A.	Health		-	-	100%	-	100%
Bio Saúde Serviços Médicos Ltda.	Health care plan		-	-	100%	-	100%
Hospital do Coração de Londrina Ltda.	Health		-	-	100%	-	100%
Notre Dame Intermédica Minas Gerais Ltda.	Holding		-	-	100%	-	100%
Notre Dame Intermédica Minas Gerais Saúde S.A.	Health care plan		-	-	99.96%	-	100%
Hospital e Maternidade Maringá S.A.	Health		-	-	100%	-	100%
IMESA – Instituto de Medicina Especializada Alfenas S.A.	Health		-	-	99.87%	-	99.77%
Hospital Varginha S.A.	Health		-	-	99.90%	-	99.87%
Casa de Saúde e Maternidade Santa Martha S.A.	Health		-	-	100%	-	100%
CCG Participações S.A.	Holding		-	-	100%	-	100%
Centro Clínico Gaúcho Ltda.	Health care plan		-	-	100%	-	100%
Hospital do Coração Duque de Caxias Ltda.	Health		-	-	100%	-	100%

* Companies sold in the first quarter of 2024, as described in Note 38.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

The main subsidiaries operate with the following activities:

(a) Hapvida Assistência Médica S.A.
The insurance company came into operation on July 15, 1991, and is registered in the National Regulatory Agency for Private Health Insurance and Plans (ANS) under nº 36.825-3. It is primarily engaged in the sale of health and dental insurance plans focused on providing health care assistance through the network of companies under control of the Company and its subsidiaries.

(b) Grupo Notre Dame Intermédica – GNDI
Founded in 1968 and domiciled in Brazil, with headquarters in São Paulo/SP, the Grupo Notre Dame Intermédica operates healthcare plans, dental plans and occupational health. Its own Service Network has a robust structure of hospitals, Clinical Centers, Independent Emergency Rooms, Preventive Medicine Centers, clinical analysis collection points, imaging exam units and Health Centers exclusively dedicated to the elderly.

(c) HB Saúde Group
Founded in 1998, HB Saúde Group is made up of a healthcare operator of the same name, a hospital, outpatient units, a children's clinic, clinical and diagnostic centers, preventive and occupational medicine spaces and an oncology center, located mainly in the municipalities of São José do Rio Preto and Mirassol, in São Paulo. The region of operation covers, in addition to São José do Rio Preto, the regions of Barretos, Fernandópolis, Votuporanga, Catanduva, Araçatuba, Três Lagoas and Uberaba.

4 Basis of preparation

Statement of compliance

(a) Parent company and consolidated statements
The parent company and consolidated interim financial statements were prepared in accordance with CPC 21 (R1) – Interim Financial Reporting, equivalent to IAS 34, issued by the International Accounting Standards Board (IASB) and with the rules issued by the Brazilian Securities and Exchange Commission (CVM), applicable to the preparation of Quarterly Information, and evidence all relevant information specific to the interim financial statements, and only them, which are in compliance with those used by the Management in its management.

(b) Statement of added value
The presentation of the Parent Company and Consolidated Statement of Added Value is required by Brazilian corporate law and the accounting practices adopted in Brazil applicable to publicly-held companies. The Statement of Added Value was prepared in accordance with the criteria defined in Technical Pronouncement CPC 09 (R1) - "Statement of Added Value". The IFRS do not require the presentation of this statement. Accordingly, in conformity with IFRS, this statement is presented as supplementary information, without prejudice to financial statements as a whole.

5 Functional and presentation currency

These parent company and consolidated statements are being presented in Brazilian Real, functional currency of the Company and its subsidiaries. All balances have been rounded to the nearest thousand, except when otherwise indicated.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

6 Use of estimates and judgments

The preparation of these parent company and consolidated interim statements, Management used judgments, estimates and assumptions that affect the application of accounting policies of the Company and its subsidiaries, and the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from these estimates.

Estimates and assumptions are reviewed in a continuous manner. Reviews of estimates are recognized on a prospective basis.

(a) Judgments

Information about judgment referring to the adoption of accounting policies which impact significantly the amounts recognized in the parent company and consolidated interim statements are included in the following notes:

- **Note 11** – Provision for impairment of accounts receivable. Recognition and measurement of the provision for the recoverable value of trade accounts receivable, based on assumptions about the risk of default and defined expected loss rates. Judgments are applied to establish these assumptions and select data for calculating impairment, based on the history of receivables of the Company and its subsidiaries, existing market conditions and future estimates at the end of each year.

- **Note 16 -** Review of economic useful life of property, plant and equipment. Estimate of useful life of property, plant and equipment to determine the depreciation rate over our assets;

- **Note 17 -** Intangible assets. Determination of estimated useful life of intangible assets, and as a result, of the amortization rate to be used in the calculation and book records in the income (loss) for the period/year. Goodwill impairment test. Recoverable amounts of Cash Generating Units (CGUs) were determined based on the value in use calculations, by an external specialized advisory hired by the Company and its subsidiaries, which were, in turn, based on estimates and budgetary projections approved by the Management;

- **Note 18 –** Insurance contracts. Active and current contracts have undergone evaluations concerning the structure of the grouping matrix in which the Company operates, as well as the analysis of the aggregation levels of these portfolios. Such groupings have been allocated based on profitability analysis, similar risks, and managed collectively. The insurance contracts' classifications also addressed the following requirements: considering whether the contract transfers significant insurance risks, level of aggregation of insurance contracts: the identification of contract portfolios and the determination of groups of contracts that are onerous upon initial recognition and those that have no significant possibility of becoming onerous later and the measurement of insurance contracts: determining cash flow estimation techniques (BBA), risk adjustments for non-financial risks, and coverage units provided under a contract. Cash flows are estimated through projections based on contract groups and assumptions pertinent to each portfolio, according to the occurrence year sensitivity. All movements impacting the fulfillment of contracts are considered, such as consideration payments, cancellations, administrative expenses, taxes, marketing expenses, pending payment events, estimated future events, among other estimates of inflows and outflows for which the Company has a substantive obligation. For the calculation of the risk adjustment for non-financial risks, the following

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

methodologies were applied: stress testing for the remaining coverage liability, where the risk adjustment is derived from the results of projecting cost payment flows, partially using assumptions in stress scenarios (with the desired level of confidence); and Bootstrapping for incurred claims liability, which simulates the provision distribution by projecting alternative development triangles based on the inherent variability present in the original development triangle. Additionally, the number of active beneficiaries in each portfolio was used to calculate the coverage units for the Contractual Service Margin (CSM) for individual contracts. For group contracts, revenue recognition is based on an average time passage assumption by contract groups. Moreover, it also includes, in the transition to IFRS 17 (CPC 50), the determination of the fair value for the group of contracts (individual) to which the fair value approach was used for initial recognition, and the determination whether reasonable and with sufficient support are available to apply a full retrospective approach to the group of contracts (collective) for which this approach was applied upon initial recognition.

- **Note 20 –** Leases payable and Sale & Leaseback (SLB). The Company and its subsidiaries are not able to determine the implicit discount rate to be applied to their lease contracts. Therefore, the lessee's incremental borrowing rate is used to calculate the present value of lease liabilities at the initial recording of the lease. The loan incremental interest rate of the lessee is the interest rate that the lessee would have to pay when borrows funds for the acquisition of asset similar to the asset object of the lease agreement for a similar term and with similar collateral, the funds required to obtain the asset with a value similar to the right-of-use asset, in a similar economic environment. Sale & Leaseback (SLB): The determination of gain or loss in the transaction, based on the fair value of the assets sold.

- **Note 23** – Provision for tax, civil and labor risks. The Company and/or its subsidiaries are parties to administrative and judicial claims of a labor, tax, civil and regulatory nature, in which they establish accounting provisions in relation to claims assessed as probable losses. The determination of loss probability is carried out by carrying out the assessment of available evidence, law hierarchy, available case laws, the most recent decisions in courts and its relevance to the legal system, as well as opinions of its legal advisors;

- **Note 26** – Share-based remuneration. Determination of the methodology for pricing options on the share grant dates;

- **Note 33** – Deferred income tax and social contribution. Determination of realization and availability of future taxable income against which deductible temporary differences and tax losses may be used; and

- **Note 34 –** Financial instruments and risk management. Determination of fair value of derivative and non-derivative financial instruments.

(b) Uncertainties on critical assumptions and estimates

Accounting estimates and judgments are constantly assessed and are based on prior experience and other factors, including expected future events considered as reasonable in view of circumstances of the Company and its subsidiaries. Reviews of accounting estimates are recognized in the period in which the estimates are made. The actual results in future periods may be different from those estimates and judgments.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

The Company and its subsidiaries make use of assumptions to establish estimates for the future. By definition, resulting accounting estimates are seldom equal to the respective taxable income. The estimates and assumptions which present a significant risk, possibility of causing an important adjustment to the book value of assets and liabilities are shown below:

- **Note 11** – Provision for doubtful impairment of accounts - trade receivables. Recognition and measurement of the provision for the recoverable value of trade accounts receivable, based on assumptions about the risk of default and defined expected loss rates. Judgments are applied to establish these assumptions and select data for calculating impairment, based on the history of receivables of the Company and its subsidiaries, existing market conditions and future estimates at the end of each year;

- **Note 16 -** Review of economic useful life of property, plant and equipment. Estimate of useful life of property, plant and equipment to determine the depreciation rate over our assets;

- **Note 17 -** Determination of estimated useful life of intangible assets, and as a result, of the amortization rate to be used in the calculation and book records in the income (loss) for the period/year. Goodwill impairment test. Recoverable amounts of Cash Generating Units (CGUs) were determined based on the value in use calculations, by an external specialized advisory hired by the Company and its subsidiaries, which were, in turn, based on estimates and budgetary projections approved by the Management;

- **Note 18** – Insurance contracts: in determining the assumptions used in the measurement of insurance contracts, in determining the techniques for estimating cash flows and risk adjustments for non-financial risks, in the discount rate and in the recognition of CSM - Contractual Service Margin. And in the transition – fair value approach for the group of contracts in individual portfolios. The Group’s actuarial policy defines that the primary judgments used in cash flow projections include: premium adjustments, claims experience, medical inflation (variation in hospital medical costs - VCMH), VCMH adjustment by age group, cancellations by age group, claims payment patterns, mortality tables, and risk adjustment for non-financial risks, calculated both for the remaining coverage liability and the incurred claims liability. Additionally, the Group’s discount rate assumption is based on a pre-fixed ETTJ (long-term interest rate) with parameters published by ANBIMA, adding an illiquidity premium to calculate the discounts applied to cash flows. The recognition of CSM amortization in the financial results is based on the number of active beneficiaries in each portfolio;

- **Note 20 –** Leases payable. Determination of the lease term and definition of the discount rate to be applied to lease contracts. The Company and its subsidiaries are not able to determine the implicit discount rate to be applied to their lease contracts. Therefore, the lessee’s incremental borrowing rate is used to calculate the present value of lease liabilities at the initial recording of the lease. The loan incremental interest rate of the lessee is the interest rate that the lessee would have to pay when borrows funds for the acquisition of asset similar to the asset object of the lease agreement for a similar term and with similar collateral, the funds required to obtain the asset with a value similar to the right-of-use asset, in a similar economic environment.

- **Note 23** – Provision for tax, civil and labor risks. The Company and/or its subsidiaries are parties to administrative and judicial claims of a labor, tax, civil and regulatory nature,

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

in which they establish accounting provisions in relation to claims assessed as probable losses. The determination of loss probability is carried out by carrying out the assessment of available evidence, law hierarchy, available case laws, the most recent decisions in courts and its relevance to the legal system, as well as opinions of its legal advisors;

- **Note 26** – Share-based remuneration. Determination of the methodology for pricing options on the share grant dates; and

- **Note 33** – Deferred income tax and social contribution. Determination of realization and availability of future taxable income against which deductible temporary differences and tax losses may be used.

(c) Fair value measurement

A number of the Company and its subsidiary's accounting policies and disclosures requires the measurement of fair value, for both financial and non-financial assets and liabilities.

The Company and its subsidiaries establish a control structure for measurement of fair value. This includes an assessment team that has overall responsibility for reviewing all significant fair value measurements, which discusses strategies for establishing the breakdown of the investment portfolio in the Finance and Capital Markets Committee.

Appraisal team regularly reviews significant non-observable data and valuation adjustments. If third-party information, such as brokerage firms' quotes or pricing services, is used to measure fair value, then the management assesses the evidence obtained from the third parties to support the conclusion that such valuations meet the requirements of IFRS/CPC standards, including the level in the fair value hierarchy in which such valuations should be classified.

When measuring fair value of an asset or liability, the Company and its subsidiaries use market observable data as much as possible. Fair values are categorized into different levels in a fair value hierarchy based on inputs used in the valuation techniques as follows:

- **Level 1**: prices quoted (not adjusted) in active markets for identical assets and liabilities.
- **Level 2**: inputs other than quoted prices included in level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- **Level 3**: inputs for assets or liabilities, which are not based on observable market data (non-observable inputs).

The Company and its subsidiaries recognize transfers between fair value hierarchic levels at the end of the period/year of parent company and consolidated interim statements in which changes occurred.

Additional information on the assumptions adopted in the measurement of fair values is included in the following notes:

- **Note 20** – Leases payable – Sale & Leaseback operation; and
- **Note 34** – Financial Instruments.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

7 Basis of measurement

The parent company and consolidated interim statements were prepared based on the historical cost, except for the following items which are measured at fair value (as described below) and recognized in the statements of financial position:

- derivative financial instruments (at each base date);
- short and long term investments – Investment funds (at each base date); and
- contingent payments assumed in a business combination (on each base date).

8 Material accounting policies

The accounting policies used in the preparation of these parent company and consolidated interim statements are the same as those adopted in the preparation of the Company's audited annual parent company and consolidated financial statements for the year ended December 31, 2023. Therefore, this parent company and consolidated interim statements should be read together with the Company's annual parent company and consolidated financial statements for the year ended December 31, 2023, issued on May 13, 2024, which comprise the complete set of notes.

9 Operating segments

The Company and its subsidiaries have a standardized and uniform service in all Brazilian regions. Thus, it directs its operations in the supplementary health sector and its strategy to providing services in a vertical manner, in which the beneficiary is primarily served by its own network, providing medical and dental care. In this sense, its operation takes place in just one operating segment, whose operating and financial results are regularly reviewed by the Board of Directors on an aggregate basis, which more adequately reflects the way in which the Management of the Company and its subsidiaries monitors operations and the way in which decisions are made about business continuity.

Although the Group has several hospitals, clinics and other service units in its organizational structure, they operate as executors of the services demanded by the beneficiaries of the health and dental plans of the operators belonging to the Group, within the integrated verticalization model, in which the purpose is to expand operations in other geographical regions, generating synergy gains and strengthening the Company and its subsidiaries.

Among the information analyzed by Management, quantitative and qualitative factors of the operation of the Company and its subsidiaries are considered, used in monitoring and decision-making. The Board of Directors determines that the Statutory Executive Board, represented by the Chief Executive Officer (CEO), receives and analyzes information on the operating and financial results of the business and its decision-making, use of technologies and marketing strategies for the different products and services in a centralized manner.

The entire operation (revenues and expenses) of the Company and its subsidiaries comes from providing services to beneficiaries located geographically in Brazil and there is no concentration of sales by client contract.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

10 Short and long term investments

The short and long term investments of the Company and its subsidiaries are made up as follows:

	Annual remuneration	Maturities	Parent Company 06/30/2024	Parent Company 12/31/2023	Consolidated 06/30/2024	Consolidated 12/31/2023
Government and private bonds						
Bank deposit certificates (CDB)	99.5–100.2% CDI	Jan 2024-Apr 2026	-	-	200,055	229,845
National Treasury Note B (NTN-B)	IPCA + 6% p.a.	until Sep 2024	-	-	42,237	42,508
National Treasury Note B (NTN-B) – Collateral Assets (a)	IPCA + 4.81 p.a.	Mar 2025-Sep 2025	-	-	147,579	143,101
Financial Treasury Bill (LFT)	88.54-100.0% CDI	Aug 2024-Mar 2027	-	-	71,112	369,896
Financial Treasury Bill (LFT) – Collateral Assets (a)	113.7% SELIC	Sep 2024-Sep 2025	-	-	231,160	223,112
Subtotal – Government and private bonds			**-**	**-**	**692,143**	**1,008,462**
Investment funds						
Fixed income - Collateral assets (a)	92.12-108.56% CDI	No maturity	-	-	3,129,350	2,823,179
Fixed income - Exclusive (b)	94.9-110.56% CDI	No maturity	9,105	226,979	3,753,350	2,362,000
Fixed income - non-exclusive	90.30-101.60% CDI	No maturity	141	133	350,428	266,114
Subtotal – Investment funds			**9,246**	**227,112**	**7,233,128**	**5,451,293**
Total			**9,246**	**227,112**	**7,925,271**	**6,459,755**
Current			9,105	226,979	7,371,940	5,573,479
Non-current			141	133	553,331	886,276

(a) The collateral assets are used to back the technical provisions of the health care operators.

(b) Three exclusive funds are administered and managed by Banco do Brasil, Banco Santander, Banco Itaú and Banco Bradesco. These funds invest their resources in quotas of other funds administered by the managing banks. The investment policies of exclusive funds determine the concentration of resources in financial assets with low credit risk (ANBIMA classification).

The changes in short and long term investments of the Company and its subsidiaries are stated as follows:

	Parent Company 06/30/2024	Parent Company 12/31/2023	Consolidated 06/30/2024	Consolidated 12/31/2023
Balance of the beginning of the period	**227,112**	**903**	**6,459,755**	**4,596,741**
Acquisition of company	-	-	-	60,765
Investments	31,440	1,070,036	9,762,642	21,386,486
Yield	5,849	20,840	407,779	742,127
(-) Redemptions	(255,155)	(864,667)	(8,704,708)	(20,327,536)
(-) Provision for losses on yield	-	-	-	(88)
(-) Foreign exchange rate expenses	-	-	-	(41)
Mark-to-market	-	-	(197)	1,351
Reclassification of items for sale	-	-	-	(50)
Balances at the end of the period/year	**9,246**	**227,112**	**7,925,271**	**6,459,755**

Of the total balance of short and long term investments considered restricted by the Company and its subsidiaries, the amount below refers to the escrow originated by the following acquisitions:

Acquisition	06/30/2024	12/31/2023
São Francisco group	74,980	332,314
Medical group	389	31,166
São José group	22,414	25,251
NDI MG group	137,202	131,540
UNIMED ABC	-	1,026
Clinipam	173,766	165,916
Lifecenter	-	25,778
Total	**408,751**	**712,991**

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

11 Trade accounts receivable

The balance of this group of accounts refers mainly to amounts receivable arising from the provision of services by the Company and its subsidiaries, as follows:

	Consolidated	
	06/30/2024	**12/31/2023**
Breakdown of accounts receivable		
Agreements and individuals	764,311	687,029
Subtotal	**764,311**	**687,029**
(-) Provision for impairment losses	(227,719)	(211,296)
Total	**536,592**	**475,733**

Breakdown of amounts receivable by maturity age is as follows:

	Consolidated	
	06/30/2024	**12/31/2023**
Falling due (A)	**47,547**	**119,830**
Overdue – in days: (B)	**716,764**	**567,199**
≤30	160,869	83,771
31-60	81,325	40,510
61-90	65,624	46,295
>90	408,946	396,623
Total (A) + (B)	**764,311**	**687,029**

The changes in Trade accounts receivable are shown below:

	Not related to insurance contracts
Balances at 01/01/2023	**403,408**
Reclassification of items for sale	(23,778)
Acquisition of companies	4,087
Revenues from health care not related to Operators' health plans	7,119,650
(-) Receipts	(6,993,061)
Reversal/(Formation) of impairment loss	50,774
Reversal/(Constitution) of expected disallowance	4,919
(-) Write-off due to effective credit losses	(90,417)
Other changes	151
Balances at 12/31/2023	**475,733**
Revenues from health care not related to Operators' health plans	604,464
(-) Receipts	(516,267)
Reversal/(Formation) of impairment loss	2,457
Reversal/(Constitution) of expected disallowance	(18,203)
(-) Write-off due to effective credit losses	(11,583)
Reclassification	(9)
Balances at 06/30/2024	**536,592**

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Changes in the provision for impairment losses in accounts receivable are as follows:

	Not related to insurance contracts
Balances at 01/01/2023	**(367,077)**
Acquisition of companies	(54)
Reclassification of items for sale	431
(Formation) of provision	(552,008)
Reversal of provision	607,701
Other changes	99,711
Balances at 12/31/2023	**(211,296)**
Reclassification	(120)
(Formation) of provision	(286,218)
Reversal of provision	270,472
Other changes	(557)
Balances at 06/30/2024	**(227,719)**

12 Recoverable taxes

The taxes recoverable of the Company and its subsidiaries are as follows:

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Income Tax - IRPJ (i)	20,340	37,221	267,930	323,555
Social contribution on income - CSLL (i)	-	-	49,093	45,306
Withholding income tax - IRRF	149,200	163,090	404,378	368,847
Social security credit	-	-	19,201	26,844
FGTS credits	-	-	4,282	4,282
PIS and Cofins credits	2,405	2,405	34,830	30,554
ISS credit	-	-	29,154	30,511
Advance of installment payments	706	707	4,367	4,367
Other recoverable taxes	-	-	790	791
Total	**172,651**	**203,423**	**814,025**	**835,057**

(i) The balance refers mainly to the monthly advance payment of the amount due for Income Tax and Social Contribution on income. At the end of the year, the accounts are reconciled with the taxes payable.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

13 Related party transactions and balances

The main balances of assets and liabilities on June 30, 2024 and December 31, 2023, as well as the transactions that influenced the income (loss) on June 30, 2024 and June 30, 2023, relating to operations with related parties, are as follows:

	Parent Company		Consolidated	
Assets	**06/30/2024**	**12/31/2023**	**06/30/2024**	**12/31/2023**
Other credits with related parties				
Receivables with shareholders	-	-	1,258	1,258
PPAR COM Investimentos Ltda. - Amounts receivable	-	-	1,988	1,988
Other credits	940	1,688	43	1,973
Subtotal	**940**	**1,688**	**3,289**	**5,219**
Total assets	**940**	**1,688**	**3,289**	**5,219**
Liabilities				
Dividends and interest on shareholders' equity payable				
Dividends payable	1,979	1,979	12,056	12,056
Interest on shareholders' equity	573	573	573	573
Subtotal	**2,552**	**2,552**	**12,629**	**12,629**
Other debits with related parties				
Debits with shareholders	2,517	2,517	2,552	2,635
Debit with investees	4,568	-	-	-
Canadá Administradora de Bens Imóveis Ltda.	1,343	1,343	1,343	1,343
Hapvida Assistência Médica S.A. (h)	234,190	219,850	-	-
Other debits	102	551	123	1,759
Subtotal	**242,720**	**224,261**	**4,018**	**5,737**
Leases payable				
Leases payable with related parties (a)	168	168	1,210,090	1,285,175
Leases payable with related parties – LPAR Imóveis Ltda. (b)	-	-	864,294	805,428
Subtotal	**168**	**168**	**2,074,384**	**2,090,603**
Debentures				
Debentures of the 6th private issue (g)	502,454	500,000	-	-
Commercial notes (i)	330,000	-	-	-
Subtotal	**832,454**	**500,000**	**-**	**-**
Total liabilities	**1,077,894**	**726,981**	**2,091,031**	**2,108,969**

	Parent Company		Consolidated	
Transactions in income (loss)	**06/30/2024**	**06/30/2023**	**06/30/2024**	**06/30/2023**
Revenue from health care services (c)	-	-	560	489
Media broadcasting expenses (d)	-	-	-	(150)
Expenses for the use of shared assets (e)	-	-	(1,226)	(826)
Interest on leases with Canadá Administradora de Bens Imóveis Ltda. (f)	(8)	(7)	(24,263)	(22,767)
Interest on leases with Fundação Ana Lima (f)	-	-	(1,374)	(834)
Interest on leases with Quixadá Participações Ltda. (f)	-	-	(23,851)	(20,821)
Interest on leases with LPAR Imóveis Ltda. (f)	-	-	(53,449)	(17,612)
Total income (loss)	**(8)**	**(7)**	**(103,603)**	**(62,521)**

(a) Lease of commercial property and movable property intended for the development of economic activities, pursuant to an agreement entered into between related parties (Canadá Administradora de Bens Imóveis Ltda., Quixadá Participações Ltda. and Fundação Ana Lima, non-consolidated entities under common control of the same shareholders of the Company and its subsidiaries) with an average maturities of 20 and 40 years, entered into based

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

on the appraisal of the market value performed by specialized companies, comprising: a) review of the base value every 60 months of the lease term; and b) annual updating based on the accumulated change of the IPCA. Increase observed in the 2nd quarter of 2024, mainly due to the addition of the new lease agreement of Hospital Ariano Suassuna with the related party Canada Administradora de Bens Imóveis Ltda.

(b) Lease of ten real estate properties (previously owned by the Company's subsidiaries), subject to a sale & leaseback (SLB) operation, with an investment vehicle owned by the Pinheiro Family (LPAR Imóveis Ltda.), the Company's parent company. The cap rate involved is 8.5% p.a., adjusted annually by the IPCA, for a lease term of 20 years (with an option to renew for the same period and an option to buy back), by the Company, under predetermined conditions.

(c) Revenues from health care plans of the Company and its subsidiaries with services to the companies that are part of Sistema Opinião de Comunicação, under common shareholding control, in the category of collective plans.

(d) Expenses with advertising hired by the Company and its subsidiaries to advertise in companies belonging to 'Sistema Opinião de Comunicação', under common shareholding control, with the purpose of promoting the sales of health care and dental care plans through marketing actions.

(e) The balance refers mainly to the use of aircraft belonging to the related party Canadá Administradora de Bens Imóveis Ltda. on business trips by the Management of the Company and its subsidiaries.

(f) Effect of interest on lease agreements with related parties.

(g) On December 29, 2023, the minutes of the meeting of the Board of Directors of the Company and its subsidiaries approved the issue of 500,000 simple debentures, not convertible into shares, in a single series and privately placed, subscribed and paid up exclusively by Casa de Saúde e Maternidade Santa Martha S.A.

(h) It includes amounts related to the acquisition process of the PROMED group, carried out by Ultra Som Serviços Médico (later merged into Hapvida Assistência Médica S.A., in accordance with the Addendum agreed between the parties (PROMED x Ultra Som sellers), on October 18, 2022. The Company repurchased shares on behalf of the seller, in which case it must transfer these amounts to its subsidiary Hapvida Assistência Médica S.A.

(i) On June 28, 2024, the minutes of the meeting of the Company's board of directors approved the Term of issuance of the 1st issue of book-entry commercial notes, with its subsidiary Casa de Saúde e Maternidade Santa Martha S.A. The total amount of the issue was R$ 330,000, carried out in a single series, maturing in June 2034.

The Company also has the following related companies, which, as they meet the criteria of IAS 24 (CPC 05) – Related Party Disclosures, are classified as related parties, although the Company has no transactions. These are: Canadá Táxi Aéreo Ltda.; Angiomed Angiologia de Manaus Ltda.; Canadá Participações e Investimentos Ltda.; Canada Investments Ltd.

Remuneration of key management personnel

Members of the Board of Directors and members of the Statutory Executive Board are considered key management personnel of the Company and its subsidiaries. Expenses with total management remuneration were R$ 85,339 in the period ended June 30, 2024 (R$ 47,709 as of June 30, 2023), including salary, Directors' fees, bonuses, short-term benefits, profit sharing, in addition to long-term incentive, as highlighted in the Note 26.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

14 Other assets

The balance classified under "Other Assets" is made up as follows:

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Advance to suppliers	1,363	22	69,359	124,602
(-) Provision for loss with advance to suppliers	(22)	(22)	(26,729)	(46,645)
Advance to employees	1	2	44,255	41,383
Advance of lawsuits	-	-	2,041	2,041
Prepaid expenses	1,446	2,282	78,923	68,329
Security deposit	-	-	3,595	2,360
Retention premiums to be appropriated (i)	11,219	13,200	34,984	19,383
Court-ordered freezing	-	-	54,745	44,506
Sale of São Francisco Resgate (iii)	-	-	6,631	46,631
Accounts receivable from post-established contracts	-	-	44,471	26,133
Other securities receivable (ii)	5,370	6,215	250,900	173,040
Total	**19,377**	**21,699**	**563,175**	**501,763**
Current	13,192	13,114	437,295	379,989
Non-current	6,185	8,585	125,880	121,774

(i) Accrued bonuses paid to Company executives for their time at the Company.
(ii) It mainly refers to accounts receivable from credit card transactions resulting from medical-hospital services.
(iii) Amounts receivable from the sale of São Francisco Resgate Ltda.

15 Investments (parent company)

a. Composition

	06/30/2024			12/31/2023		
	Equity	**Net assets for the period**	**Percentage of interest**	**Percentage of interest**	**Investment on 06/30/2024**	**Investment on 12/31/2023**
Hapvida Assistência Médica S.A.	10,050,130	389,582	100%	100%	10,050,130	10,197,915
NotreDame Intermédica Participações S.A.	10,606,804	377,770	100%	100%	45,281,446	44,235,679
BCBF Participações S.A.	-	208,643	17.82%	18.85%	-	2,033,790
Notre Dame Intermédica Saúde S.A. (NDI Saúde)	12,804,184	246,864	16.40%	-	2,100,503	-
Life Place Hapvida Ltda.	(31)	(36)	100%	100%	(31)	5
Total					**57,432,048**	**56,467,389**

b. Changes

	Hapvida Assistência Médica S.A.	Ultra Som Serviços Médicos S.A.	Hospital Antônio Prudente Ltda.	Hapvida Participações em Tecnologia Ltda.	Notre Dame Intermédica Participações S.A.	BCBF Participações S.A.	NDI Saúde S.A.	Life Place Hapvida Ltda.	Total
Balance at 01/01/2023	**6,289,749**	**4,822,755**	**83,802**	**3,743**	**42,953,197**	**-**	**-**	**-**	**54,153,246**
Amortization of surplus of assets	-	-	-	-	(294,642)	-	-	-	(294,642)
Equity in net income of subsidiaries	(1,038,145)	995,853	(25,101)	(5,342)	321,333	81,642	-	-	330,240
Dividends and interest on shareholders' equity	(607,727)	(354,710)	-	-	-	-	-	-	(962,437)
Capital increase (a)	-	-	-	-	833,777	1,828,277	-	5	2,662,059
Advance for future capital increase	-	-	-	-	559,700	-	-	-	559,700
Merger	5,523,485	(5,464,783)	(58,702)	1,599	-	(1,599)	-	-	-
Effect from dilution of interest in subsidiaries	3,761	(3,761)	-	-	(128,864)	127,844	-	-	(1,020)
Other comprehensive income	20,526	5,856	-	-	-	-	-	-	26,382
Other property changes	6,266	(1,210)	1	-	(8,822)	(2,374)	-	-	(6,139)
Balance at 12/31/2023	**10,197,915**	**-**	**-**	**-**	**44,235,679**	**2,033,790**	**-**	**5**	**56,467,389**
Amortization of surplus of assets	-	-	-	-	(135,567)	-	-	-	(135,567)
Equity in net income of subsidiaries	(56,910)	-	-	-	168,755	37,189	41,657	(36)	190,655
Capital increase	-	-	-	-	505,700	-	-	-	505,700
Advance for future capital increase	-	-	-	-	494,400	-	-	-	494,400
Merger	-	-	-	-	-	(2,060,043)	2,060,043	-	-
Effect from dilution of interest in subsidiaries	(164)	-	-	-	12,479	(10,936)	(1,197)	-	182
Other comprehensive income	(90,811)	-	-	-	-	-	-	-	(90,811)
Other property changes	100	-	-	-	-	-	-	-	100
Balance at 06/30/2024	**10,050,130**	**-**	**-**	**-**	**45,281,446**	**-**	**2,100,503**	**(31)**	**57,432,048**

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

16 Property, plant and equipment

The breakdown of property, plant and equipment is as follows:

		Consolidated			
	Annual average depreciation rate	**Cost**	**Accumulated depreciation (c)**	**Net 06/30/2024**	**Net 12/31/2023**
Right-of-use	7.80%	3,603,121	(807,201)	2,795,920	2,830,204
Land	-	466,124	-	466,124	459,862
Real estate	2.70%	1,390,969	(314,388)	1,076,581	1,096,603
Vehicles	11.60%	24,811	(20,721)	4,090	5,164
IT equipment	17.30%	460,142	(314,774)	145,368	150,905
Machinery and equipment	10.40%	1,717,974	(971,673)	746,301	807,849
Furniture and fixtures	9.80%	368,476	(192,101)	176,375	187,595
Facilities	3.30%	1,480,873	(470,072)	1,010,801	1,021,345
Construction in progress	-	335,317	-	335,317	323,031
Total		**9,847,807**	**(3,090,930)**	**6,756,877**	**6,882,558**

Changes in property, plant and equipment for the period ended June 30, 2024 and year ended December 31, 2023 are as follows:

	Consolidated						
	12/31/2023	**Additions**	**Write-offs**	**Depreciation (c)**	**Transfers**	**Remeasurement**	**06/30/2024**
Right-of-use	2,830,204	166,272	(33,828)	(115,616)	-	(51,112)	2,795,920
Land	459,862	2,079	(660)	-	4,843	-	466,124
Real estate	1,096,603	5,419	-	(25,747)	306	-	1,076,581
Vehicles	5,164	-	-	(1,291)	217	-	4,090
IT equipment	150,905	11,536	(15)	(29,742)	12,684	-	145,368
Machinery and equipment (a)	807,849	14,691	(178)	(72,868)	(3,193)	-	746,301
Furniture and fixtures	187,595	2,657	(51)	(16,120)	2,294	-	176,375
Facilities	1,021,345	39	(6,706)	(25,207)	21,330	-	1,010,801
Construction in progress (b)	323,031	51,024	(257)	-	(38,481)	-	335,317
Total	**6,882,558**	253,717	**(41,695)**	**(286,591)**	**-**	**(51,112)**	**6,756,877**

	Consolidated									
	12/31/2022	**Acquisition of Companies**	**Additions**	**Write-offs**	**Depreciation**	**Transfers**	**Remeasurement**	**Reclassification of items for sale**	**Sale & Leaseback effect**	**12/31/2023**
Right-of-use	2,090,968	6,510	83,328	(55,248)	(213,051)	(129)	354,258	(4,371)	567,939	2,830,204
Land	459,217	5,682	-	(39,249)	-	34,212	-	-	-	459,862
Real estate	2,080,135	1,280	-	(55,011)	(55,638)	32,396	-	(26)	(906,533)	1,096,603
Vehicles	21,469	-	-	485	(4,522)	3,538	-	(15,806)	-	5,164
IT equipment	166,830	638	23,870	(257)	(66,399)	27,329	-	(1,106)	-	150,905
Machinery and equipment	939,656	12,835	69,599	(1,190)	(149,810)	(56,372)	-	(6,869)	-	807,849
Furniture and fixtures	201,896	945	12,073	(427)	(31,745)	6,310	-	(1,457)	-	187,595
Facilities	855,138	268	3,061	-	(42,732)	207,944	-	(2,334)	-	1,021,345
Construction in progress	489,426	34,394	59,663	(490)	-	(255,228)	-	(4,734)	-	323,031
Total	**7,304,735**	**62,552**	**251,594**	**(151,387)**	**(563,897)**	**-**	**354,258**	**(36,703)**	**(338,594)**	**6,882,558**

(a) The balance refers to surgical equipment, communications equipment, machinery and non-hospital accessories, as well as refrigeration and ventilation equipment.

(b) The balance of construction in progress refers substantially to investments made in hospitals and clinics to improve and expand the physical facilities.

(c) With the adoption of IFRS 17 (CPC 50), part of the depreciation of the result was allocated to the insurance expense item.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

17 Intangible assets

The breakdown of intangible assets is as follows:

	Annual average rate of amortization	Consolidated			
		Cost	Accumulated amortization (b)	06/30/2024 Net	12/31/2023 Net
Client portfolio (c)	16.80%	5,258,840	(3,465,579)	1,793,261	2,195,982
Software	15.20%	868,996	(380,477)	488,519	378,636
Trademarks and patents	5.70%	2,797,436	(570,064)	2,227,372	2,311,648
Non-compete	20.00%	37,922	(33,896)	4,026	6,918
Goodwill	-	45,219,400	-	45,219,400	45,219,461
Other (a)	21.20%	211,396	(12,732)	198,664	172,682
Total		**54,393,990**	**(4,462,748)**	**49,931,242**	**50,285,327**

Changes in intangible asset balances for the period ended June 30, 2024 and year ended December 31, 2023 are as follows:

	Consolidated					
	12/31/2023	Additions	Write-offs	Amortization (b)	Transfers	06/30/2024
Client portfolio (c)	2,195,982	-	-	(402,721)	-	1,793,261
Software	378,636	-	(4,281)	(62,034)	176,198	488,519
Trademarks and patents	2,311,648	-	-	(84,276)	-	2,227,372
Non-compete	6,918	-	-	(2,892)	-	4,026
Goodwill	45,219,461	-	(61)	-	-	45,219,400
Others (a)	172,682	202,456	-	(276)	(176,198)	198,664
Total	**50,285,327**	**202,456**	**(4,342)**	**(552,199)**	**-**	**49,931,242**

	Consolidated								
	12/31/2022	Acquisition of Companies	Adjustments - IFRS 17 (CPC 50)	Additions	Write-offs	Amortization	Transfers	Reclassification of items for sale	12/31/2023
Client portfolio (c)	2,930,485	69,779	(29,743)	-	-	(791,433)	16,894	-	2,195,982
Software	200,392	207	-	22,919	(136)	(95,691)	265,375	(14,430)	378,636
Trademarks and patents	2,480,718	22	-	-	-	(168,560)	(529)	(3)	2,311,648
Non-compete	11,590	-	-	-	(166)	(4,662)	156	-	6,918
Goodwill	44,881,735	532,705	(27,727)	-	(167,099)	-	92	(245)	45,219,461
Others (a)	251,233	(1,811)	-	220,901	(12,552)	(878)	(281,988)	(2,223)	172,682
Total	**50,756,153**	**600,902**	**(57,470)**	**243,820**	**(179,953)**	**(1,061,224)**	**-**	**(16,901)**	**50,285,327**

(a) Balances refer mainly to software under development.
(b) With the adoption of IFRS 17 (CPC 50), part of the amortization of the result was allocated to the insurance expense item.
(c) The opening of client portfolios is shown below:

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Breakdown of client portfolio	**Cost**	**Accumulated amortization**	**Net balance 06/30/2024**	**Net balance 12/31/2023**
Promed Assistência	134,646	(118,617)	16,029	35,264
Promed Brasil	6,682	(6,682)	-	-
Promed Saúde	22,707	(22,707)	-	-
Sf Documenta	16,874	(16,874)	-	-
RN Metropolitan	32,354	(32,354)	-	-
Premium	19,937	(17,019)	2,918	5,835
Gram Jardim América Saúde	7,539	(7,539)	-	-
Gram América	4,770	(4,770)	-	187
Gram Promed	6,445	(6,445)	-	-
Sf Operadora	2,379,572	(1,876,846)	502,726	703,817
Sf Odonto	98,068	(98,068)	-	10,507
Sf Gsfrp Sfss	9,009	(7,815)	1,194	1,672
Sf Gsfrp Sfo	20,765	(20,765)	-	2,005
Gmed Medical	60,509	(51,200)	9,309	16,291
Gsj Operadora	51,789	(48,412)	3,377	10,132
Gndi Ndi Part	826,839	(406,413)	420,426	504,512
Uniplan	10,148	(10,148)	-	90
Freelife	7,602	(7,602)	-	41
Sta Casa Pirassununga	1,674	(1,524)	150	232
Tres Lagoas	552	(488)	64	91
Santa Casa Barretos	3,600	(3,143)	457	654
Fwbp	4,000	(3,245)	755	952
Irm Sta Casa Mis Leme	2,900	(2,233)	667	810
Medporto Assist Médica Ltda	400	(308)	92	112
Amhpla	24,434	(17,198)	7,236	8,442
Assoc Forn Cana Piracicaba	4,119	(2,899)	1,220	1,423
Irm Sta Casa Mis Sjrio Preto	15,301	(8,360)	6,941	7,698
Prosaude De Araras	5,652	(2,732)	2,920	3,203
Bucal Help	901	(789)	112	154
Opsfelder Help Odonto	36	(30)	6	7
Benefit	848	(572)	276	318
Oral Brasil Planos	1,050	(643)	407	459
Apo	8,000	(4,267)	3,733	4,133
Soesp	8,533	(4,732)	3,801	4,224
Dental Norte	1,367	(720)	647	714
Cojun	125	(60)	65	71
MEDES	1,800	(1,800)	-	-
AMICO	3,100	(3,100)	-	-
CLIMEP	180	(180)	-	-
SOMED	700	(700)	-	-
CRAM	1,800	(1,800)	-	-
BENEMED	9,584	(9,584)	-	-
Plamheg	23,000	(15,979)	7,021	9,418
Samedh	18,691	(12,461)	6,230	8,099
HB group	40,118	(2,214)	37,904	40,039
HRF	3,617	(2,035)	1,582	1,846
Grupo Notre Dame	8,159	(7,861)	298	307
Santamália group	18,923	(18,923)	-	-
Unimed ABC	21,892	(15,915)	5,977	7,061
Cruzeiro do Sul group	18,684	(11,060)	7,624	8,415
SAMED Group	30,313	(21,538)	8,775	10,493
Green Line group	154,271	(75,668)	78,603	84,909
Mediplan group	59,122	(30,815)	28,307	31,039
Belo Dente	46,462	(26,145)	20,317	22,335
São José group	6,378	(4,321)	2,057	2,442
São Lucas group	111,005	(49,083)	61,922	66,912
Clinipam group	178,804	(126,944)	51,860	61,545
Ecole	15,030	(10,686)	4,344	5,494
Santa Mônica group	6,554	(6,554)	-	-
Lifeday	25,491	(15,429)	10,062	12,144
Climepe	41,833	(21,928)	19,905	22,140
Bio Saúde	29,661	(18,597)	11,064	13,672
Medisanitas group	223,671	(46,765)	176,906	183,464
Serpram group	41,093	(13,661)	27,432	29,330
CCG group	301,799	(62,256)	239,543	250,828
Family	17,358	(17,358)	-	-
Total	**5,258,840**	**(3,465,579)**	**1,793,261**	**2,195,982**

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Goodwill

The goodwill balances (intangible assets with an indefinite useful life) were submitted to an impairment test on December 31, 2023. The Company and its subsidiaries perform the impairment test annually.

The Company and its subsidiaries prepared the impairment test considering the history of business combinations, as shown in the table below:

Breakdown of goodwill	**06/30/2024**
NDI Group	31,818,537
São Francisco group	1,679,040
Promed Group	1,756,282
América Group	305,399
Medical	194,406
São José	236,656
Premium	262,413
Madrecor	68,043
Octaviano Neves	109,158
Luis França	16,064
RN Metropolitan	32,723
São Lucas	39,058
Cariri	6,603
Cetro	23,682
Parauapebas	11,117
Sagratcor	15,022
Viventi	19,234
HB group	505,450
Grupo Notre Dame	480,134
Santamália group	125,405
Hospital Family	79,030
Unimed ABC	71,476
SAMCI/IBRAGE	24,052
Hospital São Bernardo	153,509
Nova Vida group	151,673
Cruzeiro do Sul group	60,578
SAMED Group	196,737
Green Line group	832,941
Mediplan group	230,334
Hospital Jacarepaguá	48,118
Belo Dente	23,916
Ghelfond group	163,187
São José group	94,264
São Lucas group	218,093
Clinipam group	2,313,674
Ecole	39,633
LabClin	4,464
Hospital Coração Balneário Camboriú	37,945
Santa Mônica group	130,829
Hospital e Maternidade Santa Brígida	22,882
Lifeday	114,405
Lifecenter	211,719
Climepe	91,023
Bio Saúde	77,594
Hospital do Coração de Londrina	197,179
NDI MG group	855,856
Hospital e Maternidade Maringá	50,117
Serpram group	112,354
Casa de Saúde Maternidade Santa Martha	129,861
CCG group	700,591
Hospital do Coração Duque de Caxias	55,818
Other	21,122
Total	**45,219,400**

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

In addition, the Company and its subsidiaries presented a sensitivity analysis of the key assumptions used in the last calculation of CGU's recoverability on the base date December 31, 2023, as per Note 34.

According to the recoverability analysis prepared by an independent consultant hired by the Company and its subsidiaries to support Management's conclusion, for the last year ended December 31, 2023, it was concluded that the value in use of the CGU is higher than its respective book value, indicating that there were no indications of impairment.

No contrary indications were observed for the period ending June 30, 2024.

18 Insurance contracts (Consolidated)

The following are the reconciliation tables for contracts measured using the General Measurement Model (BBA) and the simplified model (PAA), as well as the openings by component and the measurement of the insurance Contractual Margin (CSM).

a. Reconciliation of balances for contracts measured using the General Measurement Model (BBA)

Individual - Health and Dental

	06/30/2024				12/31/2023 (ii)			
	Assets/Liabilities for remaining coverage (LRC/PCR)				Assets/Liabilities for remaining coverage (LRC/PCR)			
	Exclusion of loss component	Loss component	Liability for incurred claims (LIC/PSI)	Total	Exclusion of loss component	Loss component	Liability for incurred claims (LIC/PSI)	Total
Insurance contract assets at the beginning of the period/year	123,878	(37)	(541)	123,300	1,719,899	(49,479)	(491,615)	1,178,805
Insurance contract liabilities at the end of the period/year	640,210	(4,452)	(675,057)	(39,299)	-	-	-	-
Net balance of assets (liabilities) at the beginning of the period/year (A)	**764,088**	**(4,489)**	**(675,598)**	**84,001**	**1,719,899**	**(49,479)**	**(491,615)**	**1,178,805**
Insurance revenue (B)	**2,884,719**	**-**	**-**	**2,884,719**	**5,234,473**	**-**	**-**	**5,234,473**
Contracts measured using the retrospective fair value approach	1,273,442	-	-	1,273,442	1,181,730	-	-	1,181,730
Other contracts	1,611,277	-	-	1,611,277	4,052,743	-	-	4,052,743
Insurance service expenses (C)	**(89,400)**	**4,166**	**(2,533,551)**	**(2,618,785)**	**(145,674)**	**49,963**	**(4,552,008)**	**(4,648,219)**
Claims incurred and other expenses	-	-	(2,642,220)	(2,642,220)	-	-	(3,999,443)	(3,999,443)
Amortization of acquisition cost flows	(89,400)	-	-	(89,400)	(145,674)	-	-	(145,674)
Losses on onerous contracts and reversals of said losses	-	4,166	-	4,166	-	49,963	-	49,463
Changes in liability for claims incurred	-	-	108,669	108,669	-	-	(552,565)	(552,565)
Result of Insurance service (D) = (B) + (C)	**2,795,319**	**4,166**	**(2,533,551)**	**265,934**	**5,088,799**	**49,963**	**(4,552,008)**	**586,254**
Insurance financial expenses (E)	**11,213**	**(259)**	**(29,888)**	**(18,934)**	**(15,280)**	**(4,312)**	**(72,374)**	**(91,966)**
Cash flows (F)	**(3,245,467)**	**-**	**2,575,549**	**(669,918)**	**(6,029,330)**	**-**	**4,440,399**	**(1,588,931)**
Premiums received	(3,366,743)	-	-	(3,366,743)	(6,284,902)	-	-	(6,284,902)
Claims and other expenses paid (i)	-	-	2,575,549	2,575,549	-	-	4,440,399	4,440,399
Cash flows from acquisition of insurance	121,276	-	-	121,276	234,469	-	-	234,469
Paid consideration - business combination	-	-	-	-	21,103	-	-	21,103
Other changes (G)(ii)	**-**	**-**	**-**	**-**	**-**	**(161)**	**-**	**(161)**
Net closing balance of assets (liabilities) for the period/year (A) + (D) + (E) + (F) + (G)	**325,153**	**(582)**	**(663,488)**	**(338,917)**	**764,088**	**(4,489)**	**(675,598)**	**84,001**
Insurance contract assets at the end of the period/year	94,095	(476)	(311)	93,308	123,878	(37)	(541)	123,300
Insurance contract liabilities at the end of the period/year	231,056	(107)	(663,173)	(432,224)	640,210	(4,452)	(675,057)	(39,299)

(i) Considering the verticalized model of the Company and its subsidiaries, this line also includes the costs of using the Company’s own network, paid during the provision of the service to beneficiaries.
(ii) Balance as of December 31, 2023 (twelve months).

b. Reconciliation of balances for contracts measured using the simplified model (PAA)

Collective - Health and Dental

	06/30/2024				12/31/2023			
	Assets/Liabilities for remaining coverage (LRC/PCR)	Liability for incurred claims (LIC/PSI)			Assets/Liabilities for remaining coverage (LRC/PCR)	Liability for incurred claims (LIC/PSI)		
	Exclusion of loss component	Cash flow from the claim	Risk adjustment	Total	Exclusion of loss component	Cash flow from the claim	Risk adjustment	Total
Insurance contract assets at the beginning of the period/year	36,334	(5,833)	(108)	30,393	33,951	583	9	34,543
Insurance contract liabilities at the beginning of the period/year	1,314,310	(3,376,859)	(64,126)	(2,126,675)	454,598	(2,942,803)	(58,565)	(2,546,770)
Net balance of assets (liabilities) at the beginning of the period/year (A)	**1,350,644**	**(3,382,692)**	**(64,234)**	**(2,096,282)**	**488,549**	**(2,942,220)**	(58,556)	**(2,512,227)**
Insurance revenue (B)	**10,500,620**	**-**	**-**	**10,500,620**	**21,567,299**	**-**	**-**	**21,567,299**
Other contracts	10,500,620	-	-	10,500,620	21,567,299	-	-	21,567,299
Insurance service expenses (C)	**(476,361)**	**(8,916,098)**	**(192)**	**(9,392,651)**	**(986,716)**	**(17,231,963)**	**2,685**	**(18,215,994)**
Claims incurred and other expenses	-	(9,210,323)	(29,242)	(9,239,565)	-	(17,994,416)	(70,800)	(18,065,216)
Amortization of acquisition cost flows	(476,361)	-	-	(476,361)	(986,716)	-	-	(986,716)
Changes in liability for claims incurred	-	294,225	29,050	323,275	-	762,453	73,485	835,938
Result of insurance service (D) = (B) + (C)	**10,024,259**	**(8,916,098)**	**(192)**	**1,107,969**	**20,580,583**	**(17,231,963)**	**2,685**	**3,351,305**
Insurance financial expenses (E)	**(32,488)**	**(143,938)**	**(2,742)**	**(179,168)**	**(69,070)**	**(420,460)**	**(8,363)**	**(497,893)**
Cash flows (F)	**(10,418,617)**	**8,906,709**	**-**	**(1,511,908)**	**(19,649,418)**	**17,211,951**	**-**	**(2,437,467)**
Premiums received	(10,901,618)	-	-	(10,901,618)	(20,618,248)	-	-	(20,618,248)
Claims and other expenses paid (i)	-	8,906,709	-	8,906,709	-	17,211,951	-	17,211,951
Cash flows from acquisition of insurance	483,001	-	-	483,001	968,830	-	-	968,830
Net closing balance of assets (liabilities) at the end of the period/year | (A) + (D) + (E) + (F)	**923,798**	**(3,536,019)**	**(67,168)**	**(2,679,389)**	**1,350,644**	**(3,382,692)**	**(64,234)**	**(2,096,282)**
Insurance contract assets at the end of the period/year	29,284	(6,663)	(124)	22,497	36,334	(5,833)	(108)	30,393
Insurance contract liabilities at the end of the period/year	894,514	(3,529,356)	(67,044)	(2,701,886)	1,314,310	(3,376,859)	(64,126)	(2,126,675)

(i) Considering the verticalized model of the Company and its subsidiaries, this line also includes the costs of using the Company's own network, paid during the provision of the service to beneficiaries.
(ii) Balance as of December 31, 2023 (twelve months).

For contracts measured by PAA, there was no loss component for the remaining coverage (LRC/PCR) in the period.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

c. Changes by component for insurance contracts other than those to which the simplified approach has been applied (PAA)

	06/30/2024				12/31/2023			
	VP estimate of Cash Flows	**Risk adjustment**	**Contractual service margin**	**Total**	**VP estimate of Cash Flows**	**Risk adjustment**	**Contractual service margin**	**Total**
Net balance of assets (liabilities) at the beginning of the period/year (A)	**5,521,987**	**(422,904)**	**(5,015,082)**	**84,001**	**4,242,594**	**(430,671)**	**(2,633,118)**	**1,178,805**
Changes to the current service (B)	**(596,910)**	**21,536**	**721,131**	**145,757**	**28,649**	**115,841**	**943,527**	**1,088,017**
CSM recognized as a service provided	-	-	721,131	721,131	-	-	943,527	943,527
Risk adjustment recognized as expired risk	-	21,536	-	21,536	-	115,841	-	115,841
Experience adjustments	(596,910)	-	-	(596,910) (i)	28,649	-	-	28,649
Changes relating to future service (C)	**809,276**	**(21,316)**	**(786,176)**	**1,784**	**2,960,634**	**51,384**	**(2,976,042)**	**35,976**
Contracts initially recognized in the period/year	483,370	(27,768)	(455,664)	(62)	737,091	(47,555)	(689,735)	(199)
Changes in estimates affecting CSM	316,139	7,037	(323,176)	-	2,168,396	95,540	(2,263,936)	-
Losses on groups of onerous contracts and reversals of these losses	9,767	(585)	(7,336)	1,846	55,147	3,399	(22,371)	36,175
Changes relating to past service (D)	**102,661**	**15,734**	**-**	**118,395**	**(487,687)**	**(50,214)**	**-**	**(537,901)**
Adjustments to liabilities for Events that occurred	102,661	15,734	-	118,395	(487,687)	(50,214)	-	(537,901)
Insurance result (E) = (B) + (C) + (D)	**315,027**	**15,954**	**(65,045)**	**265,936**	**2,501,596**	**117,011**	**(2,032,515)**	**586,092**
Insurance financial expense (F)	**231,363**	**12,481**	**(262,778)**	**(18,934)**	**387,669**	**(109,244)**	**(370,391)**	**(91,966)**
Cash Flows (G)	**(669,920)**	**-**	**-**	**(669,920)**	**(1,609,872)**	**-**	**20,942**	**(1,588,930)**
Consideration received	(3,366,743)	-	-	(3,366,743)	(6,284,901)	-	-	(6,284,901)
Events and expenses paid	2,575,549	-	-	2,575,549	4,440,399	-	-	4,440,399
Acquisition costs	121,274	-	-	121,274	234,469	-	-	234,469
Paid consideration – business combination	-	-	-	-	161	-	20,942	21,103
Net closing balance of assets (liabilities) at the end of the period/year (A) + (E) + (F) + (G)	**5,398,458**	**(394,469)**	**(5,342,905)**	**(338,917)**	**5,521,987**	**(422,904)**	**(5,015,082)**	**84,001**

The experience adjustment is due to the higher-than-expected increase in insurance expenses caused by the dengue epidemic and other viruses observed in Brazil in the first half of 2024.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

d. Impacts on the period/year of the transition approaches adopted to establish CSM

	06/30/2024			12/31/2023		
	Fair value approach	Other contracts	Total	Fair value approach	Other contracts	Total
Margin of insurance contracts at the beginning of the year (A)	**2,353,642**	**2,661,440**	**5,015,082**	**1,658,894**	**974,224**	**2,633,118**
Changes related to current services (B)	**(371,354)**	**(349,777)**	**(721,131)**	**(520,497)**	**(423,030)**	**(943,527)**
Contractual service margin recognized for services provided	(371,354)	(349,777)	(721,131)	(520,497)	(423,030)	(943,527)
Changes that relate to future services (C)	**333,675**	**452,501**	**786,176**	**1,012,656**	**1,963,386**	**2,976,042**
Contracts initially recognized in the period/year	-	455,664	455,664	-	689,735	689,735
Changes in estimates that adjust the contractual service margin	333,675	(3,163)	330,512	1,012,656	1,273,651	2,286,307
Result of insurance service (D) = (B) + (C)	**(37,679)**	**102,724**	**65,045**	**492,159**	**1,540,356**	**2,032,515**
Insurance financial expenses (E)	**114,154**	**148,624**	**262,778**	**202,589**	**167,802**	**370,391**
Other changes (F)	**-**	**-**	**-**	**-**	**(20,942)**	**(20,942)**
Contractual service margin at the end of the period/year (A) + (D) + (E) + (F)	**2,430,117**	**2,912,788**	**5,342,905**	**2,353,642**	**2,661,440**	**5,015,082**

e. New business components

	06/30/2024					12/31/2023				
	Contracts Issued		Acquired Contracts			Contracts Issued		Acquired Contracts		
	Not onerous	Onerous	Not onerous	Onerous	Total	Not onerous	Onerous	Not onerous	Onerous	Total
Insurance contracts assets/liabilities										
Estimated PV of future cash flow outflows, excluding acquisition costs	3,893,642	-	291,318	-	4,184,960	2,441,050	-	1,602,397	-	4,043,447
Estimates of future cash flow outflows at present value	**3,893,642**	**-**	**291,318**	**-**	**4,184,960**	**2,441,050**	**-**	**1,602,397**	**-**	**4,043,447**
Estimated PV of future cash flow inflows	(5,933,250)	-	(1,037,949)	-	(6,971,199)	(5,555,273)	-	(2,654,205)	-	(8,209,478)
Risk adjustment	261,975	-	199,664	-	461,639	223,451	-	263,686	-	487,137
CSM	2,919,670	-	2,423,235	-	5,342,905	2,569,493	-	2,445,589	-	5,015,082
Other changes	-	-	-	-	-	-	-	-	-	-
Total amount included in insurance contract assets/liabilities for the period/year	**1,142,037**	**-**	**1,876,268**	**-**	**3,018,305**	**(321,279)**	**-**	**1,657,467**	**-**	**1,336,188**

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

f. Realization of the Contractual Insurance Margin (CSM)

	06/30/2024					
Insurance contracts issued	**≤05 years**	**05–10 years**	**10–15 years**	**15–20 years**	**>20 years**	**Total**
Individual – BBA	3,707,726	1,130,422	345,365	110,432	48,961	5,342,905
Total	**3,707,726**	**1,130,422**	**345,365**	**110,432**	**48,961**	**5,342,905**

	12/31/2023					
Insurance contracts issued	**≤05 years**	**05–10 years**	**10–15 years**	**15–20 years**	**>20 years**	**Total**
Individual – BBA	3,277,866	1,202,599	365,728	116,845	52,044	5,015,082
Total	**3,277,866**	**1,202,599**	**365,728**	**116,845**	**52,044**	**5,015,082**

19 Loans, financing and debentures

a. Breakdown

			Parent Company		Consolidated	
Type	**Maturity**	**Interest rate**	**06/30/2024**	**12/31/2023**	**06/30/2024**	**12/31/2023**
Working capital	until Feb 2026	USD 5.2 + 6.84 p.a.	-	-	282,758	247,728
Commercial notes (v)	June 2034	Fixed rate	330,000	-	-	-
Debentures – 1st issue – Hapvida Participações	until Jul 2026	109% – 110.55% DI rate	867,405	875,299	867,405	875,299
Debentures – 2nd issue – Hapvida Participações	until Apr 2029	CDI + 1.45–1.65% p.a.	2,540,610	2,545,843	2,540,610	2,545,843
Debentures – 3rd issue – Hapvida Participações	May 2029	CDI + 1.60% p.a.	2,024,027	2,026,182	2,024,027	2,026,182
Debentures – 4th issue – Hapvida Participações	Feb 2024	CDI + 1.70% p.a.	-	838,292	-	838,292
Debentures – 5th issue – Hapvida Participações	Jan 2030	CDI + 1.75% p.a.	993,782	995,656	993,782	995,656
Debentures – 6th private issue – Hapvida Participações (iii)	Jan 2030	Fixed rate	502,454	500,000	-	-
Debentures – 7th issue – Hapvida Participações	May 2031	CDI + 1.60% p.a.	1,009,657		1,009,657	-
Debentures – 3rd issue – NDI Saúde	Aug 2024	CDI + 1.60% p.a.	-	-	279,481	281,226
Debentures – 4th issue – Hapvida Participações (ii)	Sept/25	CDI + 2.65% p.a.	101,467	101,386	101,467	101,386
Debentures – 5th issue – Hapvida Participações (ii)	Nov 2025	CDI + 2.65% p.a.	297,150	297,165	297,150	297,165
Debentures – 6th issue – Hapvida Participações (ii)	Oct 2027	CDI + 1.45% p.a.	1,228,384	1,230,591	1,228,384	1,230,591
CRI – Hapvida Assistência Médica (i)	Dec 2031	IPCA + 5.7505%	-	-	1,117,919	1,083,401
CRI – NDI Saúde – series 1 (iv)	Dec 2027	CDI+0.75% p.a.	-	-	534,746	533,697
CRI – NDI Saúde – series 2 (iv)	Dec 2029	IPCA + 7.0913 p.a.	-	-	383,014	372,063
CRI – NDI Saúde – series 3 (iv)	Dec 2034	IPCA + 7.2792 p.a.	-	-	100,925	97,885
Total			**9,894,936**	**9,410,414**	**11,761,325**	**11,526,414**
Current			955,070	1,800,299	1,274,341	2,109,941
Non-current			8,939,866	7,610,115	10,486,984	9,416,473

(i) Transaction with a contracted hedge instrument, aimed at swapping the IPCA rate + 5.7505% for the CDI rate of 113.32%. With the merger of Ultra Som Serviços Médicos S.A. into Hapvida Assistência Médica S.A. on December 01, 2023, the latter assumed the debt previously held by Ultra Som Serviços Médicos S.A.

(ii) Debentures assigned by the former subsidiary BCBF Participações S.A. to the Company, with the Company becoming the issuer of the respective debentures for all purposes and effects. The transfer is part of the simplification of the Company's corporate structure.

(iii) On December 29, 2023, the minutes of the meeting of the Board of Directors of the Company and its subsidiaries approved the issue of 500,000 simple debentures, not convertible into shares, in a single series and privately placed, subscribed and paid up exclusively by Casa de Saúde e Maternidade Santa Martha S.A.

(iv) On March 28, 2024, the subsidiary BCBF Participações S.A. (BCBF) was merged into Notre Dame Intermédica Saúde S.A., which currently holds the Real Estate Receivables Certificate – CRI previously issued by BCBF.

(v) On June 28, 2024, the minutes of the meeting of the Company's board of directors approved the Term of issuance of the 1st issue of book-entry commercial notes, with its subsidiary Casa de Saúde e Maternidade Santa Martha S.A. The total amount of the issue was R$ 330,000, carried out in a single series, maturing in June 2034.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

b. Changes

	Parent Company			Consolidated			
	Debentures	**Commercial note**	**Total**	**Loans and financing**	**Debentures**	**Real Estate Receivables Certificate - CRI**	**Total**
Balances at 01/01/2023	**6,089,004**	**-**	**-**	**328,434**	**9,379,856**	**2,009,391**	**11,717,681**
Acquisition of companies	-	-	-	10,833	-	-	10,833
Transfer of debentures	1,823,832	-	-	-	-	-	-
Funding	2,250,000	-	-	260,000	1,750,000	-	2,010,000
Appropriation of issue costs	(2,085)	-	-	-	10,799	7,964	18,763
Incurred interest	1,060,442	-	-	17,451	1,212,531	237,733	1,467,715
Payment of principal	(819,335)	-	-	(332,909)	(1,946,003)	-	(2,278,912)
Payment of interest and exchange-rate change	(993,314)	-	-	(20,998)	(1,217,413)	(165,387)	(1,403,798)
Exchange-rate change	-	-	-	(15,083)	-	-	(15,083)
Issue costs	1,870	-	-	-	1,870	(2,655)	(785)
Balances at 12/31/2023	**9,410,414**	**-**	**9,410,414**	**247,728**	**9,191,640**	**2,087,046**	**11,526,414**
Funding	1,000,000	330,000	1,330,000	-	1,000,000	-	1,000,000
Appropriation of issue costs	2,822	-	2,822	-	3,265	12,517	15,782
Incurred interest	498,650	-	498,650	9,621	512,344	124,807	646,772
Payment of principal (i)	(750,000)	-	(750,000)	-	(750,000)	-	(750,000)
Payment of interest and exchange-rate change	(591,043)	-	(591,043)	(8,672)	(609,379)	(79,214)	(697,265)
Exchange-rate change	-	-	-	34,081	-	(8,552)	25,529
Issue costs	(5,907)	-	(5,907)	-	(5,907)	-	(5,907)
Balances at 06/30/2024	**9,564,936**	**330,000**	**9,894,936**	**282,758**	**9,341,963**	**2,136,604**	**11,761,325**

(i) Due to the re-profiling of financial liabilities, the debentures were settled as part of a financial strategy. This action was motivated by the finding that the financial cost of the debenture, represented by the CDI rate plus 1.70% p.a., exceeded the percentage applied in the aforementioned operation.

The loans and financing of the Company and its subsidiaries are guaranteed by: (i) guarantors, (ii) chattel mortgage of the financed hospital assets, or (iii) short and long term investments held in the same institutions where the credits were contracted.

Working capital loan agreements have restrictive contractual clauses that are specific to the nature of the operation, which, if not complied with, may result in the early maturity of the respective operations.

These clauses, among other conditions, require that the Company and its subsidiaries do not default on their obligations; lawsuits, claims or proceedings pending or about to be filed, which, if decided against the Company and its subsidiaries, would have a detrimental effect on their financial condition or impair their ability to fulfill their obligations.

The management of the Company and its subsidiaries assesses compliance with the contractual clauses of financial and non-financial covenants monthly, through a detailed analysis of each restrictive clause by the respective responsible area of the Company and its subsidiaries, formalized in a memorandum. On June 30, 2024, the Company and its subsidiaries are fully complying with the contractual clauses and restrictions related to early maturity.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

c. Aging - Loans, financing and debentures

As of June 30, 2024 and December 31, 2023, loans, financing and debentures had the following maturity:

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
2024	959,286	1,800,299	1,281,128	2,109,941
2025	705,624	706,937	697,646	703,266
2026	1,136,293	1,137,396	1,404,724	1,905,387
2027	1,019,675	1,020,769	1,554,123	1,017,097
>2028	6,074,058	4,745,013	6,823,704	5,790,723
Total	**9,894,936**	**9,410,414**	**11,761,325**	**11,526,414**

d. Debentures

d.1 *Issue of debentures*

The main information regarding debenture issues by the Company and its subsidiaries is detailed below:

Issuer	Security	Modality	Issued units	Issue	Final maturity	Average charges	Funding
Hapvida Part. e Inv. S.A.	HAPV11	1st Issue - series 1	1,764,888	07/10/2019	07/10/2024	109% CDI	R$ 1,764,888
Hapvida Part. e Inv. S.A.	HAPV21	1st Issue - series 2	235,112	07/10/2019	07/10/2026	110.55% CDI	R$ 235,112
Hapvida Part. e Inv. S.A.	HAPV12	2nd Issue - series 1	1,250,000	10/30/2021	04/30/2027	CDI + 1.45% p.a.	R$ 1,250,000
Hapvida Part. e Inv. S.A.	HAPV22	2nd Issue - series 2	1,250,000	10/30/2021	04/30/2029	CDI + 1.65% p.a.	R$ 1,250,000
Hapvida Part. e Inv. S.A.	HAPV13	3rd Issue	2,000,000	05/10/2022	05/10/2029	CDI + 1.60% p.a.	R$ 2,000,000
Hapvida Part. e Inv. S.A.	HAPV15	5th Issue	1,000,000	12/27/2023	01/27/2030	CDI + 1.75% p.a.	R$ 1,000,000
NDI Saúde S.A.	NDMI13	3rd Issue	800,000	08/01/2019	08/01/2024	CDI + 1.60% p.a.	R$ 800,000
Hapvida Part. e Inv. S.A. (*)	BCBF 14	4th Issue	750,000	09/22/2020	09/22/2025	CDI + 2.65% p.a.	R$ 750,000
Hapvida Part. e Inv. S.A. (*)	BCBF 15	5th Issue	700,000	11/04/2020	11/04/2025	CDI + 2.65% p.a.	R$ 700,000
Hapvida Part. e Inv. S.A. (*)	BCBF 16	6th Issue	1,200,000	10/07/2021	10/07/2027	CDI + 1.45% p.a.	R$ 1,200,000
Hapvida Part. e Inv. S.A. - Private	HAPV16	6th Issue	500,000	12/29/2023	01/29/2030	Fixed rate	R$ 500,000
Hapvida Part. e Inv. S.A.	HAPV17	7th issuance	1,000,000	05/10/2024	05/10/2031	CDI + 1.60% p.a.	R$ 1,000,000

d.2 *Collaterals*

The debentures of the 1st series, 2nd series and single series (first, second, third, fifth and seventh issues, respectively), issued by Hapvida Participações e Investimentos S.A., have a personal guarantee in the form of a surety bond provided by the guarantor Hapvida Assistência Médica S.A., a subsidiary of the Company, as joint and several debtor and principal payer of all the obligations assumed.

The third issue of single series debenture, issued by Notre Dame Intermédica Saúde S.A., has a personal guarantee in the form of a surety bond.

The debentures of single series, fourth, fifth and sixth series, initially issued by BCBF Participações S.A. and subsequently transferred to Hapvida Participações e Investimentos S.A., have a personal guarantee in the form of a surety bond provided by the guarantor Notre Dame Intermédica Saúde S.A. – "NDI Saúde S.A.", as joint and several debtor and principal payer of all the obligations assumed.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

d.3 *Covenants*

The debentures and Real Estate Receivables Certificates (CRI) issued by the Company and its subsidiaries have contractual clauses and restrictions related to early maturity, including, but not limited to, those that oblige the Company and its subsidiaries to comply with the "financial ratio" defined in their respective deeds, measured quarterly. Below are the contractual financial ratios to be fulfilled, per issue:

Title	Required financial ratio
HAPV11	Net debt/Adjusted EBITDA ≤ 3,0
HAPV21	Net debt/Adjusted EBITDA ≤ 3,0
HAPV12	Net debt/Adjusted EBITDA ≤ 3,0
HAPV22	Net debt/Adjusted EBITDA ≤ 3,0
HAPV13	Net debt/Adjusted EBITDA ≤ 3,0
HAPV15	Net debt/Adjusted EBITDA ≤ 3,0
NDMI13	Net debt/Adjusted EBITDA ≤ 2,5
BCBF 14	Net debt/Adjusted EBITDA ≤ 3,0
BCBF 15	Net debt/Adjusted EBITDA ≤ 3,0
BCBF 16	Net debt/Adjusted EBITDA ≤ 3,0
HAPV16	Net debt/Adjusted EBITDA ≤ 3,0
HAPV17	Net debt/Adjusted EBITDA ≤ 3,0

In addition to the financial covenants, the debentures and CRIs have non-financial restrictive contractual clauses that involve a series of conditions such as compliance, transfer of corporate control and others, which, if not met, may result in the early maturity of the respective operations.

On June 30, 2024, the Company and its subsidiaries fully complied with the financial and non-financial restrictive contractual clauses related to early maturity.

e. Real Estate Receivables Certificates (CRI)

e.1 *CRI Issue – Ultra Som Serviços Médicos S.A. (Incorporated by Hapvida Assistência Médica S.A.)*

On November 2, 2021, the Company approved the grant of a personal guarantee, in the form of a surety bond, to guarantee the obligations assumed by its direct subsidiary, Ultra Som Serviços Médicos S.A. (Ultra Som) within the scope of its 1st issue of unsecured simple debentures, not convertible into shares, in a single series (Ultra Som Debentures). The Ultra Som Debentures are linked to the 378th series of the 4th issue of real estate receivables certificates by Virgo Companhia de Securitização of R$ 1,001,700, (Hapvida CRI Guarantee), in the context of a securitization operation. The Hapvida CRI Guarantees are the object of a public distribution, which was carried out under the terms of CVM Instruction 400 of December 29, 2003.

The funds are intended for: i) payment of expenses, costs and expenditures not yet incurred directly related to the construction, expansion, development and refurbishment of certain properties and real estate projects; and ii) reimbursement of predetermined real estate expenses, costs and expenditures incurred by the Company and its subsidiaries in the 24 months immediately prior to the closing date of the public offering of the CRI, directly related to the acquisition, construction and/or refurbishment of business units located in the projects backed by this operation.

The funds were raised on December 21, 2021, and will mature in December 2031 (principal + inflation adjustment). The spread is paid every six months.

With the merger of Ultra Som Serviços Médicos S.A. into Hapvida Assistência Médica S.A. on December 01, 2023, the latter assumed the debt previously held by Ultra Som Serviços Médicos S.A.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

e.2 *CRI Issue – BCBF Participações S.A. (Incorporated by NDI Saúde S.A.)*

On December 12, 2022, the subsidiary BCBF Participações S.A. signed the "First Amendment to the Private Deed of Issue of Unsecured Simple Debentures, Not Convertible into Shares, with Additional Personal Guarantee, in up to three series of the Company's 7th issue. The debentures are linked to the 62nd issue, in up to three series of Real Estate Receivables Certificates (CRI) by Virgo Companhia de Securitização, of R$ 1,000,000 (one billion reais), with a nominal unit value of R$ 1 (one thousand reais).

The total CRI issued was in three series, the first series of 542,426 (five hundred and forty-two thousand four hundred and twenty-six) CRI, the second series 362,151 (three hundred and sixty-two thousand one hundred and fifty-one) CRI and the third series 95,423 (ninety-five thousand four hundred and twenty-three) CRI.

The funds are intended for: i) payment of expenses, costs and expenditures not yet incurred directly related to the construction, expansion, development and refurbishment of certain properties and real estate projects; and ii) reimbursement of predetermined real estate expenses, costs and expenditures; and iii) partial early redemption of debts.

The fundraising was completed on December 27, 2022. The remuneration of the three series issued is as follows:

- **1st series of CRI:** remuneration will take place on December 15, 2027 (principal + interest corresponding to 100% of the accumulated change of the average daily DI rates) exponentially increased by a spread or surcharge of 0.75%;
- **2nd series of CRI:** remuneration will take place on December 17, 2029, (Principal + fixed compensatory interest corresponding to 7.0913% (seven integers and nine hundred and thirteen ten thousandths of a percent) p.a., based on 252 (two hundred and fifty-two) Business Days).
- **3rd series of CRI:** remuneration will take place on December 15, 2034, (Principal + fixed compensatory interest corresponding to 7.2792% (seven integers and two thousand seven hundred and ninety-two ten thousandths of a percent) p.a., based on 252 (two hundred and fifty-two) business days.

With the merger of BCBF Participações S.A. by Notre Dame Intermédica Saúde S.A. on March 28, 2024, the latter assumed the debt previously held by BCBF Participações S.A.

On June 30, 2024, the Company and its subsidiaries fully complied with the financial and non-financial restrictive contractual clauses related to early maturity.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

20 Leases payable

The Company and its subsidiaries have real estate lease agreements with third parties and related parties, as well as other lease and service agreements with terms of more than 12 months.

a) Discount rate

The Company and its subsidiaries achieved discount rates based on risk-free interest rates observed in the Brazilian market for the terms of its contracts, adapted to Group's reality. The spreads were obtained through surveys of potential investors in the debt securities of the Company and its subsidiaries. The table below shows the rates charged by the Group:

Terms (years)	Rate % p.a.
≤02 years	10.45%
02−04	10.12%
04−06	9.34%
06−08	9.51%
08−10	9.53%
>10	9.54%

b) Changes in leases

	Consolidated	
	06/30/2024	**12/31/2023**
Balance at the beginning of the period	**3,338,009**	**2,350,044**
Acquisitions of companies	-	7,384
New contracts (addition)	166,271	53,355
New contracts (addition) – Sale & Leaseback	-	805,827
Remeasurements / Write-offs of contracts	(98,769)	288,853
Incurred interest	159,960	292,657
Payments	(242,248)	(455,568)
Reclassification of items for sale	-	(4,543)
Total	**3,323,223**	**3,338,009**
Current	480,616	475,179
Non-current	2,842,607	2,862,830

c) Maturity of contracts

The future payments of consideration for lease contracts are detailed below:

	Consolidated	
	06/30/2024	**12/31/2023**
2024	240,198	475,178
2025	478,891	462,280
2026	456,348	441,032
2027	428,277	414,569
>2028	8,147,143	7,785,337
Nominal value	**9,750,857**	**9,578,396**
(-) Embedded interest	(6,427,634)	(6,240,387)
Present value of minimum lease payments	**3,323,223**	**3,338,009**

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

d) Additional information

In accordance with IFRS 16 (CPC 06 (R2)) and Circular Letter CVM/SNC/SEP 02/2019, Management used the incremental rate as the criterion for calculating the assets and liabilities within the scope of IFRS 16 (CPC 06 (R2)) and are thus presented in the statement of financial position of the Company and its Subsidiaries.

Management believes that the rate used represents the cash flow closest to the real and is in line with the characteristics of our contracts, as determined by item 27.b of the CVM official letter.

Aiming to comply with the guidance in the circular letter and the transparency required, we inform below the impacts on the statement of financial position, with a comparison of nominal interest vs. effective interest. To calculate the effective rate, we used the index of our contracts, most of which is the IPCA, applied to the flow of annual payments, obtained by disclosing Banco Bradesco's projections for the indicators up to 2025, with the longest rate repeated for the future flow from 5 years onwards.

	Consolidated	
	06/30/2024	**12/31/2023**
Nominal flow		
Lease liabilities	9,750,857	9,578,396
(-) Embedded interest	(6,427,634)	(6,240,387)
Total	**3,323,223**	**3,338,009**
Inflated real effective flow		
Lease liabilities	10,046,005	9,983,600
(-) Embedded interest	(6,622,191)	(6,504,377)
Total	**3,423,814**	**3,479,223**

e) Sale & Leaseback (SLB) Operation

On March 27, 2023, a binding instrument was signed for the Sale & Leaseback (SLB) of 10 properties owned by the Company's subsidiaries with an investment vehicle of the Pinheiro Family (LPAR), the Company's parent company, to strengthen the cash flow of the Company and its subsidiaries. The cap rate involved is 8.5% p.a., adjusted annually by the IPCA, for a lease term of 20 years (with an option to renew for the same period, with an option to buy back), by the Company, under predetermined conditions.

21 Social security charges

	Parent Company		Consolidated	
	06/30/2024	**12/31/2023**	**06/30/2024**	**12/31/2023 (restated)(iii)**
Salaries payable	1,419	1,284	221,440	136,340
Provision for vacation pay and year-end bonus	-	259	558,937	394,535
Performance bonus payable (i)	-	-	61,138	116,352
Cash-settled share-based payment plan (ii)	35,909	-	35,909	-
Other social security obligations	1	2	31,865	10,413
Total	**37,329**	**1,545**	**909,289**	**657,640**

(i) Provision for performance bonuses payable to eligible employees of the Company and its subsidiaries.
(ii) Amount payable related to the cash-settled share-based payment plan, as detailed in Note 26.
(iii) The Group identified an amount R$ 51,921 relate to Performance bonus payable, previously presented under Salaries payable. For a better presentation of the Social security charges the balance was reclassified to the line that represents its correct nature.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

22 Taxes and contributions payable

	Parent Company		Consolidated	
	06/30/2024	**12/31/2023**	**06/30/2024**	**12/31/2023**
Service Tax (ISS)	-	-	41,036	40,800
Social security contribution	13	1,459	104,654	73,409
Contribution to the Severance Indemnity Fund (FGTS)	-	-	20,261	17,310
PIS and COFINS	16,412	16,348	70,266	100,133
Union and assistance contributions	-	-	104	191
Income tax payable on interest on shareholders' equity	-	-	-	37,500
Other	(15)	19	5,423	1,859
Taxes due payable	**16,410**	**17,826**	**241,744**	**271,202**
Income Tax – Employees	470	2,371	31,014	43,439
Income Tax – Third parties	-	22	14,707	9,746
Service Tax	14	9	15,734	14,564
Social security contribution retained	-	-	2,618	3,120
Retention of PIS/COFINS/CSLL	(137)	(83)	41,955	38,653
Withholding income tax on interest on shareholders' equity	-	-	-	-
Withholding taxes payable	**347**	**2,319**	**106,028**	**109,522**
Installment payment of taxes, fines and rates – Federal	-	-	185,202	217,210
Installment payment of taxes, fines and rates – Municipal	-	-	3,584	4,184
Installment payment of taxes, fines and rates – Other	-	-	35,566	26,736
Installment payment of taxes, fines and rates	**-**	**-**	**224,352**	**248,130**
Total	**16,757**	**20,145**	**572,124**	**628,854**
Current	16,757	20,145	430,213	467,460
Non-current	-	-	141,911	161,394

23 Provision for tax, civil and labor risks

The Company and its subsidiaries are parties to judicial and administrative lawsuits in several courts and government bodies, arising from the regular course of its operations, involving tax, labor, civil and contingency matters with the regulatory agency (ANS).

The Company and its subsidiaries make a provision for all legal and administrative proceedings classified as probable loss risk, which it considers sufficient to cover possible losses, as well as discusses other lawsuits for which the legal advisers estimate as possible loss, not creating an accounting provision.

The main issues of the lawsuits and administrative proceedings classified as probable losses by the Company and its subsidiaries are described below:

	Parent Company		Consolidated	
Lawsuits with probable loss forecast - Nature:	**06/30/2024**	**12/31/2023**	**06/30/2024**	**12/31/2023**
Provision for tax lawsuits (ANS included)	-	-	498,414	502,502
Provision for civil lawsuits	1,436	973	547,662	500,863
Provision for labor lawsuits	734	1,101	268,857	263,951
Total	**2,170**	**2,074**	**1,314,933**	**1,267,316**

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Changes incurred in provision for tax, civil and labor risks for the period ended June 30, 2024 and year ended December 31, 2023 are detailed as follows:

Provision for tax, civil and labor risks

	Parent Company
Balances at 01/01/2023	**906**
Net additions and reversals	1,859
Payments	(691)
Balances at 12/31/2023	**2,074**
Net additions and reversals	473
Payments	(377)
Balances at 06/30/2024	**2,170**

	Consolidated			
	Civil	**Labor**	**Tax**	**Total**
Balances at 01/01/2023	**445,439**	**266,119**	**649,416**	**1,360,974**
Acquisitions of companies	3,927	210	400	4,537
Reclassification of items for sale	(378)	(8,735)	(672)	(9,785)
Net additions and reversals	165,945	78,078	(28,466)	215,557
Payments	(114,070)	(71,721)	(118,176)	(303,967)
Balances at 12/31/2023	**500,863**	**263,951**	**502,502**	**1,267,316**
Net additions and reversals	142,459	33,128	25,517	201,104
Payments	(80,795)	(21,557)	(21,491)	(123,843)
Offsetting	(14,865)	(6,665)	(8,114)	(29,644)
Balances at 06/30/2024	**547,662**	**268,857**	**498,414**	**1,314,933**

Below is a breakdown of the risk amounts arising from lawsuits and administrative proceedings classified as possible loss, in which the Company and/or its subsidiaries are party, related to the period ended June 30, 2024, and the year ended December 31, 2023:

	Parent Company		**Consolidated**	
Lawsuits with possible loss forecast - Nature:	**06/30/2024**	**12/31/2023**	**06/30/2024**	**12/31/2023**
Tax (ANS included)	16,820	16,637	5,083,234	4,858,147
Civil	9,949	13,291	1,804,891	1,708,825
Labor	4,471	4,228	923,083	799,385
Total	**31,240**	**34,156**	**7,811,208**	**7,366,357**

The main matters of the lawsuits and administrative proceedings classified as probable and possible losses by the Company and/or its subsidiaries are described below:

			Probable		Possible	
Type	**Theme**	**Object**	**06/30/2024**	**12/31/2023**	**06/30/2024**	**12/31/2023**
Civil	Indemnity lawsuits - Medical Acts	The contingency addressed comes from civil proceedings filed by beneficiaries seeking compensation for damages suffered by allegedly inadequate medical conduct. In such cases, the plaintiffs seek to assign the Company and/or its subsidiaries the joint liability to the Company for the medical act practiced by their accredited professionals.	126,987	117,428	747,428	688,187
	Legal and/or contractual coverage exclusion	The contingency in question arises from civil lawsuits filed by beneficiaries seeking coverage for services not covered by law and/or contract: aesthetic, experimental procedures, not provided for in the ANS mandatory coverage list or outside the Use Guidelines – DUT, Home Care, artificial insemination, services outside the geographic scope etc. In this scenario, many judicial decisions are made in non-compliance with the applicable legislation, without due obedience to the care limits defined by law and/or contractually.	78,790	72,040	126,765	114,518
	Contractual Grace Period	The contingency addressed comes from civil lawsuits filed by beneficiaries seeking to obtain health care coverage from its health care plan without proper compliance with the grace periods. In this scenario, many court decisions are made disregarding the applicable legislation, without due obedience to the grace periods provided by law and/or contractually.	48,787	45,160	58,654	62,007
	Debts with Providers in General	This contingency arises from civil lawsuits filed by service providers in general, seeking to obtain payment of amounts supposedly owed by the Company and/or its subsidiaries on several grounds, such as: disallowances of hospital bills, contractual terminations, etc.	82,059	75,852	193,864	200,005
	Other civil matters	Contingencies with various issues arising from civil lawsuits.	211,039	190,383	678,180	644,108
		Total - Civil	**547,662**	**500,863**	**1,804,891**	**1,708,825**

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

			Probable		Possible	
Type	**Theme**	**Object**	**06/30/2024**	**12/31/2023**	**06/30/2024**	**12/31/2023**
Labor	Acknowledgment of employment relationship	The contingency addressed comes from labor lawsuits filed by individuals, service providers, seeking to obtain recognition of an alleged employment relationship maintained with the Company and/or its subsidiaries, even without the presence of the typical assumptions of an employment relationship. In this scenario, we can mention: physicians, radiology technicians, physiotherapists, phono audiologists, etc.	99,614	111,310	211,371	192,415
	Labor amounts/severance pay	The contingency addressed arises from labor lawsuits filed by former employees or employees, individually or collectively, who claim the receipt of labor amounts and severance pay related to the period in which they worked for the Company and/or its subsidiaries, including: overtime, hazardous exposure and night work bonuses, equal pay, job deviation and accumulation, fines under Articles 467 and 477 of the Brazilian Labor Code (CLT), etc.	151,522	141,104	433,255	353,852
	Tax Assessment Notices / NDFC / NFGC / NFRC	The contingency arises from Tax Assessment Notices and Debit/Fiscal Notices related to Employee Severance Guarantee Fund issued against the Company and/or its subsidiaries, in which administrative fines and FGTS payments are levied arising from alleged violations of the legal rules governing labor and employment relations.	2,028	1,917	218,520	218,555
	Other labor matters	Contingencies with various issues arising from labor lawsuits.	15,693	9,620	59,937	34,563
		Total – Labor	**268,857**	**263,951**	**923,083**	**799,385**

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

			Probable		Possible	
Type	**Theme**	**Object**	**06/30/2024**	**12/31/2023**	**06/30/2024**	**12/31/2023**
Tax						
	ANS Administrative Fines/ Reimbursement to SUS (regulatory aspects)	Administrative proceedings and tax foreclosures issued by ANS, in which administrative fines are charged for alleged noncompliance with the norms regulating the activity of health plan providers, and amounts related to reimbursement to Unified Health System (SUS), resulting from the attendance of beneficiaries of the Company and/or its subsidiaries in the public network and in the SUS, based on article 32 of law 9656/98.	220,785	120,759	760,119	507,187
	Service Tax (ISS)	The contingency now treated comes from administrative and court lawsuits filed by Municipal Treasury Secretaries, which intend to collect the service tax allegedly due by the Company and/or its subsidiaries as a result of its operating activities.	97,504	95,520	1,586,868	1,426,644
	Tax Foreclosures - Business Succession	The contingency refers to tax foreclosures originally filed against other health care companies, in which the National Treasury requested the redirection to the Company and its subsidiaries, on the grounds of alleged business succession arising from operations of disposal of the portfolio of beneficiaries.	95,322	92,752	175,208	166,533
	Social Security Matters	The contingency mainly results from tax notices of violation filed against the Company and its subsidiaries for tax credits due to alleged irregularities or lack payment of social security contributions, among other social security matters.	26,168	32,303	315,876	514,414
	Tax assessment notices - IRPJ/CSLL - goodwill	The Company’s subsidiaries have an administrative proceeding arising from tax assessment notices issued for undue collection of Corporate Income Tax (IRPJ) and Social Contribution on Net Income (CSLL).	-	-	1,197,800	955,141
	Accident Prevention Factor (FAP) on the rate set for the SAT/RAT contribution	The contingency arises from the application of the Accident Prevention Factor (FAP) on the rate set for the contribution to the SAT/RAT, ordering the co-authoring Authority to refrain from carrying out any acts aimed at collecting the amounts allegedly due, due to the application of this factor, among them the refusal to renew the Tax Regularity Certificate. Furthermore, recognition of the Petitioner’s right to credit is required. The case is in the higher levels are on hold.	14,704	14,308	8,120	7,901
	Special Tax Regularization Program (PERT)	The Company’s subsidiaries have tax foreclosures on debits included in the Special Tax Regularization Program (PERT).	-	-	47,617	26,894
	Stock option	Requests for provisional injunctive relief, against the Federal Government (Brazilian Treasury), to declare the non-existence of a legal tax relationship between the Plaintiff and Defendant regarding the requirement, due to the (past and future) exercises of stock options in the Stock Option Plan instituted in 2014. From the Plaintiff Companies, social security contributions on payroll and other third-party contributions (Education Allowance, INCRA, SESC, SENAC and Sebrae) in relation to the Participants who act as plaintiff of this claim; from the Plaintiff Companies, a fine for the alleged failure to withhold income tax when the options were exercised by the Participants who act as plaintiff	-	-	612,907	596,383

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

	of this claim; from the Participating Plaintiffs, income tax on alleged income derived from work when exercising the options.				
Health services solid waste charge (TRSS)	The Company's Subsidiaries have filed tax foreclosures for the collection of debts relating to the Health Services Solid Waste Charge (TRSS).	139	137	11,571	14,897
Enrollment	Annulment request aimed at canceling the asset seizure procedure initiated against the Company's subsidiaries.	-	-	77	36,233
Other tax matters	Contingencies with various issues arising from tax proceedings.	43,792	146,723	367,071	605,920
	Total – Tax	**498,414**	**502,502**	**5,083,234**	**4,858,147**

Judicial deposits

The Company and its subsidiaries have judicial deposits held in assets in the following amounts:

	Parent Company		Consolidated	
	06/30/2024	**12/31/2023**	**06/30/2024**	**12/31/2023**
Tax judicial deposits	562	543	497,717	448,058
Regulatory judicial deposits (i)	-	-	1,270,032	1,208,179
Civil judicial deposits	9,677	9,468	736,035	501,100
Labor judicial deposits	739	678	71,794	68,869
Total	**10,978**	**10,689**	**2,575,578**	**2,226,206**

(i) It refers substantially to judicial deposits for reimbursement of medical expenses to SUS.

24 Other accounts payable

The balance of this group of accounts is comprised as follows:

	Parent Company		Consolidated	
	06/30/2024	**12/31/2023**	**06/30/2024**	**12/31/2023**
Contractual obligations (a)	-	-	829,237	1,110,941
Third-party deposits	86	86	53,880	81,608
Advance from clients	80	80	47,598	65,608
Private Health Insurance Regulatory Tax	-	-	4,232	4,232
Debits from health care operations and not related to the plan (i)	-	-	6,811	10,074
Provisions for employee benefit plans	-	-	17,531	23,253
Deferred portion of the acquisition price	-	-	57,816	17,152
ANS fine payable	-	-	25,952	29,700
Financial institution partnership advance	25,300	28,600	37,504	42,104
Retention bonus payable (ii)	12,000	12,000	12,000	12,000
PROMED Settlement Agreement (iii)	-	-	125,070	125,070
Rentals payable	-	-	10,990	17,224
Sundry debits	81,462	3,485	522,492	552,615
Total	**118,928**	**44,251**	**1,751,113**	**2,091,581**
Current	100,228	22,251	444,105	406,911
Non-current	18,700	22,000	1,307,008	1,684,670

(i) It refers to obligations with health service providers and medical teams.
(ii) Provision for retention bonuses payable to Company executives for time spent with the Company.
(iii) On August 14, 2023, the subsidiary Ultra Som Serviços Médicos entered into the "Agreement and Other Covenants" with certain sellers of the PROMED Group. The agreement is the result of negotiations related to the acquisition of the PROMED Group, according to the Minutes of the Board of Directors' Meeting held on August 16, 2023.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

(a) Contractual obligations (consolidated)

It substantially refers to contingent consideration relating to the acquisitions of companies resulting from business combinations, as shown below for the changes below for the period ended June 30, 2024 and year ended December 31, 2023:

	Consolidated	
	06/30/2024	**12/31/2023**
Balance at the beginning of the period	**1,110,941**	**1,207,398**
Acquisition price of Companies	-	664,370
Payments	(308,194)	(727,696)
Inflation adjustment	46,794	139,088
Compensation balances	(14,268)	(167,917)
Price Adjustments/Re-measurements	(6,036)	(4,302)
Balance at the end of the period/year	**829,237**	**1,110,941**
Current	65,578	83,912
Non-current	763,659	1,027,029

25 Equity

a) Share capital

On June 30, 2024 and December 31, 2023, the subscribed and paid-up share capital was comprised as follows:

	06/30/2024	**12/31/2023**
Number of shares	7,539,463,263	7,539,463,263
Share capital	39,121,274	39,121,274
Costs with issue of shares	(255,075)	(255,075)
Total	**38,866,199**	**38,866,199**

b) Legal reserve

Formed compulsorily on the allocation of 5% of net income for the year, until it reaches 20% of the share capital.

c) Dividends

Consolidated changes in dividends and interest on shareholders' equity payable are as follows:

Balance of dividends and interest on shareholders' equity as of January 1, 2023	**13,604**
Reclassification of items for sale	(975)
Balance of dividends and interest on shareholders' equity as of December 31, 2023	**12,629**
Balance of dividends and interest on shareholders' equity as of June 30, 2024	**12,629**

d) Repurchase of shares

On June 30, 2024, the Company has a balance of R$ 423,098 referring to the repurchase of shares, equivalent to 45,073,213 (forty-five million, seventy-three thousand, two hundred and thirteen) common shares issued by the Company, carried out throughout 2021, 2022, 2023 and 2024.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

e) Earnings/(losses) per share

Basic earnings/(losses) per share are basically calculated by dividing net earnings/(losses) for the period attributed to controlling shareholders, by the weighted average number of outstanding common shares.

	06/30/2024	06/30/2023
Net income/(loss) attributable to the Company and its subsidiaries (R$ thousand)	(315,564)	(524,425)
Net income/(loss) attributable to controlling shareholders (R$ thousand)	(316,075)	(525,183)
Weighted average number of shares (thousands of shares)	7,647,584	7,417,923
Basic and diluted earnings/(losses) per share (R$ thousand)	(0.04)	(0.07)

26 Share-based remuneration plan

Stock Option

The Company has a share-based remuneration plan to promote the pursuit of long-term growth and profitability of the Company and its subsidiaries, providing professionals who are or will be involved in the Company’s growth with the opportunity to acquire an ownership right in the Company, to: (a) providing incentive for the integration, expansion, success and achievement of the social goals of the Company and its subsidiaries; and (b) to align the interests of the Company’s shareholders to the interests of the Participants.

They are long-term incentive programs with the grant of restricted shares, managed by the Board of Directors, whose plans were approved on March 29, 2021, and April 30, 2021, and whose effectiveness was conditional on the closing of the business combination between the Company and Notre Dame Intermédica Participações S.A., which took place on February 14, 2022.

Shares Granted and Strike Price

125,542,812 Shares were granted on February 14, 2022, (1st grant) and 13,660,008 on July 01, 2022 (2nd grant) to Plan Participants. The Strike Price of each Option granted under the terms of the Plan will be a fixed amount of R$ 6.50 (six reais and fifty cents) per Share.

Exercise of the Options

The Options shall become vested to the extent that the respective Participants remain continuously bound as a director or employee of the Company and its subsidiaries, as the case may be, until the vesting periods specified below have elapsed:

- 1/3 (one third) of the Options granted may be exercised from August 31, 2022;
- 1/3 (one third) of the Options granted may be exercised after 24 (twenty-four) months from the closing date of the business combination between the Company and Notre Dame Intermédica Participações S.A., i.e. February 14, 2024; and
- 1/3 (one third) of the Options granted may be exercised after 36 (thirty-six) months from the closing date of the business combination between the Company and Notre Dame Intermédica Participações S.A., i.e. February 14, 2025.

Fair value measurement

The Black & Scholes method was used to price the options on the dates of respective dates grants and at the end of period/year.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

The information used in fair value measurement on the grant date of share-based payment is as follows:

	1st grant	2nd grant
Fair value on grant dates (R$)	6.12−7.80	0.23−2.22
Share price on grant date (R$)	12.19	5.62
Strike price (R$)	6.50	6.50
Expected volatility (weighted average)	41.91%	52.61%
Option life (weighted-average life expectation in years)	0.55−3.00	0.17−2.64
Risk-free interest rate (average based on government bonds)	11.46% to 12.23%	12.59−13.35%

For the respective grant or year-end dates, the market price of the share on the date and the historical volatility (over a 12-month period) were used.

The strike price of the options was adjusted by projected dividends for the period/year and the risk-free rate based on the curve of fixed future federal government bonds in the expected average term of exercise of each lot.

	Stock option plan			
	Total number of shares granted	Number of canceled shares (*)	Current number of shares granted	Value of shares
1st grant	125,542,812	(52,855,107)	72,687,705	505,023
2nd grant	13,081,874	(7,117,404)	5,964,470	8,088
Total	**138,624,686**	**(59,972,511)**	**78,652,175**	**513,111**

* Shares canceled referring to executives of the Company and its subsidiaries who left during the period.

Restricted shares are measured at fair value on the grant date and are recognized as an expense over the period in which the right is acquired, against equity, as options granted.

The expense related to the fair value of the restricted shares, recognized in the period ended June 30, 2024, according to the period elapsed for the vesting of the restricted shares, was R$ 36,431 (R$ 24,597 on June 30, 2023).

Cash-settled share-based payment plan

At the Board of Directors' Meeting held on December 20, 2023, the new cash-settled share-based payment plan of the Company was approved.

The Plan aims to grant beneficiaries the right to receive an extraordinary award corresponding to the value of the Virtual Retention Shares, to foster: (a) the attraction and retention of Beneficiaries in the Company with a focus on their permanence in the Company and long-term development; (b) the alignment of the interests of the Company's shareholders with those of the Beneficiaries covered by the Plan; and (c) the valuation of the shares and the Company's growth potential.

Virtual Retention Shares

Virtual Retention Shares are defined as units representing the right to payment based on shares issued by the Company and granted to Beneficiaries. Each unit of Virtual Retention Share is equivalent to the gross value corresponding to the quotation of one (1) re issued by the Company in the last trading

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

session of the current period/year immediately prior to the end of each Vesting Period in question, which must be paid to the Beneficiary as an award on an extraordinary basis.

Grace period
The right to Virtual Retention Shares will be subject to compliance by the Beneficiary with the Service Condition; that is, the Beneficiary must remain continuously linked as an employee, administrator or service provider of the Company or a company under its control during each of the Vesting Periods below:

(i) 25% (twenty-five percent) of the Virtual Retention Shares will have completed their Vesting Period on the 1st (first) anniversary of the Grant Date ("1st Vesting Period");

(ii) 25% (twenty-five percent) of the Virtual Retention Shares will have completed their Vesting Period on the 2nd (second) anniversary of the Grant Date ("2nd Vesting Period");

(iii) 25% (twenty-five percent) of the Virtual Retention Shares will have completed their Vesting Period on the 3rd (third) anniversary of the Grant Date ("3rd Vesting Period"); and

(iv) 25% of the Virtual Retention Shares will have completed their Vesting Period on the 4th anniversary of the Grant Date ("4th Vesting Period").

* January 01, 2024, or another date that may be defined in the Beneficiary's Grant Agreement.

Grant date	Number of shares granted	Accumulated appropriation of the plan
01/01/2024	75,400,000	35,909

The Company recognizes personnel expenses related to grants from the Plan against the social charges caption in liabilities, based on the fair value of the virtual shares granted. The expenses recognized in income (loss) for the period ended June 30, 2024 totaled R$ 35,909.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

27 Income (loss) from insurance contracts

a) General Measurement Model (BBA) – Individual

	Consolidated			
	06/30/2024		06/30/2023 (Restated)	
Insurance revenues	**Accumulated**	**Quarter**	**Accumulated**	**Quarter**
Amounts relating to changes in LRC/PCR	**2,795,319**	**1,412,178**	**2,417,117**	**1,242,710**
Costs of claims and other insurance services	2,038,488	1,028,820	2,000,839	1,024,952
Change in the risk adjustment for non-financial risk	35,700	18,258	32,754	16,793
CSM release	721,131	365,100	383,524	200,965
Amounts relating to the recovery of cash flows from insurance acquisition costs	**89,400**	**46,032**	**67,989**	**35,488**
Allocation of premiums related to the recovery of cash flow from acquisition of insurance	89,400	46,032	67,989	35,488
Total insurance revenue	**2,884,719**	**1,458,210**	**2,485,106**	**1,278,198**

	Consolidated			
	06/30/2024		06/30/2023 (Restated)	
	Accumulated	**Quarter**	**Accumulated**	**Quarter**
Insurance				
Claims incurred and other directly attributable expenses	(2,642,220)	(1,396,754)	(2,254,300)	(1,146,990)
Past service-related changes in cash flow related to LIC/PSI	108,669	13,623	11,841	(27,629)
Losses on onerous contracts and reversals of these losses	4,166	284	23,611	4,449
Amortization of cash flow from acquisition	(89,400)	(46,032)	(67,989)	(35,488)
Total insurance expenses	**(2,618,785)**	**(1,428,879)**	**(2,286,837)**	**(1,205,658)**

b) Premium Allocation Approach (PAA) – Collective

	Consolidated			
	06/30/2024		06/30/2023 (Restated)	
Insurance revenues	**Accumulated**	**Quarter**	**Accumulated**	**Quarter**
Amounts relating to changes in LRC/PCR				
Premiums awarded for the period (PAA)	10,500,620	4,947,224	10,559,916	5,271,380
Other	-	-	154	-
Total insurance revenue	**10,500,620**	**4,947,224**	**10,560,070**	**5,271,380**

	Consolidated			
	06/30/2024		06/30/2023 (Restated)	
	Accumulated	**Quarter**	**Accumulated**	**Quarter**
Insurance				
Claims incurred and other directly attributable expenses	(9,239,565)	(4,672,057)	(9,098,088)	(4,372,119)
Past service-related changes in cash flow related to LIC/PSI	323,275	177,823	585,241	110,134
Amortization of cash flow from acquisition	(476,361)	(253,683)	(542,739)	(254,746)
Total insurance expenses	**(9,392,651)**	**(4,747,917)**	**(9,055,586)**	**(4,516,731)**

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

28 Net revenue from services rendered (Consolidated)

The revenues from the provision of clinical, hospital, laboratory and diagnostic services, as well as the provision of administration services for post-payment health and dental care plans are detailed below.

	Consolidated			
	06/30/2024		06/30/2023 (Restated)	
	Accumulated	**Quarter**	**Accumulated**	**Quarter**
Administration fee – post-payment plans	9,864	7,308	8,329	4,062
Revenues from other activities	453,377	240,615	694,000	335,652
(-) Taxes on revenue	(69,753)	(31,075)	(210,932)	(87,921)
(-) Unconditional discounts and other deductions	(8,847)	(8,388)	(719)	(716)
Total	**384,641**	**208,460**	**490,678**	**251,077**

29 Cost of services rendered (Consolidated)

The costs from the provision of clinical, hospital, laboratory and diagnostic services, as well as costs arising from the provision of administration services for post-payment health and dental care plans are detailed below.

	Consolidated			
	06/30/2024		06/30/2023 (Restated)	
	Accumulated	**Quarter**	**Accumulated**	**Quarter**
Medical and hospital costs and others	(468,052)	(206,789)	(704,127)	(337,083)
Material and medication cost	(73,395)	(40,611)	(214,954)	(103,122)
Cost with location and operation	(36,352)	(20,416)	(84,890)	(41,897)
Costs with outsourced services	(22,909)	(12,297)	(71,664)	(42,321)
Depreciation and amortization cost	(14,237)	(7,085)	(41,575)	(19,761)
Total	**(614,945)**	**(287,198)**	**(1,117,210)**	**(544,184)**

30 Sales expenses (Consolidated)

	Consolidated			
	06/30/2024		06/30/2023 (Restated)	
	Accumulated	**Quarter**	**Accumulated**	**Quarter**
Publicity and advertising expenses	(36,446)	(23,935)	(23,626)	(11,263)
Impairment loss on trade receivables	(9,126)	(5,158)	(18,916)	(7,840)
Own personnel expenses	(85,628)	(42,071)	(63,533)	(34,274)
Other sales expenses	(19,814)	(11,146)	(11,096)	(6,759)
Total	**(151,014)**	**(82,310)**	**(117,171)**	**(60,136)**

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

31 Administrative expenses

	Parent Company			
	06/30/2024		06/30/2023 (Restated)	
	Accumulated	**Quarter**	**Accumulated**	**Quarter**
Own personnel expense	(39,597)	(7,557)	(40,062)	(18,864)
Stock option plan expenses (Note 27)	(36,431)	(11,996)	(24,597)	4,534
Stock grant plan expenses (Note 27)	(35,909)	(18,484)	(22,245)	(13,151)
Outsourced service expenses	(9,490)	(3,560)	(4,936)	(2,252)
Expenses with location and operation	(1,752)	(866)	(1,402)	(394)
Expenses with depreciation and amortization (i)	(135,857)	(67,473)	(94,859)	(70,216)
Tax expenses	(349)	(202)	(404)	(401)
Indemnification, legal costs and contingency provisions	(2,299)	(751)	(856)	(697)
Sundry revenues (expenses), net	(4)	24	18	3
Total	**(261,688)**	**(110,865)**	**(189,343)**	**(101,438)**

	Consolidated			
	06/30/2024		06/30/2023 (Restated)	
	Accumulated	**Quarter**	**Accumulated**	**Quarter**
Own personnel expense	(46,369)	(15,273)	(58,952)	(30,557)
Stock option plan expenses (Note 27)	(36,431)	(11,996)	(24,597)	4,534
Stock grant plan expenses (Note 27)	(35,909)	(18,484)	(22,245)	(13,151)
Outsourced service expenses	(166,221)	(69,536)	(173,145)	(86,105)
Expenses with location and operation	(92,455)	(47,106)	(121,954)	(60,783)
Expenses with depreciation and amortization (i)	(204,349)	(105,613)	(186,458)	(111,077)
Tax expenses	(29,130)	(13,486)	(52,542)	(24,408)
Indemnification, legal costs and contingency provisions	(223,650)	(130,225)	(155,718)	(91,504)
Sundry revenues (expenses), net	(4,991)	4,506	(32,532)	(17,851)
Total	**(839,505)**	**(407,213)**	**(828,143)**	**(430,902)**

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

32 Net financial revenues (expenses)

	Parent Company				Consolidated			
	06/30/2024		06/30/2023		06/30/2024		06/30/2023 (Restated)	
Financial revenues	**Accumulated**	**Quarter**	**Accumulated**	**Quarter**	**Accumulated**	**Quarter**	**Accumulated**	**Quarter**
Interest on investments, except for collateral assets	5,849	773	18,457	18,425	214,793	118,939	156,818	108,698
Financial revenue from investments - Collateral Assets	-	-	-	-	171,708	81,257	153,957	91,208
Other revenues from short and long term investments	-	-	-	-	2	1	4,794	4,132
Late receipt	-	-	-	-	58,062	28,893	57,106	28,665
Revenues from derivative financial instruments - Debt	-	-	-	(355)	42,837	23,841	50,162	49,807
Revenues from derivative financial instruments - Equity	-	-	11,516	11,516	-	-	11,516	11,516
Foreign exchange gains	(7)	(7)	-	-	7	6	17,119	13,365
Revenues from inflation adjustments - SUS	-	-	-	-	32,301	32,301	40,170	40,170
Revenues from other inflation adjustments	-	-	14	14	36,931	18,742	46,746	27,640
Other financial revenues	1,434	441	26	(81)	10,128	3,494	9,640	834
Subtotal – Financial revenues	**7,276**	**1,207**	**30,013**	**29,519**	**566,769**	**307,474**	**548,028**	**376,035**

	Parent Company				Consolidated			
	06/30/2024		06/30/2023		06/30/2024		06/30/2023 (Restated)	
Financial expenses	**Accumulated**	**Quarter**	**Accumulated**	**Quarter**	**Accumulated**	**Quarter**	**Accumulated**	**Quarter**
Interest from debentures	(498,650)	(253,127)	(509,766)	(283,878)	(521,965)	(269,478)	(639,318)	(322,214)
Interest from right-of-use	(8)	(3)	(7)	(3)	(159,960)	(79,465)	(120,307)	(68,793)
Discounts granted	-	-	-	-	(2,024)	(1,051)	(5,389)	(2,552)
Bank expenses	(202)	(82)	(81)	(44)	(16,495)	(8,104)	(22,153)	(10,968)
Charges on taxes	-		-	-	(204)	(144)	(1,669)	(925)
Financial expenses with derivative instruments - Debt	-	-	-	-	(15,426)	(3,490)	(30,110)	10,577
Financial expenses with derivative instruments - Equity	-	-	(19,805)	(339)	-	-	(19,805)	(339)
Expense on exchange rate change	(20)	(20)	-	-	(34,106)	(26,885)	(128)	(124)
Interest on loans and financing	-	-	-	-	(124,807)	(51,860)	(146,276)	(101,719)
Expenses with other inflation adjustments	(10)	(10)	(2)	(1)	(107,864)	(52,221)	(136,407)	(67,909)
Interest accreditation expense – IFRS 17 (CPC 50) – LRC/PCR	-	-	-	-	(21,535)	12,065	121,347	(132,090)
Interest accreditation expense – IFRS 17 (CPC 50) – LIC/PSI	-	-	-	-	(176,572)	(74,355)	(256,314)	(134,096)
Other financial expenses	(5,728)	(1,845)	(5,913)	(3,967)	(12,052)	(3,577)	(26,336)	(645)
Subtotal – Financial expenses	**(504,618)**	**(255,087)**	**(535,574)**	**(288,232)**	**(1,193,010)**	**(558,565)**	**(1,282,865)**	**(831,797)**
Total - Net financial income (loss)	**(497,342)**	**(253,880)**	**(505,561)**	**(258,713)**	**(626,241)**	**(251,091)**	**(734,837)**	**(455,762)**

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

33 Income tax and social contribution

a. Reconciliation of effective rate of income tax and social contribution recognized in income (loss)

Since the amounts recorded in the parent company interim statements are not relevant, only the reconciliation of the consolidated interim statements is presented below:

	06/30/2024				06/30/2023 (Restated)			
	Accumulated		Quarter		Accumulated		Quarter	
Income/Loss before income tax and social contribution		**(440,675)**		**(564,497)**		**(552,579)**		**(373,521)**
Rates								
IRPJ, plus the additional tax rate		25%		25%		25%		25%
CSLL		9%		9%		9%		9%
Receivables (Debits) with income tax and social contribution at official rates		**(149,829)**		**(191,929)**		**(187,877)**		**(126,998)**
Permanent differences								
Tax loss on which a deferred tax asset was not formed (i)	-12.31%	54,247	-9.49%	53,545	-16.08%	88,844	-11.06%	41,305
Debt Adjustment - Business Combination	-0.00%	-	-0.01%	46	-0.04%	235	-0.01%	20
Non-deductible provision	8.71%	(38,399)	8.17%	(46,102)	-3.53%	19,521	9.27%	(34,631)
Other additions and exclusions	-3.37%	14,835	-0.12%	666	-9.65%	53,306	-9.32%	34,794
Subtotal	**-6.96%**	**30,683**	**-1.44%**	**8,155**	**-29.30%**	**161,907**	**-11.11%**	**41,488**
Impacts of the tax on entities taxed by deemed profit								
Reversal of the tax effect by the actual profit	0.00%	-	0.00%	-	0.41%	(2,256)	0.20%	(756)
Income tax and social contribution calculated at deemed profit	0.00%	-	0.00%	-	-0.16%	876	-0.12%	456
Subtotal	**0.00%**	**-**	**0.00%**	**-**	**0.25%**	**(1,380)**	**0.08%**	**(300)**
Income tax and social contribution	**27.04%**	**(119,146)**	**32.56%**	**(183,774)**	**4.95%**	**(27,351)**	**22.97%**	**(85,810)**
Current income tax	-32.30%	142,320	-11.01%	62,127	-29.51%	163,061	-29.28%	109,359
Current social contribution	-11.62%	51,225	-3.97%	22,401	-9.22%	50,960	-10.31%	38,497
Deferred income tax	50.89%	(224,241)	34.22%	(193,196)	31.92%	(176,358)	45.74%	(170,830)
Deferred social contribution	20.07%	(88,450)	13.30%	(75,106)	11.77%	(65,014)	16.82%	(62,836)
Income tax and social contribution	**27.04%**	**(119,146)**	**32.56%**	**(183,774)**	**4.95%**	**(27,351)**	**22.97%**	**(85,810)**

(i) Balance arising mainly from the companies Notre Dame Intermédica Participações S.A., BCBF Participações S.A. and CCG Participações S.A. from tax losses which were not recognized as deferred tax assets, given that the operation of these companies is of holding interests in other entities (holding companies).

Changes in liabilities payable from deferred income tax and social contribution in the period ended June 30, 2024 and year ended December 31, 2023 are as follows:

	Consolidated	
	06/30/2024	**12/31/2023**
Balance at the beginning of the period	**28,261**	**31,798**
Calculated income tax and social contribution	193,545	190,713
Recoverable income tax and social contribution	3,942	94,051
Withheld income tax and social contribution	(24,584)	(73,663)
(-) Payments made	(140,595)	(214,638)
Balance at the end of the period/year	**60,569**	**28,261**

The Company and its subsidiaries do not recognize income tax and social contribution expenses directly in the equity.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

b. Deferred income tax and social contribution

b.1 Changes

Changes in deferred income tax and social contribution, in the period ended June 30, 2024 and year ended December 31, 2023 are as follows:

	Parent Company				
	Balance at 01/01/2023	**Recognized in income (loss)**	**Balance at 12/31/2023**	**Recognized in income (loss)**	**Balance at 06/30/2024**
Provision for tax, civil and labor risks	309	397	706	33	739
Credit on tax loss and negative basis	442,242	344,728	786,970	221,202	1,008,172
Costs with issue of debentures	6,852	(15,626)	(8,774)	(2,547)	(11,321)
Deferred tax on right-of-use	16	(10)	6	1	7
Share-based payment plan expenses	184,492	20,972	205,464	(41,269)	164,195
Amortization of fair value - Assets acquired in business combination	103,459	79,248	182,707	46,092	228,799
Other tax credits/debits	6,276	(6,286)	(9)	26,403	26,393
Total	**743,646**	**423,423**	**1,167,069**	**249,915**	**1,416,984**
Deferred tax assets	743,646		1,167,069		1,416,984

	Consolidated		
	Balance at 12/31/2023	**Recognized in income (loss)**	**Balance at 06/30/2024**
Provision for tax, civil and labor risks	231,670	208,805	440,475
Impairment loss on trade receivables	240,479	26,532	267,011
Credit on tax loss and negative basis (i)	1,326,781	174,846	1,501,627
Amortization of fair value - Assets acquired in business combination	416,019	(26,437)	389,582
Deferred tax on goodwill in business combination (ii)	(1,263,524)	(229,722)	(1,493,246)
Deferred tax on right-of-use	175,747	(12,669)	163,078
Cost with issue of debentures	(18,711)	(1,927)	(20,638)
Share-based payment plan expenses	205,463	(41,270)	164,193
Effects of adopting IFRS 17 (CPC 50)	151,031	336,362	487,393
Other tax credits	284,422	(121,829)	162,593
Total	**1,749,377**	**312,691**	**2,062,068**
Deferred tax assets	3,590,915		4,133,328
Deferred tax liabilities	(1,841,538)		(2,071,260)

	Consolidated			
	Balance at 01/01/2023	**Recognized in income (loss)**	**Reclassification of items for sale (iii)**	**Balance at 12/31/2023**
Provision for tax, civil and labor risks	309,552	(74,937)	(2,945)	231,670
Impairment loss on trade receivables	218,489	22,784	(794)	240,479
Credit on tax loss and negative basis (i)	1,081,127	245,654	-	1,326,781
Amortization of fair value - Assets acquired in business combination	462,800	(46,781)	-	416,019
Deferred tax on goodwill in business combination (ii)	(808,303)	(470,280)	15,059	(1,263,524)
Deferred tax on right-of-use	86,843	89,088	(184)	175,747
Cost with issue of debentures	6,901	(25,612)	-	(18,711)
Share-based payment plan expenses	184,492	20,971	-	205,463
Effects of adopting IFRS 17 (CPC 50)	(25,287)	176,318	-	151,031
Other tax credits	87,371	196,691	360	284,422
Total	**1,603,985**	**133,896**	**11,496**	**1,749,377**
Deferred tax assets	2,990,302			3,590,915
Deferred tax liabilities	(1,386,317)			(1,841,538)

(i) Only the transaction of entities for which it is probable that future taxable income are made available for the Company and its subsidiaries to be able to use the respective benefits were included in the calculation of deferred income tax and social contribution.

(ii) Deferred tax liability constituted on the tax amortization of goodwill arising from business combinations, in accordance with Article 22 of Law 12973/14.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

b.2 Expected realization of deferred taxes

The expected periods for realizing the net deferred taxes of the Company and its subsidiaries, based on projections that may change in the future, are below:

	Parent Company	**Consolidated**
	06/30/2024	**06/30/2024**
2024	40,881	56,044
2025	40,881	56,044
2026	50,963	71,060
2027	141,698	206,207
2028	303,006	446,467
>2029	839,554	1,226,246
Total	**1,416,984**	**2,062,068**

The Company and its subsidiaries have tax losses and negative social contribution bases in the calculation of taxable income which represent a right with no statute of limitation, under the terms of current legislation. After the business combinations that took place as of 2019, the Company and its subsidiaries carried out their strategic corporate restructuring planning to support the realization of these taxes.

The main pillars of this planning are: a) Implementation of proprietary systems; b) Corporate reorganization aimed at tax optimization and synergies; and c) Realization of deferred taxes and consumption of current goodwill inventories.

During the period ended June 30, 2024, the Company carried out one (1) corporate merger, in line with its strategic planning.

34 Financial instruments

(i) Fair value hierarchy

When measuring fair value of an asset or liability, the Company and its subsidiaries use market observable data as much as possible. Fair values are classified at different levels according to hierarchy based on information (inputs), as presented in the Note 6 (c), which is used in valuation techniques.

In the period ended June 30, 2024 and year ended December 31, 2023, the Company and its subsidiaries made no transfer between financial assets or transfer among hierarchic levels.

The financial instruments of the Company and its subsidiaries are presented in the following table, which contain the book value of financial assets and liabilities, including their hierarchy levels of assessment:

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

06/30/2024	**Consolidated**						
	Book value				**Fair value**		
Financial assets measured at fair value	**Amortized cost**	**Fair value through profit or loss**	**FVOCI**	**Total**	**Level 1**	**Level 2**	**Total**
Short and long term investments - Investment Funds	-	7,233,128	-	7,233,128	-	7,233,128	7,233,128
Derivative financial instruments - Long position	-	-	-	-	-	-	-
Total	**-**	**7,233,128**	**-**	**7,233,128**	**-**	**7,233,128**	**7,233,128**
Financial assets not measured at fair value							
Short and long term investments - Bank Deposit Certificate (CDB)	200,055	-	-	200,055	-	-	-
Short and long term investments - Brazilian Treasury Note (NTN-B)	189,816	-	-	189,816	-	-	-
Short and long term investments - Financial Treasury Bill (LFT)	302,272	-	-	302,272	-	-	-
Total	**692,143**	**-**	**-**	**692,143**	**-**	**-**	**-**
Financial liabilities not measured at fair value							
Loans and financing (ii)	(282,758)	-	-	(282,758)	-	-	-
Debentures (ii)	(9,341,963)	-	-	(9,341,963)	-	-	-
Real Estate receivables certificate - CRI (ii)	(2,136,604)	-	-	(2,136,604)	-	-	-
Dividends and interest on shareholders' equity	(12,629)	-	-	(12,629)	-	-	-
Leases payable	(3,323,223)	-	-	(3,323,223)	-	-	-
Derivative financial instruments - Short position	-	(8,285)	(106,613)	(114,898)	-	(114,898)	(114,898)
Total	**(15,097,177)**	**(8,285)**	**(106,613)**	**(15,212,075)**	**-**	**(114,898)**	**(114,898)**
Financial liabilities measured at fair value							
Contingent consideration (i)	-	(829,237)	-	(829,237)	-	(829,237)	(829,237)
Total	**-**	**(829,237)**	**-**	**(829,237)**	**-**	**(829,237)**	**(829,237)**

December 31, 2023	**Consolidated**						
	Book value				**Fair value**		
Financial assets measured at fair value	**Amortized cost**	**Fair value through profit or loss**	**FVOCI**	**Total**	**Level 1**	**Level 2**	**Total**
Short and long term investments - Investment Funds	-	5,451,293	-	5,451,293	-	5,451,293	5,451,293
Derivative financial instruments - Long position	-	772	-	772	-	772	772
Total	**-**	**5,452,065**	**-**	**5,452,065**	**-**	**5,452,065**	**5,452,065**
Financial assets not measured at fair value							
Short and long term investments - Bank Deposit Certificate (CDB)	229,845	-	-	229,845	-	-	-
Short and long term investments - Brazilian Treasury Note (NTN-B)	259,868	-	-	259,868	-	-	-
Short and long term investments - Financial Treasury Bill (LFT)	518,749	-	-	518,749	-	-	-
Total	**1,008,462**	**-**	**-**	**1,008,462**	**-**	**-**	**-**
Financial liabilities not measured at fair value							
Borrowings and financing	(247,728)	-	-	(247,728)	-	-	-
Debentures	(9,191,640)	-	-	(9,191,640)	-	-	-
Real Estate Receivables Certificates - CRI	(2,087,046)	-	-	(2,087,046)	-	-	-
Dividends and interest on shareholders' equity	(12,629)	-	-	(12,629)	-	-	-
Leases payable	(3,338,009)	-	-	(3,338,009)	-	-	-
Derivative financial instruments - Short position	-	(33,386)	(15,802)	(49,188)	-	(49,188)	(49,188)
Total	**(14,877,052)**	**(33,386)**	**(15,802)**	**(14,926,240)**	**-**	**(49,188)**	**(49,188)**
Financial liabilities measured at fair value							
Contingent consideration	-	(1,110,941)	-	(1,110,941)	-	(1,110,941)	(1,110,941)
Total	**-**	**(1,110,941)**	**-**	**(1,110,941)**	**-**	**(1,110,941)**	**(1,110,941)**

(i) Contingent consideration (contractual obligations, net of their respective indemnification assets) as presented in Note 24 (a).

(ii) Measurements at amortized cost and fair value of the Company's loans, financing, debentures and Real Estate Receivables Certificates - CRI have approximate amounts.

Cash and cash equivalents, accounts receivable and suppliers are not included in the table above because their book value is close to their fair value due to the short-term maturities of these financial instruments.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

The short and long term investments in CDBs have a fair value similar to the book value, as they have a grace period of up to 90 days, are remunerated at interest rates indexed to the DI (Interbank Deposits) curve and are issued by leading financial institutions.

(ii) Measurement at fair value

Assets and liabilities at fair value are measured as follows:

a) Investment funds
Obtained from the values of the shares disclosed by financial institutions.

b) Derivative financial instruments
The fair value of derivative financial instruments is determined based on the values disclosed by the financial institutions.

(iii) Risk management

a) Market risks

The Company and its subsidiaries have a formalized policy to make investments and to use financial instruments in its activities.

The investment policy has the following characteristics: (i) limit exposure to credit, liquidity, market, operational and legal risks in respect of Short and long term investments, guaranteeing the preservation of the long-term assets of the Company and its subsidiaries; (ii) maintain efficient and optimized management in order to guarantee sufficient cash flow; (iii) not to trade derivatives of any kind or foreign currencies and financial assets with foreign exchange exposure, except when they are intended to hedge financial or operating liabilities; (iv) invest through entities of the Company and its subsidiaries or, indirectly, through open, restricted or dedicated investment funds, of which they are shareholders of: a) Federal government bonds; b) securities issued by a financial institution (CDBs, LF, LCI, LCA, DPGE, CCBs and other fixed-income products); c) securities issued by publicly traded companies (debentures, promissory notes, CRI, CRA, the like); d) repurchase agreements backed by the aforementioned assets; and e) the allocation of Collateral Assets, or Linked Short and long term investments, must follow the concentration limits in accordance with RN ANS 392 and subsequent updates.

On a regular basis, the Financial area consolidates indicators and reports on the management of investments and financial instruments with a detailed analysis of the distribution, risks, maturities, interests, performances and results, addressing the most relevant aspects of the macroeconomic environment and ensuring alignment with the financial instruments investment policy.

Market risk also involves the Company and its subsidiaries monitoring interest rate risk in a timely manner, monitoring any fluctuations and, where applicable, assessing the use of hedging instruments.

Sensitivity Analysis – Financial instruments

As of June 30, 2024, the Company and its subsidiaries have the following sensitivity of its financial assets and liabilities based on the change in the basic interest rate of the economy (CDI), whose impacts are projected according to the scenarios below: The Company and its subsidiaries consider the CDI published for the base date of June 30, 2024, as a probable scenario.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

		Risk	Scenario (-50%)	Scenario (-25%)	Scenario (Probable)	Scenario (+25%)	Scenario (+50%)
		CDI	5.20%	7.80%	10.40%	13.00%	15.60%
		IPCA	2.11%	3.17%	4.22%	5.28%	6.33%
	06/30/2024	**SELIC**	5.25%	7.88%	10.50%	13.13%	15.75%
Short and long term investments							
Balance of pledged short and long term investments	3,129,350	110.40% CDI	162,726	244,089	325,452	406,816	488,179
Balance of short and long term investments (free)	4,374,945	110.40% CDI	227,497	341,246	454,994	568,743	682,491
Balance of short and long term investments (NTN-B)	42,237	4.22% IPCA	891	1,337	1,782	2,228	2,674
Balance of short and long term investments (pledged NTN-B)	147,579	10.06% IPCA	3,114	4,671	6,228	7,785	9,342
Balance of short and long-term investments (pledged Financial Treasury Bills)	231,160	10.50% SELIC	12,136	18,204	24,272	30,340	36,408
Total	**7,925,271**						

		Risk	Scenario (-50%)	Scenario (-25%)	Scenario (Probable)	Scenario (+25%)	Scenario (+50%)
	06/30/2024	**CDI**	5.20%	7.80%	10.40%	13.00%	15.60%
Loans and financing							
Working capital	282,758	110.40% CDI	14,703	22,055	29,407	36,759	44,110
Total	**282,758**						

		Risk	Scenario (-50%)	Scenario (-25%)	Scenario (Probable)	Scenario (+25%)	Scenario (+50%)
	06/30/2024	**CDI**	5.20%	7.80%	10.40%	13.00%	15.60%
Debentures							
Debentures – series 1 – 1st issue - Hapvida Part.	619,620	110.40% CDI	32,220	48,330	64,440	80,551	96,661
Debentures – series 2 – 1st issue - Hapvida Part.	247,785	110.40% CDI	12,885	19,327	25,770	32,212	38,654
Debentures – series 1 – 2nd issue - Hapvida Part.	1,270,102	110.40% CDI	66,045	99,068	132,091	165,113	198,136
Debentures – series 2 – 2nd issue - Hapvida Part.	1,270,508	110.40% CDI	66,066	99,100	132,133	165,166	198,199
Debentures – 3rd issue – Hapvida Part.	2,024,027	110.40% CDI	105,249	157,874	210,499	263,124	315,748
Debentures – 5th issue – Hapvida Part.	993,782	110.40% CDI	51,677	77,515	103,353	129,192	155,030
Debentures – 7th issue – Hapvida Part.	1,009,657	110.40% CDI	52,502	78,753	105,004	131,255	157,506
Debentures – 3rd issue – NDI Saúde	279,481	110.40% CDI	14,533	21,800	29,066	36,333	43,599
Debentures – 4th issue – Hapvida Part. (*)	101,467	110.40% CDI	5,276	7,914	10,553	13,191	15,829
Debentures – 5th issue – Hapvida Part. (*)	297,150	110.40% CDI	15,452	23,178	30,904	38,630	46,355
Debentures – 6th issue – Hapvida Part. (*)	1,228,384	110.40% CDI	32,220	48,330	64,440	80,551	96,661
Total	**9,341,963**						

		Risk	Scenario (-50%)	Scenario (-25%)	Scenario (Probable)	Scenario (+25%)	Scenario (+50%)
		CDI	5.20%	7.80%	10.40%	13.00%	15.60%
	06/30/2024	**IPCA**	2.11%	3.17%	4.22%	5.28%	6.33%
Real estate receivables certificate							
CRI – single series – Hapvida Assistência Médica	1,117,919	10.06% IPCA	23,588	35,382	47,176	58,970	70,764
CRI - series 1 – NDI Saúde (**)	534,746	110.40% CDI	27,807	41,710	55,614	69,517	83,420
CRI - series 2 – NDI Saúde (**)	383,014	10.06% IPCA	8,082	12,122	16,163	20,204	24,245
CRI - series 3 – NDI Saúde (**)	100,925	10.06% IPCA	2,130	3,194	4,259	5,324	6,389
Total	**2,136,604**						

(*) Debentures assigned in 2023 by the subsidiary BCBF Participações S.A. to the Company, with the Company becoming the issuer of the respective debentures for all purposes and effects.
(**) With the merger of BCBF Participações S.A. into Notre Dame Intermédica Saúde S.A. on March 28, 2024, the latter assumed the debt previously held by BCBF Participações S.A.

Sensitivity analysis - goodwill

An analysis of the sensitivity of the Company and its subsidiaries to an increase or decrease of 0.35% in the main assumptions used to calculate the recoverability of the CGU on the base date December 31, 2023, assuming that all other variables remain constant, is presented below.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

December 31, 2023

Significant premise affected by possible deterioration	Sensitivity of the premise	Impact (i)
Operating margins	0.35% decrease	Value in use > Carrying amount = 3,060,647
Discount rate	0.35% increase	Value in use > Carrying amount = 377,333
Growth rate in perpetuity	0.35% decrease	Value in use > Carrying amount = 1,594,369

(i) The value in use calculated by the Company and its subsidiaries considers projections up to the year 2035. The awareness of the premise of 0.35% in operating margins is carried out gradually, starting in 2030.

Sensitivity analysis – Insurance contracts

An analysis of the Group's sensitivity to a parallel increase or decrease of 0.5% in market interest rates on the base date of December 31, 2023 for insurance contracts, assuming that all other variables remain constant, is presented below.

	Income (loss)		Equity	
December 31, 2023	**Increase**	**Decrease**	**Increase**	**Decrease**
Interest rate	6,876	(14,040)	4,538	(9,267)

b) Underwriting risk

Underwriting risk includes insurance risk, policyholder behavior risk and expense risk.

• **Insurance risk**: the risk transferred from the insurer to the Company, other than financial risk. Insurance risk arises from the inherent uncertainty about the occurrence, value or timing of claims.

• **Policyholder behavior risk**: the risk that a policyholder will cancel a contract (i.e. lapse or persistency risk), increase or reduce premiums, withdraw deposits or cancel a contract sooner or later than expected.

• **Expense risk**: the risk of unexpected increases in the administrative costs associated with servicing a contract (and not in the costs associated with the insured’s events).

Pricing policy

Companies that operate in health and dental care business are exposed to risks related to cost volatility. Dental plans are less exposed than health plans due to lower frequency of use and lower complexity of the treatments.

When the Company and its subsidiaries are developing a new product it analyzes many variables to define the price of this product, such as the demographic area where the product will be offered, the frequency profile established in the area calculated with historical records, and the costs of main inputs in the area it will be sold (doctors, health care professionals, market price of main procedures). Based on these analyses, the Company and its subsidiaries determine the price of health and dental plans.

Each client that is considered medium or large company has its medical losses ratio calculated every year when the Company and its subsidiaries are negotiating annual price increase for health and/or dental insurance plans (individual clients are regulated by ANS). Based on historical usage of the service network controlled by biometrics, and based on expectations of costs related to these clients,

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

the price increase of this contract is determined. This practice mitigates risks of clients bringing constant losses to the Company and its subsidiaries.

Regarding individual clients, the pricing of the products considers an additional value because this type of client historically has a greater use of service network.

Risk concentration
The following table shows the book values of the Group’s insurance contracts by portfolio.

Concentration of risks	06/30/2024	06/30/2023
Individual (health and dental)	2,884,719	2,485,106
Collective (health and dental)	10,500,620	10,560,070
Total	**13,385,339**	**13,045,176**

Sensitivity analysis
The following table analyzes how the Contractual Service Margin (CSM), income (loss) and equity would have increased (decreased) if the changes in the underwriting risk variables that were reasonably possible on the base date of December 31, 2023 had occurred. The analysis presents the sensitivities and assumes that all other variables remain constant.

Changes in underwriting risk variables mainly affect CSM, income and equity, as follows. The effects on income and equity are presented net of the respective income tax.

a. CSM - Changes in cash flows from contractual compliance not related to any loss components other than those recognized as revenues or expenses from insurance financing.
b. Income - Changes in the cash flows of the contractual fulfillment related to the loss of the components; - Changes in contractual compliance cash flows, which are recognized as insurance financing revenues or expenses in the statement of profit or loss.
c . **Equity -** Changes in cash flows from contractual compliance, which are recognized as revenues or expenses from insurance financing in the statement of profit or loss in accordance with (b).

December 31, 2023
In thousands of reais

Individual (health and dental)	CSM	Income (loss)	Equity
Cancellation (1% increase)	(14,171)	(3,428)	(2,263)
Cancellation (1% decrease)	13,788	3,479	2,296
Medical inflation (1% increase)	(122,139)	(12,042)	(7,948)
Medical inflation (1% decrease)	121,224	11,232	7,413
Loss ratio (5% increase)	(806,972)	(88,988)	(58,732)
Loss ratio (5% decrease)	823,815	70,762	46,703

Collective (health and dental)
With regard to collective portfolios, measured by the PAA model, the main assumption is related to the effects of discounting on LIC/PSI. Based on the sensitivity analysis of 0.5% in this assumption, the balances, on December 31, 2023, would have increased by R$ 1,656 and decreased by R$ 3,310 in income (loss) and would have, on December 31, 2023, increased by R$ 1,093 and decreased by R$ 2,185 in the equity.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

c) Operating risk

Operating risk is defined as the possibility of losses resulting from failure, weakness or inadequacy of internal processes, people and systems or external events.

The purpose of operational risk monitoring and management is to mitigate the materialization of risks that could result in damage to the quality of operations during the provision of contracted coverage and/or the provision of services. Operational risks and their associated controls are identified by mapping organizational flows, so that when they are identified, the impacts of these risks are quantified, considering the expected standard in terms of frequency and severity, using specific methodologies applicable to each risk assessed.

Mitigating actions are relevant to providing an environment with greater stability and control, insofar as they have an effectively preventive purpose. In this sense, the implementation of procedural protocols that guide the actions of the professionals who work in the operation makes a significant contribution to ensuring that the services are carried out within the technical and safety standards established by the areas responsible for drawing up the manuals. In addition, there are 24-hour control areas that monitor in real time the main user service indicators at the Company’s own network units and those of its subsidiaries. Both tools are important instruments for identifying situations that are out of line with what is expected, allowing Management to act quickly and effectively before they have an impact on operations.

d) Credit risks

Credit risk is the risk the Company and its subsidiaries have of incurring losses from a client or a party to a financial instrument, arising from their fail to comply with their contractual obligations. Risk is mainly due to trade accounts receivable and short and long term investments.

Accounts receivable/Other assets

The credit risk for the Company and its subsidiaries is considered low by Management. Most of the risk in the accounts receivable of the Company and its subsidiaries arises from the provision of clinical, hospital, laboratory and diagnostic services, as well as the provision of management services for post-payment healthcare and dental plans.

The Company and its subsidiaries established a provision for impairment which consists in the use of factors related to losses noted in recent time series, adjusting historical series to reflect the current conditions and reasonable and feasible estimates of future economic conditions related to accounts receivable and other accounts receivable. The Company and its subsidiaries recognize impairment losses as a write-off of accounts receivable unless the Company and its subsidiaries evaluate that it is not possible to recover the amount due; On this occasion, the amounts are considered irrecoverable and are recorded against the financial asset directly.

In general, the Company and its subsidiaries mitigate their credit risks by providing services to a client base that is very dispersed and has an undefined concentration.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

Short and long term investments

Regarding the credit risks from short and long term investments, a table with quantitative information of maximum risk exposure risk, including information on the ratings of financial institutions, counterparties of investments of the Company and its subsidiaries:

			Ratings of Financial Institutions (*)					
			Fitch (*)		Moody´s (*)		S&P (*)	
	06/30/2024	12/31/2023	SHORT-TERM	LONG-TERM	SHORT-TERM	LONG-TERM	SHORT-TERM	LONG-TERM
Banco Itaú Unibanco S.A.	3,412,755	2,827,565	F1+	AAA	BR-1	Aaa.br	brA-1+	brAAA
Banco Santander S.A.	2,865,586	2,235,553	-	-	BR-1	Aaa.br	brA-1+	brAAA
Banco Bradesco S.A.	90,318	196,062	F1+	AAA	BR-1	Aaa.br	brA-1+	brAAA
Caixa Econômica Federal	81,596	95,898	F1+	AA	BR-1	Aaa.br	brA-1+	brAAA
Banco do Brasil S.A.	1,133,502	513,385	F1+	AA	BR-1	Aaa.br	brB	brB
Banco Safra S.A.	22,414	25,404	-	-	BR-1	Aaa.br	brA-1+	brAAA
Banco Votorantim	1,623	1,541	-	AAA	-	Aaa.br	brA-1+	brAAA
Credit Suisse	71,124	337,943	F1+	AAA	BR-1	Aaa.br	brB	brB
BTG Pactual	13,685	111,894	F1+	AAA	-	Aaa.br	-	-
Other	232,668	114,510	-	AAA	-	Aaa.br	-	-
Total	**7,925,271**	**6,459,755**						

(*) Last disclosure. National scale.

Cash and cash equivalents

The Company and its subsidiaries held “Cash and cash equivalents” of R$ 419,682 as of June 30, 2024 (R$ 1,430,144 as of December 31, 2023), mainly comprised of balances in cash, banks and short and long term investments with immediate liquidity. Balances of cash and cash equivalents are maintained with banks and financial institutions with AA and AA+ rating, as the list disclosed by Fitch, and besides having immediate liquidity in cash, they are subject to an insignificant risk of change in value.

e) Liquidity risks

Liquidity risk is the risk of the Company and its subsidiaries encountering difficulties in performing the obligations associated with its financial liabilities that are settled with cash payments or with another financial asset. The approach of the Company and its subsidiaries in liquidity management is to guarantee, as much as possible, that it always has sufficient liquidity to perform its obligations upon maturity, under normal and stress conditions, without causing unacceptable losses or with a risk of sullying the reputation of the Company and its subsidiaries.

The Company and its subsidiaries use medical losses control to price its products and services, which helps it with the monitoring of cash flow requirements and the optimization of its cash return on investments. The Company and its subsidiaries seek to maintain the level of its cash and cash equivalents and other highly negotiable investments at an excess amount of cash outflows on financial instruments (other than trade accounts payable). The Company and its subsidiaries also monitor expected level of cash inflows deriving from ‘trade accounts receivable and other receivables’ as well as expected cash outflows related to ‘trade accounts payable and other accounts payable’.

The main sources of funds used by the Company and its subsidiaries are the volume of funds from the trading of their services. The income from investments from cash deposits is added to this amount.

Regarding the exposure to liquidity risk, contractual maturities of financial liabilities on the base date:

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

			Contractual cash flows					
Financial liabilities	**Notes**	**Book value**	**2024**	**2025**	**2026**	**2027**	**>2028**	**Total**
Suppliers	-	353,905	350,644	3,261	-	-	-	353,905
Loans, financing, debentures and CRI	19	11,761,325	1,792,629	1,807,554	2,368,076	2,395,554	9,141,977	17,505,790
Leases payable	20	3,323,223	240,198	478,891	456,348	428,277	8,147,143	9,750,857
Other accounts payable	24	1,751,113	444,105	1,307,008	-	-	-	1,751,113
Dividends and interest on shareholders' equity payable	25.c	12,629	12,629	-	-	-	-	12,629
Total		**17,202,195**	**2,840,205**	**3,596,714**	**2,824,424**	**2,823,831**	**17,289,120**	**29,374,294**

The cash flow forecast is prepared by the Company and its subsidiaries, and continuous forecasts of liquidity requirements are monitored to ensure that the Company and its subsidiaries have sufficient cash to meet legal and operating needs. This forecast takes into consideration the cash generation of the Company and its subsidiaries.

The following table provides a maturity analysis of the Group's insurance contracts, reflecting the dates on which the cash flows are expected. The remaining coverage liabilities measured by the PAA were excluded from this analysis.

LRC - Remaining coverage liabilities (assets/liabilities of insurance contracts)

	06/30/2024					
Insurance contracts	**<01 year**	**01−02 years**	**02−03 years**	**03−04 years**	**>05 years**	**Total**
Individual – BBA	(3,360,151)	(2,371,534)	(1,067,669)	(775,875)	9,611,831	2,036,602
Total	**(3,360,151)**	**(2,371,534)**	**(1,067,669)**	**(775,875)**	**9,611,831**	**2,036,602**

	12/31/2023					
Insurance contracts	**<01 year**	**01−02 years**	**02−03 years**	**03−04 years**	**>05 years**	**Total**
Individual – BBA	(3,338,578)	(2,372,695)	(1,084,844)	(793,605)	9,233,582	1,643,861
Total	**(3,338,578)**	**(2,372,695)**	**(1,084,844)**	**(793,605)**	**9,233,582**	**1,643,861**

LIC - liabilities for claims incurred

	06/30/2024					
Insurance contracts	**<01 year**	**01−02 years**	**02−03 years**	**03−04 years**	**<05 years**	**Total**
Individual – BBA	(535,980)	(168,414)	-	-	-	(704,394)
Collective – PAA	(2,335,632)	(932,488)	(708,243)	-	-	(3,976,363)
Total	**(2,871,612)**	**(1,100,902)**	**(708,243)**	**-**	**-**	**(4,680,757)**

	12/31/2023					
Insurance contracts	**<01 year**	**01−02 years**	**02−03 years**	**03−04 years**	**<05 years**	**Total**
Individual – BBA	(524,730)	(188,072)	-	-	-	(712,802)
Collective – PAA	(2,136,291)	(963,612)	(650,689)	-	-	(3,750,592)
Total	**(2,661,021)**	**(1,151,684)**	**(650,689)**	**-**	**-**	**(4,463,394)**

Liquidity risk management

The Company and its subsidiaries use medical losses control to price its products and services, which helps it with the monitoring of cash flow requirements and the optimization of its cash return on investments. The Company and its subsidiaries seek to maintain the level of its cash and cash equivalents and other highly negotiable investments at an excess amount of cash outflows on financial instruments (other than trade accounts payable). The Company and its subsidiaries also monitor expected level of cash inflows deriving from 'trade accounts receivable and other receivables' as well as expected cash outflows related to 'trade accounts payable and other accounts payable'.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

The main sources of funds used by the Company and its subsidiaries are the volume of funds from the trading of their services. The income from investments from cash deposits is added to this amount.

f) Derivative financial instruments and hedge accounting

The activities of the Company and its subsidiaries expose it to various financial risks. Risk management is carried out centrally by the Financial Vice-Presidency to minimize the adverse effects of financial risks affecting the Company and its subsidiaries.

On June 30, 2024, the Company and its subsidiaries had derivative financial instrument contracts, used to reduce exposure to interest rate and exchange rate fluctuations (interest rate swap and exchange rate swap), with no speculative purpose.

The Company and its subsidiaries adopted the cash flow hedge accounting methodology, in line with IAS 39, for their IPCA x CDI interest rate swaps intended to hedge the financial debt of the 1st issue of Real Estate Receivables Certificates (CRI) of Ultra Som Serviços Médicos S.A. (merged into Hapvida Assistência Médica S.A.) and for their foreign exchange hedge swaps. Under this system, balances are recorded as follows:

(i) the effective portion of the gain or loss resulting from the hedge instrument is directly recorded in equity (other comprehensive income); and
(ii) the ineffective portion of the gain or loss resulting from the hedging instrument is recognized in the financial result in the statement of profit or loss.

The fair value of cash flow contracts is presented in the statement of financial position account (assets, liabilities and equity). For outstanding hedge operations, the Company and its subsidiaries calculated the market value - MTM (Mark to Market).

The openings of the swap contracts of the Company and its subsidiaries, as well as their fair values on the base date are as follows:

Instrument	Maturity	Long position	Short position	Fair value	Notional (R$)	Position at 06/30/2024	Position at 12/31/2023
Swap - Interest rate	Dec 2031	IPCA + 5.7505% p.a.	107.50% CDI	(51,596)	503,475	(51,596)	(9,225)
Swap - Interest rate	Dec 2031	IPCA + 5.7505% p.a.	107.50% CDI	(63,302)	617,303	(63,302)	(15,863)
Foreign exchange swap	Feb 2026	US$ + 6.84% p.a.	CDI + 1.6% p.a.	12,154	260,000	12,154	(23,328)
Total				**(102,744)**		**(102,744)**	**(48,416)**
					Assets	12,154	-
					Liabilities	(114,898)	(48,416)

The change in interest rate swap derivative financial instruments of the new contracts is shown below:

	06/30/2024	12/31/2023
Balance at the beginning of the period - Liabilities/(Assets)	**25,088**	**-**
Accrual	(1,001)	9,287
Market value – MTM	90,811	15,801
Balance at the end of the period/year - Liabilities/(Assets)	**114,898**	**25,088**

On June 30, 2024, as part of the prospective assessment of effectiveness, Management carried out an analysis of the economic relationship of its hedge structures and did not identify any material impacts on the hedge relationships. Thus, the hedge transactions were considered effective.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

35 Insurance coverage (unaudited)

The Company and its subsidiaries maintain insurance contracts with coverage determined in accordance with the orientation of specialists, considering the nature and the degree of risk, in amounts considered sufficient to cover possible losses on its assets and/or responsibilities.

The breakdown of the insurance coverage of the Company and its subsidiaries is as follows:

Item	Type of coverage	Insured amount
Buildings, facilities, machinery, furniture, fixtures, and inventories	Fire (including due to riots, strikes and lock-outs), lightning, explosions of any kind and aircraft crashes, electrical damage, equipment leased or assigned to third parties, movable and fixed equipment RD, falling glass, fixed expenses (6 months), rental losses/payments (6 months), theft/general theft of goods, windstorm, impact of vehicles through smoke, landslides, electronic equipment, portable objects (Brazilian territory) and theft of medicines.	713,821
D&O	Civil liability, officers, administrators and directors.	100,000
Cyber	Cyber risk insurance.	25,000
Judicial litigation	Legal disputes in the civil, tax and labor spheres, and acquisition and tax law guarantees.	2,393,637
Vehicle fleet	Comprehensive, property damage, bodily injury and mobile equipment.	100% FIPE table per vehicle
Employees	Group Life Insurance. Trainees, disability and funeral assistance.	Variable according to salary range
Guarantee insurance	Guarantees on customer contracts.	1,153
Other insurance	Adm. Tax management, construction, supply or provision of services	22,209

36 Transactions that do not involve cash or cash equivalents

During the periods ended June 30, 2024 and 2023, the Company and its subsidiaries carried out the following investment and financing activities not involving cash; therefore, they are not reflected in the statement of cash flows:

	Parent Company		Consolidated	
	06/30/2024	06/30/2023	06/30/2024	06/30/2023
Right of use - Additions/Write-offs and remeasurements	-	238	81,332	19,372
Share transfer write-off - Stock grant (i)	48,256	-	48,256	-
Other accounts payable - Contractual obligations	-	-	-	34,359

(i) Partial transfer of shares from the Stock Grant Plan to its beneficiaries.

37 Adjusted equity and Regulatory capital

To operate in the health insurance market regulated by the National Agency for Supplementary Health (ANS), health care operators must comply with solvency indices, as set out in NR 569/22. Adjusted Equity (PLA), for example, needs to be higher than the legal requirement for Risk-Based Capital (RBC). The PLA is calculated considering the equity minus i) direct or indirect holdings in other regulated entities, ii) tax credits arising from tax losses and negative bases, iii) deferred and iv) prepaid expenses, v) intangible non-current assets and, vi) the value of goodwill from direct or indirect holdings in other non-regulated entities, as indicated in Article 7 of NR 569/2022.

The operators controlled by the Company adopted the standard RBC model in advance when calculating regulatory capital. Therefore, in accordance with the criteria set out in Article 9 of Section II of Chapter III of NR 569/2022, the calculation of their regulatory capital, as of January 2023,

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

considered the highest value between the Base Capital and the RBC. The RBC considers the following risks: (i) Underwriting risk, (ii) Credit risk, (iii) Operating/legal risk, and (iv) Market risk.

In the period ended June 30, 2024, consolidated solvency, when observed on an aggregate basis involving the operators controlled by the Company, reached the sufficiency indicated below:

	Consolidated
	06/30/2024
Adjusted equity (PMA) (A)	7,470,484
Risk-based capital (CBR) (B)	4,333,622
Sufficiency/(Insufficiency) calculated (A) - (B)	**3,136,862**

38 Discontinued operations

The divestment of Maida Health Participações Societárias S.A. and subsidiaries fits into the context of focusing Management's efforts on its core business. In this scenario, the Company and its subsidiaries classified these transactions as discontinued operations.

Maida Health Participações Societárias S.A. and subsidiaries

On October 27, 2023, the subsidiary BCBF Participações S.A. entered into a share purchase agreement and other covenants for the sale of the subsidiary Maida Health Participações Societárias S.A. and its subsidiaries to MV Sistemas SP Ltda.

On February 01, 2024, the subsidiary BCBF Participações S.A. (merged into Notre Dame Intermédica Saúde S.A.) signed the Closing Agreement for the Purchase and Sale of Shares and Other Covenants with the buyer MV Sistemas SP Ltda. for the sale of the wholly-owned subsidiary Maida Health Participações Societárias S.A. and its subsidiaries Maida Infoway Tecnologia e Gestão em Saúde Ltda.; Maida Haptech Soluções Inteligentes Ltda.; Lifeplace Maida Ltda.; and Tercepta Consultoria em Informática Ltda.

Under the agreed terms, the enterprise value of the transaction is R$ 26,700, subject to price adjustment mechanisms common in similar transactions, as well as potential additional annual installments (earn-out) to be priced over the next 5 years.

The consolidated result of Maida Health and its subsidiaries in the period (one month of 2024) up to the date of the effective sale is presented below.

Retained earnings of the period

On June 30, 2024, the consolidated net income from discontinued operations for the period of Maida Health Participações Societárias S.A. and its subsidiaries was R$ 5,965.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

39 Subsequent events

(i) New hospitals – Rio de Janeiro and São Paulo

The Company entered into a memorandum of understanding with Riza Gestora de Recursos Ltda. for two new hospitals in the Build to Suit (BTS) modality. The properties subject to acquisition, which are in the final stage of negotiation by the Company, will be located in the cities of Rio de Janeiro/RJ and São Paulo/SP.

The transaction foresees an initial amount of R$ 300,000, which will be used to acquire the land under negotiation. In addition, Riza will raise an additional amount of up to R$ 300,000, under the best efforts regime, for the full development of the BTS works, totaling R$ 600,000.

The transaction is in line with the Company's strategy of seeking to be asset light, optimizing capital allocation for the business, which will enable the acceleration of other assistance projects foreseen in the investment plan (Capex) for 2024/2025.

The operation will have a Cap rate of 9.5% p.a. until the completion of the BTS, according to Riza's disbursement flow. After the obtainment of the occupancy permits for properties, 9.0% adjusted annually by the IPCA. The lease term will be 20 years, with the option to renew for additional 20 years, with the option to purchase at pre-determined periods and conditions, according to stipulated multiples.

The completion of the transaction depends, as usual, on the fulfillment of certain conditions precedent, including, but not limited to, the satisfactory completion of the due diligence on the assets subject to acquisition and the approval of the Transaction by Riza's investment committee.

DocuSign Envelope ID: 9D05BE55-3692-4538-BF37-DA1290E2C138

* * *

Cândido Pinheiro Koren de Lima
Chairman of the Board of Directors

Jorge Fontoura Pinheiro Koren de Lima
President

Luccas Augusto Adib
Vice-President and Chief Finance and Investor Relations Officer

Fernando Miguel Augusto
Chief Accounting Officer
CRC SP-319932/O-0

Rafael Sobral Melo
Actuary
MIBA 1,572